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1. Clinical guidelines all recommend history taking, physical 
examination and mammography to breast cancer survivors. 
2. Early detect�on of isolated loco-regional or contra-lateral breast 
cancer recurrences in patients without symptoms has a beneficial 
impact on the survival of breast cancer patients when compared to 
late symptomatic detection. (This thesis) 
3. All guidelines endorse a less intensive clinical follow-up excluding 
distant metastasis related tests in the absence of evidence that early 
treatment of metastatic disease will prolong life. 
4. For one-third of these patients the time of stopping their hospital 
follow-up was earlier than it should have been based on the 
guidelines. (This thesis) 
5. The results show that patients with contralateral breast cancer 
detected by routine mammography have better survival rates than 
patients with contralateral breast cancers detected by other means. 
(This thesis) 
6. Routine physical examination may be most valuable for women 
with a history of breast cancer younger than 60 years. (This thesis) 
7. Shortening the follow-up time in the hospital leads to a significant 
reduction in costs and maintains the same clinical effects. (This 
thesis). 
8. Frankness is the most advisable maneuver. 
9. The important thing in life is to have a great aim, and the 
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Aim of this thesis 
The aim of this thesis is to describe the current follow-up care after a 
diagnosis of early breast cancer, to evaluate current strategies to 
early detect localized recurrences of breast cancer, and to propose a 
cost-effective strategy to early detect these localized recurrences. In 
this introduction, a brief introduction is given to epidemiology of 
breast cancer including incidence and survival. The goals of follow­
up surveillance after breast cancer are given. The follow-up tests will 
be discussed. Current guidelines for the follow-up of breast cancer 
to early detect a local recurrence will be described. This chapter is 
ended with an outline of this thesis. 
Breast cancer is the most common malignancy in women in North 
America and Western Europe, accounting for more than 1 in 4 
cancers diagnosed in US and European women [1-2]. The crude 
incidence of breast cancer in the European Union is 109.9/100 000 
females per year, the mortality 38.4/100 000 females per year [3]. 
The age-adjusted incidence is low in most Asian countries, although 
world -standardized rates are greater than 50 per 100,000 in Manila, 
Philippines, and in Karachi, Pakistan. In China, where the author of 
this thesis comes from, the absolute number of new cases of breast 
cancer is high, and 21.3% of new cases of breast cancer of the 
world are diagnosed despite the rather low incidence (about 25 per 
100,000 nationwide; around 50 per 100,000 in big cities) compared 
to western countries [4]. 
In most countries, incidence rates increased over the past decade. 
The continuing existence of some of the risk factors, age at 
menarche, age at first childbirth, number of children and the 
proportion of nulliparous women have all changed in an adverse 
way and have probably a negative impact on the increasing trend of 
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breast cancer incidence [5]. On the other hand, substantial 
improvements in survival has been achieved with the 5 year age­
adjusted relative survival of breast cancer patients increased from 
74% to 83% in European countries from 1988 to 1999 [6]. The 
improvement of survival was attributed to the improved treatment 
such as the application of tamoxifen in postmenopausal patients and 
chemotherapy in premenopausal patients. The rising breast cancer 
incidence and survival are both partly influenced by the presence of 
organised breast screening programmes or opportunistic screening 
through increased detection of smaller and less aggressive tumours 
resulting in a decreasing mortality after 5-8 years. 
As a consequence of increasing incidence and improvement of 
survival, breast cancer is now recognised as a chronic disease that 
can recur even after 20-30 years and that will put an increasing 
burden on follow-up oncology clinics as most of patients with a 
history of breast cancer need follow-up care after primary treatment. 
Goals of follow-up after a diagnosis of breast cancer 
Regular follow-up surveillance after a diagnosis of breast cancer 
should aim to achieve 4 principal objectives: 
1. To provide patients with support and counselling 
Breast cancer survivors can experience a variety of physical and 
psychological symptoms during their follow-up. Certain types of early 
symptoms, such as soft-tissue swelling, hematomas, seromas of the 
breast area, and numbness or stiffness of the upper arm, are 
attributable to surgery. Later symptoms may be due to surgery (e.g., 
postmastectomy syndrome); to irradiation (e.g., erythema, swelling, 
tenderness and skin edema); to lymphedema; or to menopausal 
symptoms associated with tamoxifen and induced by ovarian 
ablation or chemotherapy. Quality of life decreased initially but 
improved over time. Psychosocial problems are most pronounced 3 
during the first year after breast cancer diagnosis [7] whereas long­
term psychosocial adjustment is generally excellent. Although most 
women adjust well over time, younger women are especially 
vulnerable and at risk for ongoing psychological distress and social 
disruption after breast cancer treatments [8]. It is through follow-up 
visits that physical and psychological issues can be discussed, and 
treatment and reassurance can be provided, as required. 
2. To detect potentially curable conditions such as local recurrence 
and contra-lateral breast cancer. 
One of the main purposes of follow-up is the earliest possible 
diagnosis of a relapse with a view to applying curative second line 
treatment for patients who had early stage primary breast cancer. 
Women with a history of breast cancer have an increased risk of 
local regional recurrence and contra lateral breast cancer which 
would worsen their prognosis. Additionally, local recurrence and 
contra-lateral breast cancer are the only relapses that might be 
detected at routine follow-up and that are potentially curable. Local­
regional recurrence is defined as a recurrence of breast cancer in 
the same breast or chest wall or regional lymph node area, including 
supraclavicular lymph node involvement. The rate of local 
recurrence at 20 years of follow-up has been reported to be between 
8.8% [9] and 14.3% [1 O]. Breast cancer patients after mastectomy 
lived with a risk of local recurrence in the chest wall [9]. Because 
many women choose breast conservation treatment as their initial 
management, the magnitude of the problem of local recurrence is 
substantial. Local recurrence was considered as a strong 
independent predictor of the risk of developing distant metastatic 
disease [11]. Among patients with a local recurrence at or near the 
original tumour site a better distant disease-free survival was 
observed for patients with recurrences measuring 1 cm or less, 
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compared to those with larger recurrences [12]. This suggests, 
though does not prove, that early detection of local recurrence can 
improve the treatment outcome. 
Contra-lateral breast cancers are defined as new cancers in the 
opposite breast. Contra-lateral breast cancer is the most frequent 
second cancer reported after primary breast cancer, comprising 
between 30 and 50% of all second cancers [13, 15]. It is estimated 
that women who have had breast cancer are at 2 to 6 times greater 
risk of a new primary cancer in the contra-lateral breast than are 
women who have not had breast cancer and the cumulative risk 
increased with 0.4% per year [12-14]. Patients who developed CBC 
were found to be at increased risk of disease recurrence and death 
[16, 17]. Meta-chronous CBC stage 11 or higher was associated with 
worsened survival [14]. As with earlier diagnosis of first tumours, the 
early detection of MCBC was associated with an 81 % reduction in 
risk of breast cancer death in the SEER database [18] that 
addressed the post-treatment follow-up screening. The follow-up 
visits aim to detect local recurrence and contra-lateral breast cancer 
at an early stage and improve the survival of patients with a history 
of breast cancer. 
3. To provide care for patients in whom distant metastasis develops 
Distant recurrence means the cancer is metastatic and incurable so 
treatments are designed to improve and lengthen life. Breast cancer 
patients have a high risk of distant metastasis and death with 10-
year cumulative rate of more than 30% [19,20]. The most common 
sites of metastases for rest cancer include the liver, lungs, bone and 
brain. Randomized controlled trials [21-22] had shown that early 
detection of distant metastases by intensive tests does not improve 
survival. Patients are encouraged to report new, persistent 
symptoms promptly, without waiting for the next scheduled 
appointment. The sufficient surveillance of the needs and concerns 
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of patients developing distant metastasis and their family will 
contribute to providing appropriate palliative care to patients and 
timely help to their family as well. Patients must be seen frequently 
enough to provide best possible palliation of symptoms and quality 
of life [23]. 
4. To monitor outcome 
Cancer specialists recognize that monitoring patient outcomes, such 
as suNival, morbidity and quality of life, is an important aspect of 
determining the effectiveness of treatment. In order to compare 
treatment outcomes with national and international standards, such 
information must be collected systematically, completely and in a 
format that allows for regular analysis. 
Follow up tests 
Clinical guidelines all recommend history taking, physical 
examination and mammography though with some variation in terms 
of frequency of visits. 
Follow-up tests to early detect distant metastases 
Follow-up test to early detect distant metastases are: blood counts, 
chemistry, chest X-ray, bone scan, liver ultrasound, CT scans of 
chest and abdomen and any tumour markers such as CA 15-3 or 
CEA. All guidelines endorse a less intensive clinical follow-up 
excluding distant metastasis related tests in the absence of 
evidence that early treatment of metastatic disease will prolong life. 
One should avoid the inconvenience and expense of carrying out 
routine tests to detect it. In GIVIO trial, 655 patients who were 
randomly assigned to receive intensive suNeillance consisting of 
physician visits, bone scanning, liver echographic examination, 
chest radiography and laboratory tests had an almost identical 6-6 
year survival and health-related quality of life to that of a control 
group of 665 women who received only tests that were clinically 
indicated [21]. Both groups had annual mammographic examination 
of the contra-lateral breast. Another randomized trial reported that 
chest radiographs and bone scans obtained every 6 months had no 
influence on mortality at 5 years [22,25]. Scientific evidence does 
not support the routine use of any other instrumental or laboratory 
test aiming to detection of distant metastasis [26]. 
Physical examination 
Physical examination is valued highly and recommended during the 
follow up visits by all guidelines. The guidelines have in common the 
fact that emphasis is placed on providing frequent clinical 
examination in the first 3-5 years after diagnosis aiming to check the 
influence of treatment in the initial years after primary treatment 
besides to early detect recurrences. In the long term follow-up, the 
main aim of physical examination is to early detect curable 
recurrences. It is still uncertain whether physical examination 
contributes to the early detection of loco-regional recurrences and 
contra-lateral breast cancer. In literature published after 2000, 15% 
of the treatable recurrences were detected by physical examination 
and there is no evidence to suggest that physical examination 
confers a survival advantage compared with other methods of 
detection [24]. Other study suggests that women may receive 
different amounts of benefit from having physical examination 
included in a mammography screening program, depending upon 
their age and breast density in screening first breast cancer [27]. 
The contribution of routine physical examination might be related to 
patients' age and previous surgical treatment during follow-up after 
primary treatment of breast cancer. The influence of age on the 
potential added contribution of physical examination to treatable 
relapse detection over mammography alone deserves further 
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investigation. 
Routine surveillance mammography 
Routine suNeillance mammography is recommended in following up 
breast cancer patients with the goal in mind to early detect ipsi­
lateral recurrences after breast conseNing surgery and detection of 
meta-chronous contra-lateral breast cancers. Numerous randomized 
trials and population-based screening evaluation have clearly shown 
that early detection of breast cancer through mammography greatly 
improves treatment options, the chances for successful treatment 
and suNival [28-31]. There is no randomized control trial of post­
treatment suNeillance mammography for women with a history of 
breast cancer have been published, and debates remains about the 
benefit of post-treatment suNeillance mammography on prognosis 
of breast cancer patients. The findings of obseNational studies 
indicate that the contribution of mammography appears to be 
important in both the conseNed breast and the contra-lateral breast 
regarding to early detection of loco-regional recurrence and contra­
lateral breast cancer [32,33]. With routine follow-up mammography, 
more early stage contra-lateral cancers can be diagnosed than with 
palpation only [24,34 ]. However the suNival benefit of loco-regional 
recurrences and diagnosing meta-chronous contra-lateral breast 
cancer by mammography has not been well studied yet. 
Current guidelines 
Currently there is no consensus on the optional approach to follow 
up breast cancer patients including frequency and examination 
modality. Several international practice guidelines (ANAES 2000, 
ASCO 1999, Australasian 1997, BCCA 2001, Canadian Med As 
1998, ESMO 2001, ICSI 2003, Malaysian MOH 2002, Mauriac 2003, 
NCCN 2004, NHMRC 2001, NHMRC 2003, NICE 2002, SIGN 1998, 
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Temple 1999) all recommend that breast cancer survivors receive 
routine follow up care [26]. Follow-up protocols vary widely-both 
within and between countries-and are not always evidence based. 
In the Netherlands, guidelines regarding follow-up are developed 
by Dutch Institute for Healthcare Improvement (Kwaliteitsinstituut 
voor de Gezondheidszorg CBO) and the National Breast Cancer 
Group (Nationaal Borstkanker Overleg Nederland NASON). The 
CBO and NASON guidelines (2002; the version use at the time of 
this study started) regarding follow up consist of follow up visits 
( including history taking and physical examination) every third 
month during the first year, every sixth month during the second 
year and thereafter every year. Mammography is recommended 
once a year for patients younger than 60, once in two years for 
patients from age at 60. For women over 75, the follow-up can be 
stopped. In 2008, four new follow-up strategies were proposed. The 
frequency and procedures for follow-up are same as the 2000 
version in the first two years. Differentiated follow-up strategies were 
formulated with taking into account patients' age, previous surgical 
methods and time after primary treatment. The underlying 
healthcare problem is that these guidelines for follow-up are not 
evidence-based regarding the trade-off between effectiveness, costs 
and patients' attitude. The further information on the performance of 
routine follow-up and the determinants need to be investigated. 
In China there is no national recommended guideline for follow-up 
of breast cancer patients. The recommended guidelines for follow-up 
in the Tianjin Medical University Cancer Institute and Hospital 
included visits every 3 months during the first 2 years, visits every 6 
months during the third to fifth year, and annual visits thereafter. The 
follow-up tests included physical examination every time and other 
tests based on doctor's recommendations such as chest X-ray, CT, 
and mammography. Patients were encouraged to report new 
symptoms promptly without waiting for the next scheduled 
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appointment. There were no recommendations regarding regular 
mammography in follow-up. 
This thesis will provide data to evaluate the performance of follow­
up in practice by analysis of follow-up database of breast cancer 
patients from four hospitals in the north of the Netherlands. 
Objectives and thesis outline 
The aim of this thesis is to describe the current follow-up care after a 
diagnosis of early breast cancer, to evaluate current strategies to 
early detect localized recurrences of breast cancer, and to propose a 
cost-effective strategy to early detect localized recurrences of breast 
cancer. 
The follow up program can extend survival when two assumptions 
are made: (1) most recurrences are detected at an early stage (i.e. 
are without symptoms at diagnosis) during the surveillance visits 
and (2) the early treatment of recurrences leads to better survival. A 
previous systematic review showed the effectiveness of routine 
follow-up after treatment for primary breast cancer that about 40% of 
recurrences were asymptomatic at diagnosis [35]. Subsequently, 
available evidence on the impact on survival of early detection of 
loco-regional recurrences and contra-lateral breast cancer were 
searched and reviewed in Chapter 2. The hypothesis is that 
detection of isolated breast cancer recurrences in patients without 
symptoms has beneficial impact on survival of breast cancer 
patients when compared to late symptomatic detection. 
Long term follow-up information of women with a history of breast 
cancer was extracted from four hospitals in the north of The 
Netherlands. To define the optimum approach to follow-up care, we 
have to understand what is happening in the real world in terms of 
the extent to which breast cancer survivors are engaged in 
surveillance testing. Under-utilization and over-utilization were 
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reported in a few studies which were based on either self-report of 
patients or Medicare documents within 5 years follow-up time after 
primary treatment [36,37]. In Chapter 3, the utilization was evaluated 
of both recommended follow up surveillance tests (including physical 
examination and mammography) and non-recommended distant 
metastasis related tests up to 10 years after primary treatment. Such 
patterns of utilization of follow-up surveillance testing are particularly 
valuable for identifying subgroups of women who may receiving less 
than recommended care so that more attention could be paid in 
practice and intervention studies to improve care can targeted at 
those subgroup. 
Despite of the relative low incidence of breast cancer, the number of 
women with a history of breast cancer remains rather high in China, 
due to the big population. The clinical characteristics and prognosis 
were worth being evaluated in China. In Chapter 4, a retrospective 
study was conducted to determine the patients and tumour features, 
survival rate, relapse and follow up practice in Chinese breast 
cancer patients. 
The contribution of post-treatment surveillance mammography 
and clinical breast examination was assessed in Chapters 5 and 6. 
Chapter 5 describes the contribution of mammography on early 
detecting contra-lateral breast cancer and the impact on survival of 
breast cancer patients. We evaluate the diagnostic value of annually 
surveillance mammography and the benefit on survival of patient 
with MCBC detected by mammography alone. In addition, the 
compliance with yearly mammography was evaluated in patients 
with MCBC and its potential impact on diagnostic performance of 
mammography and survival of patients with MCBC was assessed. 
Physical examination was considered as an important complement 
to mammography in detecting curable conditions especially in 
detecting loco-regional recurrences in patient after mastectomy. In 
Chapter 6 the contribution of physical examination in addition to 
1 1  
mammography in the early diagnosis of breast cancer recurrences 
was evaluated and the influence of patient's age, previous treatment 
and the time since primary diagnosis was assessed. A pilot analysis 
regarding to the workload of physical examination was carried out 
with the calculation of the number of physical examination 
performed for one additional loco-regional recurrences detected by 
physical examination alone. 
To compare the cost-effectiveness of four proposed follow-up 
strategies we performed a model simulation. The optimal design to 
compare different follow-up strategies is a randomised trial which is 
quite time-consuming and costly. Alternatively, in the absence of 
adequate clinical trial data on follow up strategies, micro-simulation 
modelling can be used to integrate available data, to evaluate follow­
up strategies and to provide guidance on the costs and benefits 
required for different strategies in the years prior to the publication of 
long-term results from randomized trials. In Chapter 7, results of a 
model-based study are presented. 
Finally, in Chapter 8, the findings in previous chapters are 
summarized and discussed and will provide recommendations for 
follow up of breast cancer patients and related research in the area 
of health care of breast cancer survivors. Perspectives will be 
discussed on the topic of screening of breast cancer and follow-up 
care of Chinese women with a history of breast cancer. 1 2  
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Chapter 2 
Impact on survival of early detection of isolated 
breast recurrences after the primary treatment for 
breast cancer: a meta-analysis 16  Wenli Lu Liesbeth Jansen Wendy J Post J Bonnema Cornelis J Van de Velde Geertruida H. De Bock Breast Cancer Res Treat 2009;1 14:403-12. 
ABSTRACT 
Purpose: The purpose was to establish the impact on survival of 
early detection of a local recurrence of breast cancer as compared 
to late detection. 
Design: A meta-analysis was carried out using Cochrane review 
manager software (RevMan version 4.2). Studies were included if 
women were treated for primary breast cancer without evidence of 
distant metastasis at primary diagnosis and if these concerned 
routine follow-up strategies focusing on the early detection of 
curable recurrences. Data regarding the risk for death were derived 
from each study. Multi level models were used to study 
heterogeneity by using MLWin. 
Results: Thirteen studies concerning 2,263 patients were included. 
Early detection of breast cancer recurrences during follow-up gave a 
significantly better survival as compared to late detected 
recurrences (HR: 1 .68 (95% Cl: 1 .48 to 1 .9 1  )). Survival was better 
when the recurrence was found by mammography instead of 
physical examination or in patients without symptoms as compared 
to those with symptoms (HR: 2.44 (95% Cl: 1 .  78-3.35); HR: 1 .56 
(95% Cl: 1 .36-1 .79), respectively). If all breast cancer recurrences 
would be detected earlier, that 5-8 deaths (i.e. an absolute reduction 
in mortality of 1 7-28%) would be avoided by performing routine 
follow-up during a 1 0  year-period for 1 ,000 breast cancer patients. 
Conclusion: These data support the hypothesis that detection of 
isolated loco-regional or contra-lateral breast cancer recurrences in 
patients without symptoms has beneficial impact on survival of 
breast cancer patients when compared to late symptomatic 
detection. 




Screening for breast cancer has resulted in increasing numbers of 
patients diagnosed with early breast cancer. The combined effect of 
early diagnosis and improved treatment for breast cancer has led to 
a significant decrease in breast cancer-related mortality. As a 
consequence, the prevalence of breast cancer survivors rises. After 
curative treatment for breast cancer it is common practice to enter 
patients in a surveillance program for many years. There will be 
more breast cancer survivors followed by more need for long-term 
surveillance [1]. At the same time, there is an increasing pressure on 
breast services from new referrals and urgent cases [2]. It is 
predicted that there will be a 48% increased need for cancer 
services by 2020. This puts an increasing burden on follow-up 
oncology clinics [3]. There is a need to quantify the benefits of 
follow-up to organise the follow-up more efficiently. 
One of the important goals of surveillance is improvement of 
survival. The surveillance program can extend survival when two 
assumptions are made: (1) most recurrences are detected at an 
early stage (i.e. are without symptoms at diagnosis) during the 
surveillance visits and (2) the early treatment of recurrences leads to 
better survival [4]. About 40% of loco-regional recurrences were 
asymptomatic at diagnosis in an earlier systemic review and meta­
analysis that involved 5,045 patients and 378 isolated loco-regional 
recurrences [5]. The risk of breast carcinoma-related death is 
increased for patients with a local recurrence compared to those 
without local recurrence [6,7]. Still, the effect of early detection of 
curable recurrence on overall survival remains questionable and 
controversy remains on the benefits of regular follow-up [8]. The aim 
of this study is to perform a meta-analysis of the impact of early 





Pubmed Medline, Cancerlit, Cochrane, Web of sciences and 
Embase were searched for relevant studies. Studies in any 
language were examined published between 1966 and 2006. MESH 
words used were "Breast Neoplasms", "Follow-Up Studies", 
"Mammography", "Physical Examination" and "Survival". Title and 
abstract were searched for the words: "breast cancer'', "follow-up", 
"detection", "survival" and "recurrence". Reference lists and reviews 
were searched by hand. 
Selection of papers 
Studies were included in the meta-analysis when they met the 
following inclusion criteria. Target population: Studies were included 
if women were treated for primary breast cancer without evidence of 
distant metastasis at primary diagnosis. Follow-up: Studies were 
included if they concerned routine follow-up strategies or tests 
focusing on the early detection of curable recurrence (loco-regional 
recurrence and contra-lateral recurrence). Contrast: Studies were 
included if they focused on comparing early detection (recurrences 
without symptoms) versus late detection (recurrences with 
symptoms). Outcome: Studies were included when they presented 
survival data. Data presentation: Studies were included when they 
presented hazard ratios expressing the risk of death or when they 
presented information for calculating these hazard ratios (number of 
deaths and exact p-values). 
Two researchers (GHdeB and LWL) independently examined 
titles (n=1369) and abstracts (n=413) to decide if the full text articles 
should be obtained. Cases of disagreement were resolved by 
discussing the titles and abstracts (n=14). Six studies fulfilled the 
inclusion criteria regarding follow-up, contrast and outcome, but did 
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not present hazard ratios or information for calculating these hazard 
ratios. For two of these six studies, the number of deaths among the 
patients with recurrences was not available [9, 1 O]. For two studies, 
no (exact) p-value was available [11, 12]. For two studies, the 
number of deaths among the patients with recurrences was not 
available, nor the (exact) p-value was available [13,14]. As a 
consequence 13 of 68 full-text articles that were examined could be 
included in the analysis. For an overview of studies included in the 
analysis, see Table 1. 
Data extraction and definition 
Data were extracted independently by the two researchers (GHdeB 
and LWL), by means of a predefined form. For an overview of the 
topics, see Table 1. Loco-regional recurrences were defined as the 
presence of cancer in the breast or axilla on the same side. Contra­
lateral recurrences were defined as cancer in the other breast after 
the primary treatment of the first breast cancer. Distant metastases 
were defined as the evidence of breast cancer in any part of the 
body except breast and axilla. It was registered whether follow-up 
time was measured from the time of primary treatment or from the 
time of recurrence. A follow-up scheme was considered as standard 
when patients received regular mammography with or without 
physical examination. A follow-up scheme was considered as 
intensive when patients received additional blood tests and bone 
scans regularly and independent of symptoms. A recurrence was 
considered as being detected early when it was mammographically 
detected during a routine clinic visit in a patient without symptoms. A 
recurrence was considered as being detected late when it was 
detected by patient themselves. 
Assessment of methodological quality and publication bias 
Methodological quality was assessed independently by the 
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investigators (GHdeB and LWL) by means of a predefined form. 
Because there is no generally accepted standard for measuring 
methodological quality in prognostic studies, this form was derived 
from the work of Altman and Laupacis and is presented in Table 3 
[ 1 5, 16]. A score six or of higher was considered as a high quality 
score. The cut-off point was based on the median. 
To investigate publication bias, in Figure 1 studies are presented 
based on sample size to get an impression of a potential relationship 
between sample size and effect size. To quantify this relation, 
Kendall's tau coefficient was calculated [ 1 7]. To estimate whether 
publication bias is likely to be a problem in this meta-analysis, the 
fail-safe number was assessed to calculate how many studies are 
needed to counterbalance the results [ 1 8]. 
Statistical analysis 
The main outcome in this analysis was the hazard ratio (HR) and its 
standard error (SE). If these data were not directly available, these 
were estimated based on the total number of events in both groups 
and the two-sided p-value by using the method described by Parmar 
[ 1 9]. Based on the SE, 95% confidence intervals (Cls) were 
calculated. HRs were directly presented in only one study [20]. 
In the next step, HRs were combined by using Review Manager 
Version 4.2. By using the Generic Inverse Variance method, logHRs 
and SErs were entered. The pooled result was expressed as 
combined HRs with fixed effects with a 95% Cl , and an overall test 
on heterogeneity was performed using the Chi-square test. Despite 
non significant results, we still explored heterogeneity because of 
the small number of studies. The following potential sources of 
heterogeneity were explored: the type of recurrences considered, 
the starting point for computation of follow-up time, type of follow-up 
scheme, comparisons made, quality score, and type of outcome. For 
each potential source of heterogeneity, a multilevel model was 
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developed with the logHR as dependent variable and the source of 
heterogeneity as well as the SE as independent variables. To 
quantify the theoretical extent of survival improvement, if the loco­
regional or contra-lateral recurrence would be early detected, the 
population attributable risk was calculated [21 ]. 
Results 
Study characteristics 
In the analysis, 2263 patients from 1 3  studies were included having 
724 loco-regional recurrences, 627 contra-lateral recurrences, 459 
distant metastases, 30 loco-regional recurrences with distant 
metastases combined and 423 not specified recurrences (see Table 
1 ). Fifty-eight percent (1 223) of these patients had a recurrence 
detected early and 42% were with late detection. The included 
studies were comparable regarding the distribution of age, primary 
tumour stage and primary surgical treatment. In the majority of 
studies, the time of follow-up was measured from date of primary 
diagnosis (n=1 0; 77 %). In seven studies (54%) patients were 
offered routine follow-up, including regular mammography and 
physical examination, and in six studies patients were offered 
intensive follow-up including routine additional tests. Seven studies 
(54%) focused on patients diagnosed with recurrences without 
symptoms as compared to patients diagnosed with recurrences with 
symptoms. One study focused on recurrences found during routine 
follow-up or outside routine follow-up. Five studies focused on 
recurrences diagnosed by mammography or symptoms. Eleven 
studies had death as primary outcome, and two studies had a mixed 
outcome (death of distant metastases). 
Quality score and publication bias 
Seven studies had a quality score of 5 or lower (Table 3). There 
were no indications of publication bias because increasing sample 
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size was not related to increasing effect size (Kendall's tau 
coefficient: -0.194 (P=0.36)). The fail-safe number was 210, which 
means 210 contrary studies would need to be included to 
counterbalance the result in this meta-analysis at a significance level 
0.05. 
Survival 
Overall, survival was significantly better with early detection of the 
recurrence (HR: 1.68 (95% Cl: 1.48 to 1.91, p<0.0001; see Figure 1 ). 
In all 13 studies, the HR showed a trend for better survival with early 
detection, but five out of the 13 included studies presented no 
significant result {Table 2). There was no significant heterogeneity 
among the studies (Chi-square=13.12, p=0.37; Figure 1 ) .  
The chance of benefit of early detection was statistically 
significant higher in the studies that presented the data regarding 
loco-regional recurrence and contra-lateral recurrence separately 
from distant metastases (HR: 2.55 (95% Cl: 1.76-3.70) as compared 
to the studies that did not (HR: 1.59 (95% Cl: 1.38-1.82; p= .02); see 
Table 4 ). When analyzing the studies that calculated follow-up time 
from the date of primary treatment separately from the studies that 
calculated follow-up time from the date of recurrences, we observed 
that the HR for the studies excluding lead-time bias were 
comparable for the studies that calculated time to follow-up from the 
date of recurrence. (HR: 1.64 (95% Cl: 1.41-1.91 ), HR: 1. 77 (95% Cl: 
1.39-2.25), respectively). Studies focusing on the impact of an 
intensive regimen for follow-up gave a HR for survival comparable to 
studies focusing on a standard regimen for follow-up (HR: 1.56 (95% 
Cl: 1.33-1.83), HR: 1.92 (95% Cl: 1.55-2.38), respectively; p=0.12). 
Recurrences assessed in patients without symptoms were related to 
a higher probability of survival than when symptoms were present 
(HR: 1.56 (95% Cl: 1.36-1.79)). Survival was better in studies where 
recurrences were found by mammography instead of studies where 
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recurrences were being assessed clinically (HR: 2.44 (95% Cl: 1.78-
3.35)). This advantage is significantly higher for studies 
mammographically assessed than for tumours clinically assessed 
(p=0.01 ). Studies with a higher quality score were not related to a 
different HR than studies with a lower quality score (HR: 1. 73 (95% 
Cl: 1.45-2.06) ,  HR: 1.81 (95% Cl: 1.45-2.27) , respectively; p=0.61 ). 
Studies focusing on death or distant metastases had a non­
significant higher HR for survival than studies focussing on death 
only (HR: 2.20 (95% Cl: 1.37-3.54) ,  HR: 1.64 (95% Cl: 1.44-1.88), 
respectively; p=0.24 ). 
Absolute effects 
There would be an absolute reduction in mortality of 17-28% of 
breast cancer patients with recurrences, if all recurrences would be 
early detected, given the pooled HR of 1.68 (95% Cl: 1.48 to 1.91) 
and the proportion of the early detected recurrences (40%) [5]. 
Given the fact that nowadays nearly all patients in Western countries 
are in follow-up, the incidence of recurrence (10%) during a 10 year­
period and the survival rate at 10 years (70%) of breast cancer 
patients with recurrence [22], 5-8 deaths would be avoided by 
performing routine follow-up during a 10 year-period for 1,000 breast 
cancer patients. 
Discussion 
This meta-analysis shows that early detection of isolated 
recurrences in patients without symptoms by routine follow-up or 
mammography improves survival of patients with breast cancer 
recurrences (HR=1.68; 95% Cl: 1.48 to 1.91 ). Given the proportion 
of early detected loco-regional recurrences is 40%, there would be 
an absolute reduction in mortality of 17-28% of breast cancer 
patients with recurrences, if all loco-regional recurrences would be 
detected early. Individual studies have been inconclusive in 
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answering the question whether early detection of breast cancer 
recurrences is related to longer life. Five studies included did not 
show a significant difference in improving survival between early 
detection versus late detection of loco-regional recurrence [23-27]. 
One explanation might be that these studies had too small sample 
sizes. The meta-analysis allowed us to include the observations of 
more than 2000 patients, and yields a far more precise estimate of 
the effect on survival of early detection of loco-regional or contra­
lateral breast cancer recurrences. 
A topic of debate in follow-up of breast cancer is the role of 
mammography and physical examination. Several studies 
concluded that the early detection of local disease recurrence 
require both clinical examination and mammography [28-30]. One 
study reported that the tumour size of local recurrences detected by 
mammography alone were smaller than those detected by physical 
examination [29]. Several studies [20, 31, 32] suggested that breast 
cancer patients who received regular mammograms were less likely 
to die than breast cancer patients who did not, and that recurrences 
found by mammography are associated with a better survival [33,34]. 
A similar effect was seen in this meta-analysis. Our findings 
suggested that survival is better when the recurrence is found by 
mammography instead of physical examination (HR: 2.44 (95% Cl: 
1. 78-3.35)). There were insufficient data to study the contribution of 
yearly mammogram as compared to 6 month mammogram. In this 
meta-analysis, late detected recurrences included those recurrences 
detected by breast self-examination or by symptoms. Recurrences 
assessed in patients without symptoms are also related to a higher 
probability of survival than when symptoms are present (HR: 1 .56 
(95% Cl: 1.36-1. 79)). This advantage is higher for tumours assessed 
by mammography (p=0.01 ). These findings indicate that the actual 
survival benefit of early detection of a local recurrence by 
mammography may be higher than the pooled overall data reported 
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in this meta-analysis. In the absence of related studies, the 
contribution of breast self-examination is not clear. According to the 
favorable effect size of early detection of curable recurrence by 
mammography, the result is in line with ASCO guideline that women 
should be made aware that monthly BSE does not replace 
mammography as a breast cancer screening tool to early detect 
isolated breast recurrences after a primary treatment for breast 
cancer [35]. 
In this meta-analysis, some studies were included that did not 
present data for loco-regional recurrence and contra-lateral 
recurrence separately from distant metastases, although the primary 
focus was loco-regional recurrence or contra-lateral recurrence [8, 
24-26, 36, 37]. We found that the chance of benefit of early 
detection is significantly higher in the studies that presented the data 
regarding loco-regional recurrence and contra-lateral recurrence 
separately from distant metastases (HR: 2.55 (95% Cl: 1. 76-3. 70) 
as compared to the studies that did not (HR: 1.59 (95% Cl :  1.38-
1.82; p=0.02)). The combined HR was attenuated in the studies 
which included distant metastasis because the early detection of 
distant metastasis unlikely had benefit on survival [38, 39].These 
findings may indicate that the actual survival benefit of early 
detection of a local recurrence is even higher than found in this 
meta-analysis. 
There was no statistically significant difference in HR for survival 
between studies in this meta-analysis that used an intensive 
regimen compared to a standard regimen for follow-up (HR: 1.92 
(95% Cl: 1.55-2.38; HR: 1.56 (95% Cl: 1.33-1.83), respectively). 
This is in line with previous publications in which it is found that 
intensive follow-up schemes focusing on the early detection of 
distant metastases does not improve the chances of survival [38,39]. 
Lead time bias may have influenced the outcome of an analysis 26 
like we did [37,40]. Lead time bias means that patients with disease 
detected by early diagnosis survive longer than those whose 
disease is detected on the occurrence of new signs or symptoms, 
even when treatment is without effect. When analyzing the ten 
studies that calculated follow-up time from the date of primary 
treatment separately from the three studies that calculated follow-up 
time from the date of recurrences we observed that the HR for the 
studies excluding lead-time bias is comparable with the HR for the 
studies that calculated time to follow-up from the date of recurrence. 
(HR: 1.64 (95% Cl: 1.41-1.91), HR: 1.77 (95% Cl: 1.39-2.25, 
respectively). Studies focusing on death or distant metastases had a 
non-significant higher HR for survival than studies focussing on 
death only (HR: 2.20 (95% Cl: 1.37-3.54 ), HR: 1.64 (95% Cl: 1.44-
1.88), respectively; p=0.24 ). This means that in this analysis, the 
effect of lead-time bias does not explain the effect of early detection 
that we found. 
Studies with a higher quality score were not related to better 
outcome than studies with a lower quality score (HR: 1.73 (95% Cl: 
1.45-2.06), HR: 1.81 (95% Cl: 1.45-2.27), respectively; p=0.24). 
Identical benefits were presented in studies with high quality scores 
and studies with low quality scores. Increasing sample size was not 
related to increasing effects size (Kendall's tau coefficient: -0. 194 
(P=0.36)). The fail-safe number of 21 0 indicates that 210 contrary 
studies would be needed to counterbalance the result in this meta­
analysis at a significance level 0.05. So even if publication bias 
existed, it is not a problem that weakened the results of this meta­
analysis. 
A limitation of this meta-analysis is that all included studies were 
retrospective. The optimal design would be a clinical trial in which 
patients are randomized to follow-up versus no-follow-up. Such a 
study is not feasible for ethical and psychological reasons. Besides 
the early detection of recurrence, there are many other factors that 
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have impact on breast cancer patients' survival. Due to the 
incomplete information on some important prognostic factors like 
age of the women, tumour stages or surgical treatment, we were not 
able to analyze the impact of these factors on the survival related to 
early detection of recurrences. 
These data support the hypothesis that detection of breast cancer 
loco-regional or contra-lateral recurrences in asymptomatic patients 
during routine follow-up or assessed by mammography improves 
survival, when compared to late symptomatic detection and give an 
indication of the absolute effect. Further studies should focus on 
improvement of follow-up strategies aiming at early detection of 
loco-regional or contra-lateral recurrences and on cost-effectiveness 
of these strategies. 
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Table 1 Characteristics of the paeers that met the inclusion criteria 
Patients with primary 
Type of recurrence Starting point for Type of Type of Age of the women under Primary surgical treatment• 
Author 
breast cancer (N) 
(N) computation of follow- Follow-up Com(l3rison made Outcome study• 
Stage of primary tumour• (N) (N) u lime scheme 
pN0 ( 1 52/55) 
pTI ( 1 97/61)  
Ciano S,  - 339 CLR Pnmary treatment Standard Asympt vs. Sympt Death Mean(Rangc): pN+(40/3 I )  
2004/1990 54.7(30-90) pT2+ (39/40) 
pNx (42/19) 
pTx (4/8) 
Imoto s. 291.RR 
Agc<36yrs.o•5 Slage 1 (8) 
Total mastectomy (59) 
1998 
550 36DM Pnmary treatment lnleosivc Asympt vs. Sympt Death 50;;,Agc;;,36yrs:o-32 
Slage ll (37) 
Par11al mastectomy(6) 
Agc>36yrs:ll"28 Stage Ill (20) 
Kmdler M, 
1004 175 LRR+DM Pnmary treatment Intensive Asympt vs. Sympt Death 
1989 
Pmone MA, 104 LRR 408 98 OM Pnmary trclllmeol Intensive Asympt vs. Sympt Death 
2004 9 (LRR+DM) 
Mcan(Rangc): Modified 
Sucrer M, 40LR 




Primary treatment Intensive Asympt vs. Sympt Death 59(33-82) - Quadrantectom}{76 J 
Group Sympt Simple mastectom}{3) 
6 1 (30-80) 
Tc Bockhorst S, 68 1.RR Meao(SD): 
Slage I (12/14) Breast cooservauon (58181) 
2001 
- 1 8 1  OM+ Primary treatment Standard Asympt vs. Sympt Death 53(13)/54(13) Slage II (52194) Mastectomy (42189) 
21 (LRR+DM) Stage Ill (36/62) 
Radical mastectom}{ 1 23) 
Tomin R. 
1230 248 LRR+DM Recurrence Intensive Asympt vs. Sympt Death 
Modified radical masctomy ( I  05) 
1987 - Simple mastectom}{ 18) 
Surgical mental resecllon{2) 
Wag11111D lD, 
Sta&e I ( I I) 
1991 
- 13CLR+51DM Primary treatmenl Intensive Routine vs. interval Death - Stage II (45) 
Stagc lll(H) 
Doyle T. - 1 12 LRR Primary treatment Standard Mammo vs. Chruc ,� Death/OM Agc<40yrs:26 
2001 Age;;,4oyrs:67 
Hussain ST, 
354 331.RR Primary treatment Slandard Mammo vs. Clmic ,� Death 
Slage I (13/3) 
1995 - Stage II (15/2) 
Mean(SE) 
Kaas R, - 275 CLR Recurrence Standard Mammo vs. Clinic 'l'o Death (Recurrence): 
2001 52(13XLRJ 
58(13XCLRR) 
Agc<36yrs:ll"I I Stage ns c I I  J 
Orel SG, 
1636 72 LRR Pnmary treatmenl Standard Mammo vs. Clinic % Death S I ;;, Age;;, 36yrs:n--2 7 
Slage I (4 1 )  Salvage mastectomy (72} 
1993 Stage II (9) Agc>Sl yrs:11"34 Stage IV (3) 
Voogd AC, Mean(Range): 
Stage I( 150) 
7000 266 LRR Recurrence Standard Mammo vs. Cliruc ,. Death/OM Slllgc II ( 1 1 1 ) Breast conservation therapy (all) 
1999 45(16-81) Sta e lll (4) 
* Age of the women under study, stage of primary tumour and primary surgical treatment as presented in the study. 
% Clinically assessed implies by physical examination of based on symptoms. 29 
Table 2 Outcomes in the papers that met the inclusion criteria Number of death Number of death Log-rank Author Time of follow-up among early detected among late detected HR SE Qatients Qatients p-value Ciatto S, 1 -3 1  yrs -/234 -/1 05 0. 008 2. 0408 0. 730 1 2004/1990 Imoto S, Median: 878 days 14.57/306. 17.25/356. 0. 48 1. 2865 0. 3556 1 998 ( 1 96-1 806) Kindler M, 1 09/12 1 6.  54/546. 0. 2 1. 2652 0. 1696 1 989 Perrone MA, Median: 94.7 mnth 87/ 10 1  80/ 1 1 0  0. 001 1 .  6656 0. 1 549 2004 (9.7-1 98.3) Stierer M, Median:4 1 mnth 8/376. 26/566. 0. 1 105 1 .  7705 0. 3504 1 989 Te Boekhorst 0-1 6 yrs 1 53/1 70 8 1 /1 00 0. 0003 1 .  6599 0. 1 354 S, 200 1 Tomin R, 0-1 6  yrs 67/896. 143/1 596. 0. 0017 1 .  6010 0. 1 439 1987 Wagman LD, 5 yrs + 26/266. 24/386. 0. 009 2 .  1 505 0. 2879 199 1  Doyle T, 0-20 yrs 1 1/42 4/47 0.06 2. 6493 0. 5 172 200 1 Hussain ST, 0-1 l yrs 14/28 0/5 0.03 9. 5421 0. 7454 1 995 Kaas R, Median:82.5( 1 0-1 66) 5 1/ 166 1 6/ 109 0,0 1 5  3. 0320 0. 446 1 200 1 Orel SG, 0-1 3  yrs 6/38 2/34 0.28 2. 1 5 17  0. 7082 1 993 Voogd AC, 2-4 yrs 6 1 / 141  1 0/47 0.02 2. 088 1 0. 274 1  1 999 6. Estimated from survival curve 
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Table 3 Qual it� rating of included stud ies 
Ciatto Imoto Kindler Perrone Stierer Te Tomin Wagman Doyle Hussain .Kass Orel Voogd Boekhorst 
No. Item s s M MA M. s R LD T ST R SG AC 
2004 1 998 1 989 2004 1 989 200 1 1 987 1 99 1  200 1 1 995 200 1 1 993 1 999 
Is the population under study 
defined with inclusion and Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 
exclusion criteria? 
Were all patients with a diagnosis of 
2 breast cancer included (also those No Yes Yes Yes Yes No Yes No No Yes Yes Yes Yes 
without recurrences)? 
3 Were patients included within the Yes No No No No No No No No No No Yes No context of any clinical trial? 
4 Were the patients included from Yes No No No No No Yes No No No Yes Yes Yes more than one center or hospital? 
Are the main prognostic patient and 
5 disease characteristics presented (at Yes Yes No No No Yes No No No No No Yes Yes least: age at onset of primary 
diagnosis and stage of tumour)? 
Is the treatment for the first tumour 
6 specified (at least: primary surgical No Yes No No Yes Yes Yes No No No No Yes Yes 
treatment)? 
Is the time of follow-up long 
7 enough (mean or meadian 5 years or Yes No No Yes No Yes Yes Yes Yes Yes Yes Yes No 
more)? 
8 Is the loss during follow-up Yes No Yes Yes Yes Yes Yes No No Yes Yes Yes Yes specified? 
9 Is the follow-up scheme (including Yes Yes Yes Yes Yes Yes Yes Yes No Yes Yes No Yes mammography scheme) specified? 
1 0  Are the outcomes prospectively No No No No No No No No No No No No No assessed? 
Quality scores 7 5 4 5 5 6 7 3 2 5 6 8 7 
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Table 4 Comparison of HRs for six sources of heterogeneity 
Sources of hetero�enei!i'. 
[)'P!l of recurtel!ce 
Only loco-regional or contra-lateral recurrences 







Patient reported symptoms (no versus yes) 





Death or distant metastases 
Death 
* Assessed clinically, during interval or routine visit. 
** based on estimations of the multilevel model 
Number of studies Combined HR 95% CI 
6 2.55 1 .76-3.70 
7 1 .59 1 .38- 1 .82 
9 1 .64 1 .4 1 - 1 .9 1  
3 1 .77 1 .39-2.25 
7 1 .92 1 .55-2.38 
6 1 .56 1 .33-1 .83 
7 1 .56 1 .36- 1 .79 
6 2.44 1 .78 - 3 .35 
6 1 .73 1 .45-2.06 
7 1 .8 1  1 .45-2.27 
2 2.20 1 .37-3 .54 








Studies Ciatto S Kaas R Te Boekhorst S Voogd AC Tomin R Perrone MA Kindler M Stierer M Doyle T Orel SG Imoto S Wagman LD Hussain ST 
Total (95% Cl)  
log[Hazard Ratio] (SE) 
0 . 7 1 3 4 ( 0 . 7 3 0 1 )  
1 .  1 0  9 2  ( 0 . 4 4 6 1 )  
0 . 5 0 6 7  ( 0 . 1 3 5 4 )  
0 . 7 3 62 ( 0 . 2 7 4 1 ) 
0 . 4 7 0 6  ( 0 . 1 4 3 9 )  
0 . 5 1 0 2  ( 0 . 1 5 4 9 )  
0 . 2 3 5 2  ( 0 . 1 6 9 6 )  
0 . 5 7 1 2  ( 0 . 3 5 0 4 ) 
0 . 97 4 3  ( 0 . 5 1 7 2 )  
0 . 7 6 6 3  ( 0 . 7 0 8 2 )  
0 . 2 5 1 9  ( 0 . 3 5 5 6 )  
0 . 7 6 57  ( 0 . 2 8 7 9 )  
2 . 2 5 5 7  ( 0 . 7 4 5 4 ) 




Test for heterogeneity: Chi square= 1 3.02, df = 1 2  (P = 0.37), 
Test for overall effect: Z = 7.93 (P < 0.00001 )  
0. 1 0.2 0.5 2 
► 
5 10 
Late detected Early detected 
Hazard Ratio (fixed) Sample 
95% CI Size 
2 . 0 4 [ 0 . 4 9 ,  8 . 5 4 ]  3 3 9  
3 . 0 3 [ 1 . 2 6 ,  7 . 2 7 ] 2 7 5  
1 . 6 6 [ 1 . 2 7 ,  2 . 1 6 ]  2 7 0  
2 . 0 9  [ 1 . 2 2 ,  3 . 5 7 ]  2 6 6  
1 . 6 0 [ 1 . 2 1 ,  2 . 1 2 ]  2 4 8  
1 .  6 7  [ 1 . 2 3 ,  2 . 2 6 ] 
1 .  2 7  [ 0 . 9 1 ,  1 . 7 6 ] 2 i :\z 5  
1 .  7 7  [ 0 . 8 9 ,  3 . 5 2 ]  1 3 3  
2 . 65 [ 0 . 9 6 ,  7 . 3 0 ]  1 1 2  
2 . 1 5 [ 0 . 5 4 ,  8 . 62 ]  7 2  
1 . 2 9  [ 0 . 6 4 ,  2 . 5 8 ]  6 5  
2 . 1 5 [ 1 . 2 2 ,  3 . 7 8 ]  6 4  
9 . 5 4 [ 2 . 2 1 ,  4 1 . 1 3 ]  3 3  
1 . 68 [ 1 . 4 8 ,  1 . 9 1 ]  
Comparison: Early detected recurrences versus late detected recurrences 
Figure 1 :  Impact on survival of early detection of recurrences after the primary treatment for breast cancer 
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ABSTRACT 
Background: After primary treatment for breast cancer, patients are 
recommended to use hospital follow-up care routinely. Long-term data on 
the utilization of this follow-up care are relatively rare. 
Methods: Information regarding the utilization of routine hospital follow-up 
care was retrieved from hospital documents of 662 patients treated for 
breast cancer. Utilization of hospital follow-up care was defined as the use of 
follow-up care according to the guidelines in that period of time. 
Determinants of hospital follow up care were evaluated with multivariate 
analysis by generalized estimating equations (GEE). 
Results: The median follow-up time was 9.0 (0.3-18.1) years. At fifth and 
tenth year after diagnosis, 16.1 % and 33.5% of the patients had less follow­
up visits than recommended in the national guideline, and 33.1 % and 40.4% 
had less frequent mammography than recommended. Less frequent 
mammography was found in older patients (age> 70; OR: 2.10; 95%CI: 1.62-
2. 74 ), patients with comorbidity (OR: 1.26; 95%CI: 1.05-1.52) and patients 
using hormonal therapy (OR: 1.51; 95%CI: 1.01-2.25). 
Conclusions: Most patients with a history of breast cancer use hospital 
follow-up care according to the guidelines. In older patients, patients with 
comorbidity and patients receiving hormonal therapy yearly mammography 
is performed much less than recommended. 
Key words: Breast neoplasm; Utilization; Follow-up; Mammography 
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Background 
Breast cancer is the commonest incident form of malignancy among women 
in Europe [1]. Advances in the early diagnosis and treatment of breast 
cancer increase the number of breast cancer survivors [2]. Nowadays, it is 
estimated that more than 80% of the patients with a history of breast cancer 
will survive longer than 5 years and more than 60% of these patients will 
survive longer than 10 years [3,4]. After primary treatment, these patients 
are offered routine hospital follow-up. One of the main aims is to early detect 
loco-regional recurrences and second primary tumours. Approximately 40% 
of the isolated loco-regional recurrences are diagnosed during routine visits 
and routine tests in asymptomatic patients treated for early-stage invasive 
breast cancer [5]. In a recently published meta-analysis it was shown that 
the detection of isolated loco-regional or contra-lateral breast cancer 
recurrences in patients without symptoms has beneficial impact on survival 
of breast cancer patients when compared to late symptomatic detection, 
indicating that regular hospital follow-up might be beneficial for some 
patients [6]. Although recommendations vary to some extent with regards to 
timing, routine hospital follow-up visits include history taking, physical 
examination and mammography are part of the schedule. Health care 
utilization after primary treatment for women with a history of breast cancer 
represents a major public health issue with increasing importance [7,8] .  
Routine hospital follow-up care is a major portion of health care use of 
breast cancer survivors [8]. There is a limited number of studies examining 
the health care use of long-term follow up care of breast cancer survivors 
including hospital visits (history taking and clinical examination) and 
mammography [9, 1 O]. Data on utilization of long-term follow-up care beyond 
five years of breast cancer patients are relatively rare as well as on factors 
associated with the utilization of long-term follow-up care [7, 11]. The aim of 
the current study was to assess the use of long-term routine hospital follow­
up care, to describe the reasons of stopping this follow-up care, and to 
assess the determinants of the use of this routine hospital follow-up care. 
For that we derived information from hospital documents of 662 patients 
treated for breast cancer. 
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Method 
Settings and subjects 
The regional cancer registry of the Comprehensive Cancer Centre North­
Netherlands (CCCN, merged into the Comprehensive Cancer Centre 
Northeast-Netherlands in 2009) was used to select the patients who were 
diagnosed with breast cancer from January 1 989 to January 2003. This 
cancer registry contains data on diagnosis, stage, and treatment actively 
abstracted from the patient's medical records in all hospitals within the 
CCCN catchment area using the registration and coding manual of the 
Dutch Association of Comprehensive Cancer Centres. Passive follow-up of 
vital status through municipal population registries is conducted and the vital 
status of patients is updated annually. 
Of these 5,589 women a total of 1 39 patients developed contra lateral 
breast cancer (CBC) after six months since the first tumour and those contra 
lateral breast cancers were registered in the database. Because follow-up 
data was not available in the cancer registry, and we were not able to 
retrieve the follow-up data from all 5,495 patients from the hospital files. We 
decided to over-sample the women with contra-lateral breast cancer and 
sampled a subset of women without contra-lateral breast cancer. This cohort 
is representative of breast cancer survivors at a greater risk of secondary 
breast cancer supposed to have a better utilization of follow-up procedures. 
For each woman with CBC, four to five patients without evidence of CBC -
matched with hospital of diagnosis, age at first primary tumour, and duration 
of follow-up - were selected randomly in this cohort. Based on this a cohort 
of 736 patients was constructed including all women with a CBC. Medical 
documents were unavailable for 67 (9. 1 %) patients, and for seven (1 .0%) 
patients there was no information available on the follow-up. Finally, there 
were 662 (89.9%) patients in our study with information concerning at least 
one year follow-up (See Figure 1 ). 
Data abstraction 
For all patients in our study, the follow-up information was retrieved actively 
from hospital documents, including date and content of visits, date of 
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mammography. In addition, data on family history and comorbidity were 
retrieved for the patients in our study, as these data were not included in the 
cancer registry. Comorbidity was assessed with the use of the slightly 
modified Charlson comorbidity index [1 2, 1 3]. Per visit, it was retrieved 
whether patients came to the hospital with or without symptoms. In addition 
information on the following events was retrieved: the incidence of any loco­
regional recurrences, contra-lateral breast cancers, distant metastasis or 
death. The time of ending hospital follow-up and the reason was retrieved as 
well. The information on whether the patient went to the Dutch National 
Breast Cancer Screening Program was derived from linkage between the 
CCCN and the Dutch National Breast Cancer Screening Program. 
Follow-up guidelines in the study period 
After surgical treatment for breast cancer, follow-up was offered four times a 
year in the first two years. After two years it was offered two times a year 
and after five years it was offered once a year. Follow-up included history 
and physical examination. Mammography was offered once in two years 
(guidelines published in 1 987). In 1 994 the preferred frequency of 
mammography was changed from once in two years to yearly. The duration 
for follow-up was not specified. In the Northern part of the Netherlands, in 
1 999 follow-up was stratified for age groups. If the patient was under the age 
of 70 at the start of surgical treatment, hospital follow-up was offered for a 
period of 1 0  years, and after that period patients were referred back to their 
General Practitioner. If the patient was 70 or older at the start of surgical 
treatment, hospital follow-up was offered for a period of 5 years, and after 
that period patients were referred back to their GP. In 2003 the age cut-off 
was changed from 70 to 65 and the option to refer patients to the Dutch 
National Breast Cancer Screening Program was added after the ending of 
the hospital follow-up. That time breast cancer screening in the Dutch 
National Breast Cancer Screening Program was offered to all women from 
50 till 75 years of age. 
Definitions 
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For each patient, the time for routine hospital follow-up was assessed. The 
routine hospital follow-up time was considered to be ended if the patient was 
diagnosed with a loco-regional recurrence, a contra-lateral recurrence, a 
distant metastasis or death. In addition, the routine hospital follow-up time 
was considered to be ended if there was a note in the files about ending the 
follow-up which was not followed by any other follow-up visit. When there is 
no record of ending the routine hospital follow-up, the retrieval date was 
considered as the last date of follow-up. 
If a visit or a diagnostic mammography was related to a patient that 
presented with symptoms, the related visit and the related diagnostic 
mammogram were not considered as being part of routine hospital follow-up 
and these visits were excluded from the analysis. 
The utilization of hospital follow-up for every follow-up person-year was 
evaluated after 1994 when the frequency of follow-up was recommended to 
be given once a year. This hospital follow-up was evaluated according to the 
guidelines of follow-up of patient with a breast cancer. Underuse of hospital 
follow-up was defined as there was no hospital follow-up in patients who 
supposed to have hospital follow-up during that period according to the 
guidelines. The underuse of mammography was defined as having no 
mammogram in a period of at least 14 months in women who were followed­
up in hospital. Women whose time between two mammograms was less 
than 10 months were first identified and then evaluated whether the second 
mammogram was appropriate according to the guidelines, if not, it would be 
considered as an overuse of annually mammography. 
Statistical analysis 
Determinants potentially related to the underuse of hospital follow-up care, 
mammography were evaluated in a multivariate model by generalized 
estimating equations (GEE) which accounted for the dependent outcomes 
within breast cancer survivors. Odds ratios (OR) were calculated to reflect 
the potential associations between determinants and outcomes. Outcomes 
considered were whether patients underused hospital visits or yearly 
mammography after primary treatment (yes or no). Determinant potentially 
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related were age at primary diagnosis, year at diagnosis, year after primary 
treatment, whether the first tumour was detected during national breast 
cancer screening program, family history, comorbidity, characteristics of first 
tumour and treatment for first tumour. The periods of each constant 
guideline were taken into accounted as covariate. Only results from 
multivariate analyses are presented. 
Results 
Patients ' characteristics 
Of the 662 women included in this study, 197 (29.8%) patients were younger 
than 50 years of age at diagnosis of the first tumour and the median age was 
57.7 (26-93). Family history of breast cancer was present in 150 (22.7%) 
patients and comorbidity was present in 276 (41.7 %) patients. 423 (63.9%) 
patients had mastectomy and 214(32.3%) had had breast conserving 
therapy for their first tumour. 20.1 % of the patients received chemotherapy, 
and 138(20.8%) of the patients received hormonal therapy. The median 
follow-up time was 9.0 years (0.3-18.1) (See Table 1 ). 
Ending of hospital follow-up 
Of the 662 women, routine hospital follow-up was documented to be ended 
for 247(37.3%) among which 90 (36.4%) patients the time of stopping their 
hospital follow-up was earlier than it would have been based on the 
guidelines. Out of these 90 patients, 38 (42.2%) patients followed the 
doctor's advice to stop being hospital follow-up. 18 (20.0%) patients 
themselves decided to stop hospital follow-up, 9 (10.0%) patients stopped 
routine hospital follow-up because of comorbidity and 25 (27.8%) patients 
were transferred to the National Breast Cancer Screening Program sooner 
than was recommended by guidelines. 178 (72.1%) out of 247 patients were 
younger than 75 years of age at the time of ending their routine hospital 
follow-up. Of these, 156 (63.2%) patients were between 50 and 75 years 
and, 48 (30.7%) patients were transferred to the National Breast Cancer 
Screening Program. For 90 (36.4%) patients the time of stopping their 
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hospital follow-up was earlier than it would have been based on the 
guidelines. 
Utilization of hospital follow-up visits 
The long-term routine hospital follow-up visits decreased over time gradually. 
2.4%, 16.1 % and 33.5% patients had less follow-up visits than 
recommended in the national guideline at the first, fifth and tenth year after 
treatment (see Table 2). The total number of registered contacts was 10,553. 
Patients had an average of five visits in the first year, three times in the 
second year, twice in the third to fifth year and once in the years after. 
During their hospital follow-up, 109 (16.5%) patients were found both to 
underuse and to overuse hospital follow-up visits, 221 (33.4%) patients were 
found to underuse hospital follow-up visits, 99 (15.0%) patients were found 
to overuse hospital follow-up visits and 233 (35.2%) patients were compliant 
with the recommended frequency of hospital follow-up visits. 
In the multivariate model, as compared to patients aged 50-69 years, 
women who had breast cancer diagnosed after 70 years of age were less 
likely to underuse hospital follow up (OR: 0.64, 95%-CI: 0.44-0.89). Women 
who receive radiotherapy for the first tumour were less likely to underuse the 
hospital follow-up (OR: 0.53, 95%-CI: 0.29-0.95). Compared to the first five 
years after primary treatment, women were more likely to underuse the 
hospital follow up in the sixth to the tenth year from the primary treatment of 
first tumour (OR: 2.86, 95%-CI: 2.26-3.62). 
Utilization of mammography 
Only 44.1 % patients had a mammogram with 14 months after completion of 
primary treatment. 33.1 % and 40.4% of the patients had less mammogram 
in the fifth and tenth year after primary treatment, respectively (see Table 2). 
During their hospital follow-up, 112 (17.0%) patients were found both to 
underuse and to overuse mammography, 506 (76.7%) patients were found 
to underuse mammography, 12 (1.8) patients were found to overuse 
mammography and 30 (4.5%) patients were compliant with the 
recommended frequency of mammography. 
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In the multivariate model evaluating the potential factors associated with 
the underuse of mammography, older age (age>70; OR: 2.10; 95%CI: 1.62-
2.74), patients with co-morbidities (OR: 1.26; 95%CI: 1.05-1.52) and 
hormonal therapy (OR: 1.51; 95%CI: 1.01-2.25). Patient with their first 
tumour diagnosed after 1994 (OR: 0.74; 95%CI: 0.60-0.92), patients with 
positive lymph node at the first tumour (OR: 0.65; 95%CI: 0.42-0.98) and 
patients who received radiotherapy (OR: 0.73; 95%CI: 0.55-0.98) were less 
likely to underuse yearly mammography. After five years of follow-up, 
patients were more likely to underuse yearly mammography according to the 
guidelines (for 6-10 year was OR: 1.74; 95%CI: 1.48-2.06 and OR for 1 O+ 
year was 8.21, 95%-CI: 6.05-11.14, see Table 3). 
Discussion 
This study evaluated utilization of hospital follow-up in a cohort of 662 
patients with a median follow-up time of 9.0 years (range: 0.1-18.2). At fifth 
and tenth year after diagnosis, 16.1 % and 33.5% of the patients were under 
using hospital follow-up care, respectively, where of the patients in hospital 
follow-up, 33.1 % and 40.4% of the patients were under using mammography, 
respectively. Underuse of yearly mammography was found in older patients 
(age>70; OR: 2.10; 95%CI: 1.62-2.74), patients with comorbidity (OR: 1.26; 
95%CI: 1.05-1.52) and patients with hormonal therapy (OR: 1.51; 95%CI: 
1.01-2.25). 
Routine hospital follow-up care was ended for 37.3% (n=247) 
recurrence-free patients. For one-third of these patients (n=90; 36.4%) the 
time of stopping their hospital follow-up was earlier than it should have been 
based on the guidelines. According to the guidelines, women with a history 
of breast cancer should be advised to be followed-up until age of 75 either in 
hospital or being transferred to the National Breast Cancer Screening 
Program. Only one-third of the patients who were at age of between 50 and 
75 at the time of ending follow-up were indeed transferred to the National 
Breast Cancer Screening Program. Patients between the age of 50 and 75, 
ending their routine hospital follow-up program should be well actively 
referred to the National Breast Cancer Screening Program. Recently this 
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was added to the Dutch national guideline for breast cancer screening 
[http://www.oncoline.nl/index.php?pagina=/richtlijn/item/pagina.php&richtlijn 
id=593]. 
Patients who received radiation therapy for their primary tumours and 
women with positive lymph node at the first tumour were less likely to 
underuse the routine hospital follow-up. This might be a reflection of more 
concern about the risk of breast cancer recurrences and the more 
consequent recall policy of the radiation oncologist. 
Compared to first five years after primary treatment, women were more 
likely underuse the hospital follow up in the sixth to the tenth year from the 
primary treatment of first tumour (OR: 2.86, 95%-CI: 2.26-3.62). This finding 
is consistent with another research and the decreasing concern about the 
risk of breast cancer over time may be a possible explanation for declining 
routine hospital follow-up visits [14]. 
In this study, the utilization of mammography was evaluated in women 
who were followed up in hospital. For patients who stopped their hospital 
follow-up, the utilization of mammography was not evaluated. 
Mammography is the only recommended imaging test for the routine follow­
up of women with a history of breast cancer and is recommended by most 
guidelines [15]. Underutilization of mammography was still found in 30-40% 
patients during the routine hospital follow-up phase in this study. Several 
studies reported that elderly patients are less likely to receive routine 
mammography [14, 16] which is also the case in this study; patients over 70 
had a lower chance to receive yearly mammography. An explanation might 
be that among elderly, there is a decreasing concern about the risk of breast 
cancer recurrences [16]. Lower use among the elderly could be related to 
competing medical needs and/or perceived diminishing benefit from regular 
mammography with advancing age also. Patients who had comorbidity and 
patient who received radiation therapy had fewer mammograms than 
advised. These findings may reflect potentially appropriate decisions by 
patients or their physicians for less intensive care as a result of competing 
comorbid illness causing that follow-up mammography became a lower 
priority in these patients [14, 16-17]. The finding that the patients who 
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received hormonal therapy had less frequent mammography than advised 
might be a reflection of the awareness of the decreasing efficiency of 
mammography in follow-up after recalculating the incidence of local 
recurrences which is reduced by hormonal therapy. The patients with a first 
tumour diagnosed after 1994 were more likely to have yearly mammography 
probably due to the increasing awareness of the benefit of mammography 
and the publications of guideline on follow-up of breast cancer which 
addressed the importance of mammography [18-20]. 
As well as the use of routine hospital follow-up, the use of yearly 
mammography decreased gradually over years. It may be an effective and 
safe choice to transfer women with a history of breast cancer to their general 
practitioner to keep the continuity of care at an appropriate time[21]. This 
may reflect tailored follow-up schedules, where the estimated risk of 
recurrence influences the choice to adhere to the follow-up schedule as in 
the national guidelines or to decrease the number of follow-up visits and 
examinations. Because the recurrence rate in the study population cannot 
be assessed reliable from the present data, this hypothesis cannot be tested. 
Caution is needed when generalizing study results and conclusions to 
other population and settings. Our study cohort consists of patients with 
meta-chronous contra-lateral breast cancers and random group stratified on 
hospital of diagnosis, age and duration of follow-up. This cohort is 
representative of breast cancer survivors at a greater risk of secondary 
breast cancer who are expected to be under close surveillance. The other 
limitation of present study is we only reviewed the utilization of hospital 
follow-up. It is still unclear whether patients who stop their hospital follow-up 
were followed up in the National Breast Screening Program or in general 
practice routinely or not. From other research it became clear that patients 
who continued to see cancer specialists after their initial cancer treatment 
were more likely than other patients to undergo routine follow-up 
mammography [22, 23]. The utilization of follow-up care elsewhere such as 
the National Breast Screening Program or in general practice for long term 
survivors deserves further research. The consequence of underuse of 
hospital follow-up is not clear due to the lack of conclusive evidence in the 
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literature about the benefit of regular hospital follow-up visits, either in terms 
of early detection of recurrences or in relation to psychological well-being. 
Conclusion 
Most patients with a history of breast cancer use hospital follow-up care 
according to the guidelines. In older patients, patients with comorbidity and 
patients receiving hormonal therapy we should be careful to ensure the use 
of yearly mammography. 
48 
5589 patients with a 
new breast cancer 
94 patients with synchronous CBC 
r (excluded) 
5495 patients with a 
ipsilateral breast cancer 
i i 
1 39 patients with 597 patients were 
CBC matched 
I , ... , I I 67 patients without available medical rl documents (excluded) 669 patients with available medical documents 
... I I I 7 patients without available follow-up ---, infonnation (excluded) 
662 patients were 
included 
Figure 1 Graphical illustration of the sampling of study cohort 
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Table 1 Characteristics of patients and their first breast cancer n (%) 
Characteristics N % 
Age at diagnosis [median(range) yrs] 57.7 26-93 
Age group at diagnosis 
<50 1 97 29.8 
50-59 1 72 26.0 
60-69 1 63 24.6 
70+ 1 30 1 9.6 
Year of diagnosis 
1 989-1 993 3 1 3  47.3 
1 994-2002 349 52.7 
Detecting first tumour by Screening programme 
No 335 72.0 
Yes 1 30 28.0 
No applicable 1 97 
Co morbidity 
No 386 58 .3 
Yes 276 4 1 .7 
Pathologic T stage 
pTis/T l 376 57.7 
pT2-3 276 42.3 
Unknown 1 0  
Pathologic N stage 
NO 435 62.2 
N l -3 2 1 2 37.8 
Unknown 1 0  
Surgery 
BCT 2 14 33.6 
Mastectomy 423 66.4 
Unknown 25 
Radiation therapy 
Yes 284 42.9 
No 378 57. 1 
Chemotherapy 
Yes 98 20.8 
No 564 79.2 
Hormonal therapy 
Yes 1 3 8  79.2 
No 524 20.8 
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Table 2 Utilization of breast cancer follow-up care in breast cancer survivors 
Time 
Disease free Patients used hospital Patients used yearly 
after treatment 
(years) 
Patients* follow-up visit mammography 
n n % n % 
1 662 639 96.5 282 44. 1 
2 634 587 92.6 4 1 2  70.2 
3 6 1 3  548 89.4 368 67.2 
4 590 503 85.3 33 1 65.8 
5 570 478 83.9 320 66.9 
6 538 447 83 . 1  277 62.0 
7 5 1 6 400 77.5 246 6 1 .5 
8 470 340 72.3 208 6 1 .2 
9 425 300 70.6 1 94 57 . 1 
1 0  36 1  240 66.5 1 43 59.6 
* Patients who have a loco-regional recurrence or contra-lateral breast cancer were excluded. Patients 
who have distant metastasis were excluded. 
Table 3 Predictive factor of underuse of follow-up care in breast cancer 
survivors (multivariate results) 
Variable OR 95% CI 
Underuse of hospital follow-up 
Age at diagnosis <50 1 .42 0.95-2 . l l 
50-69 l 
70- 0.64 0.42-0.96 
Year at diagnosis 1 989-1 993 l 
1 994-2002 0.63 0.44-0.89 
Year after primary treatment l -5 l 
6-1 0  2.86 2.26-3.62 
I O+ 
Radiation therapy No l 
Yes 0.53 0.29-0.95 
Underuse of yearly of mammography 
Age at diagnosis <50 1 .29 1 .00- 1 .67 
50-69 l 
70- 2. 1 0  1 .62-2.74 
Year at diagnosis 1 989-1 993 l 
1 994-2002 0.74 0.60-0.92 
Year after primary treatment l -5 l 
6-1 0  1 .74 l .48-2.06 
I O+ 8 .2 1  6.05- 1 1 . 1 4  
C o  morbidity No l 
Yes 1 .26 l .05-1 .52 
pN stage NO l 
N l / N2 /N3 0.65 0.42-0.98 
Radiation therapy No l 
Yes 0.73 0.55-0.98 
Hormonal therapy No l 
Yes 1 .5 1  1 .0 1 -2.25 
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ABSTRACT 
Background: The absolute number of new cases of breast cancer is high, 
and 21.3% of new cases of breast cancer of the world are diagnosed in 
China. The clinical characteristics and prognosis were worth being evaluated 
in China. 
Methods: A random selection was made of 1,197 records out of 5,987 
patients diagnosed with breast cancer. 
Results: The median age at diagnosis of patients was 48.0 years (range 19-
80 years). 59% of the patients (645) had a T2 tumour, and 48% of the 
patients (521) were in N1-3 stage. Most women (1041; 96%) underwent 
mastectomy; 588 (54%) received radiotherapy; 896 (82%) chemotherapy; 
and 374 (43%) endocrine therapy. The 5-year local recurrence rate was 2.9 
%; the 5-year contra-lateral recurrence rate was 0. 7 %, and the 5-year 
distant metastasis rate was 6. 7%. Main predictors for recurrences were T­
and N- stage. 
Conclusions: In Tianjin where breast cancer screening was not routinely 
carried out, the stage of tumour was higher and treatment for breast cancer 
was more aggressive than in Western countries. The overall recurrence rate 
was very low and overall was comparable to that in Western countries. 
Key words: Breast cancer; Local recurrence; Contra-lateral recurrence; 
Survival ; Follow up; 
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Introduction 
With an estimated 1.15 million new cases worldwide each year, breast 
cancer is by far the most frequent cancer in women. The incidence of breast 
cancer in the United States is about 87.1 per 100,000 women per year; the 
incidence of breast cancer is about 68.3, 67.4, 49.5, and 35.9 per 100,000 
women per year in northern, western, southern and eastern European 
countries. The incidence of breast cancer in China has been increasing from 
11.7 per 100,000 in 1998 [1] to 18.7 per 100,000 in 2002 [2]. Despite the 
lower incidence of breast cancer in China, the absolute number of new 
cases is high due to the large population (there are 1.31 billion inhabitants), 
and 21.3% of new cases of breast cancer of the world are diagnosed in 
China. In addition, cancer registries in China are recording annual increases 
in incidence of 3% to 4% which is higher than in other countries [2]. 
In China, there is no nationwide breast screening program because of 
relatively lower breast cancer incidence and resource constraint. In contrast 
to Western countries, breast conservation therapy is uncommon and most of 
the patients receive mastectomy along with more widespread use of 
adjuvant therapy. The clinical characteristics and prognosis were worth 
being evaluated in China. Therefore, we conducted a retrospective study to 
determine the patients and tumour features, survival rate, relapse and 
prognostic factors in Chinese breast cancer patients. 56 
Patients and methods 
Setting 
In the Tianjin Medical University Cancer Institute and Hospital every year 
about 1,000 patients were treated for breast cancer in 1995 to 2000. As part 
of a standard routine, all treated patients were registered in an electronic 
database including the following information: name and day of birth of the 
patient; type of cancer and date of diagnosis. As a part of the routine of the 
Tianjin Medical University Cancer Institute and Hospital, all patients are 
contacted to assess disease and survival status annually. Patients are 
declared lost to follow up if the patients and their affiliations including their 
family could not be contacted after two telephone calls and one confirmation 
letter. The medical records were updated when the patients visited the 
hospital. 
Radical mastectomy and modified radical mastectomy (MRM) were 
common surgical procedures for stage I and stage 11 breast cancer patients 
in this hospital during 1995 to 2000. Breast conserving therapy was 
introduced to patients who had smaller tumour and who were without lymph 
node involvement as alternative treatment to mastectomy. Neo-adjuvant 
chemotherapy was standard approach to stage Ill patients before radical 
mastectomy surgery. Post-mastectomy chemotherapy was recommended 
for all patients, except for stage I patients. Post-operative radiotherapy was 
recommended for all patients, except for patients older than 70 years of age 
and with positive estrogen receptor (ER) ,  negative axilliary nodal status, T1 
stage and negative margins. Endocrine therapy was recommended 
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treatment to those patients with positive ER or positive progesterone 
receptor (PR). 
The recommended guidelines for follow-up in the Tianjin Medical 
University Cancer Institute and Hospital included visits every 3 months 
during the first 2 years, visits every 6 months during the third to fifth year, 
and annual visits thereafter. The follow-up tests included physical 
examination every time and other tests based on doctor's recommendations 
such as chest X-ray, CT, and mammography. Patients were encouraged to 
report new symptoms promptly without waiting for the next scheduled 
appointment. There were no recommendations regarding regular 
mammography in follow-up. 
Patients included in this sample 
Patients included in our study were treated for breast cancer at least five 
years ago and were without symptoms of distant metastases during the 
diagnosis of primary breast cancer. Between 1 September 1995 and 1 
September 2000, 5,987 patients were treated for primary breast cancer in 
the Tianjin Medical University Cancer Institute and Hospital. From this large 
database, 1, 197 records of patients were selected using the systematic 
sampling method. A starting point was chosen at random, and based on five 
regular intervals, the cases were selected. Patients and tumours' 
characteristics, treatment and information regarding follow-up visits were 
extracted from available paper medical records. 111 (9.27%) patients were 
excluded because they had distant metastasis (21; 1. 75%) at the moment of 
primary diagnosis or their medical records were not available (90; 7.52%). 
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Latest follow-up was assessed at September 2006. For 1,086 patients 
baseline information was available, for 830 patients 5-year follow-up, and for 
178 patients 10-year follow-up information was available. Ethical approval to 
conduct the study was obtained from the hospital ethics committee. 
Data collection and data definition 
A structured form was developed to extract the following information from 
paper medical records: age at diagnosis, tumour size, pathological TNM 
stage, surgical therapy, adjuvant radiotherapy and chemotherapy, hormonal 
therapy, estrogens receptor (ER), progesterone receptor (PR), date of 
follow-up visits, any tests performed during follow-up, recurrences and 
survival . 
Loco-regional recurrence was defined normally as recurrence of breast 
cancer in the same breast or chest wall or regional lymph node area. Contra­
lateral recurrence was defined as any primary tumour in the other breast 
after the diagnosis of the first breast cancer. Distant metastasis was defined 
as the evidence of cancer in all tissues except breast and axilla. 
Statistical analysis 
Life table method was used to calculate the annual incidence rate and 
cumulative incidence rate of loco-regional recurrences, contra-lateral 
recurrence, distant metastasis, disease-free and overall survival. 
Frequencies of follow-up visits were summarized in term of durations of the 
first one year, the first two years and the first five years. Univariate and 
multivariate analyses with Cox regression models were undertaken to 
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identify the factors associated with relapse, disease-free and overall survival 
as dependent variables. Variables for the multivariate analyses were 
selected by Conditional forward entry Cox regression analysis. Relapse was 
defined as loco-regional recurrences, contra-lateral recurrence or distant 
metastasis. Disease-free survival was defined as the time from primary 
treatment to first occurrence of: relapse or death without prior cancer event. 
Overall survival was defined as time from primary treatment to death from 
any cause. As covariates were considered: age at diagnosis; tumour size; 
axillary node status; TNM stage; surgical therapy; adjuvant radiotherapy; 
neo-adjuvant chemotherapy; adjuvant chemotherapy; estrogens/ 
progesterone (ER/PR) receptor status; number of follow-up visits and 
physical examinations. 
Results 
Patients' and disease characteristics 
For an overview of the patients and tumour characteristics, see Table 1 .  All 
patients (n= 1 ,086 patients) in the analysis were female. The median age at 
diagnosis of patients was 48.0 years (range 1 9-80 years), and 431 (39.7%) 
women were older than 50. The pathologic stage was T1 and T2 in 8 1 4  
(75.0%) patients. 475 patients (43.7%) were in pathologic stage NO. A 
minority of women (n=44, 4.1 %) received breast conserving treatment and 
all of these patients with specified stage information 31 (70.5%) were in 
stage I and stage 11. 
Besides 95 (48.0%) stage Ill patients, 23 (22.5%) stage I and 264 (38.4%) 
stage II patients received neo-adjuvant chemotherapy. A majority of women 
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received post-treatment adjuvant therapy, with 588 (54.1 %) receiving 
radiation therapy, 896 (82.5%) receiving adjuvant chemotherapy and 374 
(34.4%) receiving endocrine therapy. 497 out of 1041 patients (47.7%) 
received mastectomy combined with radiation therapy and chemotherapy. 
Of the 475 patients with NO stage, 230 (48.4%) patients received radiation 
therapy and 382 (80.4%) patients received adjuvant chemotherapy. Of the 
102 patients with a stage I tumour, 81 (79.4%) patients received mastectomy 
and 36 (44.4%) patients received mastectomy as well as radiotherapy. In 
683 patients with stage 11 tumours, 580 patients received mastectomy and 
354 (61.0%) patients received mastectomy as well as radiotherapy. 
Loco-regional recurrence and contra-lateral recurrence 
Local recurrence occurred in 20 patients, nodal recurrence in 17 patients. 
The five-year cumulative incidence of loco-regional recurrence was 2.9 % 
(95% Cl: 1.9-3.9). Contra-lateral recurrence was found in 10 patients. The 
five-year cumulative incidence of contra-lateral recurrence was 0. 7 % (95% 
Cl: 0.2-1.2), see Table 2. 
In the 47 patients with loco-regional or contra-lateral recurrences, 29 
patients (61.7%) had visited the out-patients clinic because of symptoms and 
18 (38.3%) recurrences were detected during routine follow-up. 
Distant metastasis 
Distant metastasis was found in 82 patients. The five-year cumulative 
incidence was 6.7% (95% Cl: 5.1-8.2) see Table 2. Bone (42.7%) was the 6 1  
most frequent site of distant metastasis followed by lung (39.0%) and liver 
(22.0%), brain (4.9%) and pleura (3.7%). 
Disease free survival and overall survival 
In 5 and 10 years, disease free survival rates were 83.6% (95% Cl: 80.0-
84.6) and 77.0% (95% Cl : 73.8-80.1 ), respectively. In 5 and 10 years, overall 
survival rates were 88.1% (95% Cl: 86.1-90.0) and 82.8% (95% Cl : 80.1-
85.5), respectively see table 3. 
Compliance with follow-up guidelines 
Of the patients who were followed for at least one year, 246 patients (23.1 %) 
had four or more follow-up visits, and 246 patients (23.1 % ) had no follow-up 
visits in this year. Of the patients who were followed for at least two years, 
86 patients (8.4%) had eight or more visits, and 198 patients (19.2%) had no 
follow-up visits. Of those patients who were followed for more than five year, 
34 (4%) patients were fully compliant with the guidelines (14 visits in 5 years 
of follow-up) 
In 1,086 patients, 193 patients never came back for follow up after primary 
treatment and 903 patients completed a total 5,720 visits over a period of 
2.2-132.9 months (median=81.8) of follow-up. The patients received physical 
examinations during most of their follow-up visits (91.5%, 5,232/5, 720). 
Many patients received additional tests including 1230 (21.5%) chest X-rays, 
1275 (22.3%) ultrasound tests, 165 (2.9%) CTs and 72 (1.3%) 
mammographies. As a part of the follow-up all patients were contacted 
yearly by telephone to assess disease and survival status. 
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Factors associated with overall survival, disease free survival and 
relapse 
In univariate analyses (see Table 5), having larger tumour size, higher T and 
N stage and having more involved axillary nodes were associated with 
worse overall survival. Besides mentioned above tumour characteristics, 
adjuvant radiation therapy was associated with higher risk of relapse. 
Surgical modalities, neo-adjuvant chemotherapy, adjuvant chemotherapy, 
follow-up with physical examination were not associated with overall survival 
and disease free survival after adjustment with primary tumour 
characteristics (tumour size, T stage, N stage and axillary nodal involvement 
status). 
In multivariate analyses, a higher T stage and N stage appeared to be 
independent prognostic factors for worse survival and worse disease free 
survival. A higher T stage was also an independent prognostic factor to 
develop relapse. Patients arranged to receive radiotherapy and hormonal 
therapy appeared to have a worse disease free survival and higher 
incidence of relapse (See table 6). 
Discussion 
After more aggressive treatment, patients with breast cancer showed a low 
incidence of relapse and good overall survival in this study. The main 
prognostic factors were T-stage and N-stage. Breast cancer patients in this 
series were younger and had more advanced tumour status at diagnosis. 
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In our study, the median age of diagnosis of breast cancer was 48 years, 
which is in line with other studies in China (median age:47)[3,4] and a study 
in Korea (median age: 47) [5]. In contrast, the median age of diagnosis of 
breast cancer is higher in European Countries and the United States 
(median: 58-63)[6-9]. Related to that, in our study nearly 60% of the women 
were pre-menopausal, while in Western Countries, about 75% of the women 
diagnosed with breast cancer are postmenopausal women despite there is 
non-significant difference in age at menopause [10, 11]. The peak of age­
specific incidence rate was located in 44-54 in China [4] whereas the age­
specific incidence rate keeps increasing until 80 [9]. These differences can 
not be explained by differences in life-expectancy, as there are only small 
differences in life-expectancy between China (about 75), Korea (about 82), 
and Western Countries (about 79-83) [12]. These differences can also not be 
explained by the absence of a nation wide screening program, as in Western 
countries without screening program the median age at diagnosis of breast 
cancer is about 60[8]. In a multi-ethnic cohort study, the breast cancer risk of 
Asian postmenopausal women appeared to be comparable to American 
women after adjusted for the risk factors such as overweight and alcohol 
consumption [13]. It seems reasonable to hypothesize that environmental 
factors play a role. 
The patients in our study had more advanced stages of breast cancer than 
those in the United States and European studies. The proportion of patients 
with early breast cancer (stage T1 and T2) was rather low as compared to 
studies from Western countries (75% versus 83 - 88%), especially the 
percentage of T1 was much lower in our study (16% versus 34% - 57%) [6, 
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14]. The patients in our study had worse N stages with a smaller proportion 
(44%) of patients with stage NO than in a United States study (67%) [14] and 
a study from Europe (55%) [6]. The possible explanation might be the 
absence of a nationwide breast cancer screening program in China, 
whereas such programs are fully or partly implemented in the majority of 
developed countries [15]. The ER/ PR status is also different with a higher 
proportion of negative ER/PR patients than in other studies [6, 14]. This can 
be explained by the younger ages of the patients in our study. 
Most (96%) of the patients underwent mastectomy and 46% of the 
patients received mastectomy combined with radiation therapy and 
chemotherapy. This was according to the treatment protocol of our hospital 
in 1995-2000, which was based on the recommended guidelines for 
treatment by UICC (Committee of the International Union against Cancer) 
and CACA (Chinese Anti-Cancer Association) [16]. Breast conservation 
therapy was uncommon in China until the late 1990s even in those areas 
with more westernization culture because of the relatively small breast size 
of Chinese women and uncertainty about the long-term clinical and cosmetic 
outcome in this ethic group. Mastectomy was still widely perceived as the 
only curative treatment for Chinese women [17]. Furthermore, the adjuvant 
therapies were accepted widely. The more aggressive treatment strategies 
are carried out after taking into accounts the patients' preferences, financial 
status and knowledge. 
Despite the unfavorable primary tumour status, the patients in our study 
show a good disease-free survival and overall survival, being 84% and 88% 
at five years and 77% and 83% at 10 years respectively. This was 
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comparable to survival data from the United States and Europe [8,9, 18]. The 
endpoint evaluated was death from any cause in this study, so the 
competing risk should be taken into consideration because the patients in 
western countries are at higher risk of dying from other causes due to the 
older age [11]. The incidence of relapse was smaller compared to some 
other studies (4% versus 4-9%) [19-21]. The combination of mastectomy 
with systemic adjuvant radiotherapy and chemotherapy in our hospital was a 
reasonable explanation for the lower incidence of loco-regional recurrence. 
There might be some other genetic and environmental factors needed to be 
clarified. 
Most patients (96%) had less follow up visits than recommended in this 
hospital in which there were many patients (16%) hadn't visited hospital in 
the first five years. History taking was the most common item taken during 
follow-up visits of breast cancer patients, and the proportion of women 
receiving mammography after primary was very small (72 in 5720 follow-up 
visits) in our series. In contrast, 21.5% (1230/5720) of the patients received 
a chest X-ray and 22.3% (1275/5720) of the patients received an ultrasound 
in present study. Both the patients' perception and the physicians' view and 
capacity might affect the implementation of follow up in practice [22-26]. The 
conclusive reason of low compliance of follow-up guidelines was 
unobtainable out of medical records without further investigation the patients 
and their physicians. Compliance of guidelines and possible related factors 
deserve further research attention because not a single follow-up strategy 
would have an efficient yield given such low compliance. 
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The findings of multivariate analysis indicated T stage and N stage were 
the most important predictive factors for survival in this study that was in 
accordance with the results in a systematic review [27]. The patients 
arranged to receive radiotherapy and hormonal therapy appeared to have a 
higher risk of relapse and thereafter worse disease-free survival. Although 
there was strong evidence for a reduction in loco-regional recurrence rate 
and an increased disease free survival following post-mastectomy 
radiotherapy worldwide [28], in some studies, assignment to radiotherapy or 
endocrine therapy was associated with an increased risk of failure after 
adjustment for known prognostic factor [21,29,30]. Nonetheless they could 
provide useful elements on how to use adjuvant treatment. An explanation 
could be the residual confounding bias due to lacking of information some 
prognostic factor, for example, histological grade and lacking of power of 
other available factor such as N stage and axillary lymph nodal involvement. 
There are limitations in a retrospective study like ours and these results 
should be interpreted with caution. There was no significant impact on 
survival of follow-up visits and physical examination which was in line with 
other study [31]. In addition, it was a logical consequence of the low 
incidence of loco-regional recurrence and low compliance of routine follow­
up. 
There were several limitations with the present study that should not be 
overlooked. First, challenges existed in using historical medical record and 
some important information of tumour was unavailable that likely resulted in 
residual confounding bias when we intend to determine the predictive factors. 
Secondly, the endpoint we evaluated was death from any cause because of 
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many missing death cause in records which should be taken into account 
when someone compared survival rates between different series. 
Furthermore, caution is needed when generalizing study results and 
conclusions to other population because the sample was randomized 
collected from the patients of only one institute despite the distribution of 
patients' and tumour characteristics was comparable to that in the other 
study which was carried out independently of current study [3]. 
The breast cancer patients in our series had more advanced tumour 
stages, even so the clinical outcome was comparable to the other western 
countries and less relapse took place after more aggressive treatment. Our 
findings indicated the more aggressive treatment was reasonable in those 
areas without breast screening program. 
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Table 1 Characteristics of breast cancer patients n= 1 086(%) 
Characteristics N (¾) 
Age at diagnosis 
<=40 I 87( 17.2) 
4 1 -50 468(43 . 1 )  
5 1 - 43 1 (39.7) 
Stage 
I 1 02( 9.4) 
II 683(62.9) 
III 1 98( 1 8 .2) 
Unknown 1 03( 9.5) 
Pathological tumour size 
:S2 206( 19.0) 
2. 1 -3 .0 350(32.2) 
3 . 1 -5 .0 306(28.2) 
5 . 1 - 1 4 1 ( 1 3 .0) 
Unknown 83( 7.6) 
Pathological T stage 
T l  1 69( 1 5 .6) 
T2 645(59.4) 
T3 1 28( 1 1 .8) 
T4 47( 4.3) 
Unknown 97( 8.9) 
Pathological N stage 
NO 475 (43.7) 
N I  403 (37. 1 )  
N2 /N3 I I 8 ( 1 0.9) 
Unknown 90 ( 8.3) 
ER/PR status 
ER+ / PR+ 332(30.6) 
ER+ / PR- 1 78( 16.4) 
ER- I PR- 85( 7.8) 
ER- / PR- 2 14( 19.7) 
Unknown 277(25 .5) 
Surgery 
Radical mastectomy 443 (40.8) 
Modified radical mastectomy 599 (55 .2) 
BCT -breast conserved treatment 44 ( 4. 1 )  
Radiation therapy 
Yes 588 (54. 1 )  
No 360 (33 . 1 )  
Unknown 1 38 ( 12.7) 
Neo-chemotheapy 
Yes 4 1 5(38.2) 
No 652(60.0) 
Unknown 1 9( 1 .7) 
Chemotherapy 
Yes 896 (82.5) 
No 1 64 ( I S . I )  




Unknown 2 1 0( 1 9.8) 
Follow-up visit 
Yes 903(83 . 1 )  
No 1 83( 16.9) 
Physical examination follow-up 
Yes 880(8 1 .0) 
No 206( 19.0) 69 
Table 2 Annual incidence rate and cumulative incidence of relapse 
Loco-regional recurrences Contra-lateral recurrences Distant metastases 
Annual Cumulative Annual Cumulative Annual Cumulative year number number number 
Cases incidence incidence Cases incidence incidence Cases incidence incidence 
at risk at risk at risk 
(%) (%) (%) (%) (%) (%) 
1 086 1 6  1 .5 1 .5 1 086 1 0. 1 0. 1 1 086 9 0.8 0.8 
2 1 049 7 0.7 2.2 1 062 l 0 . 1  0.2 1 059 25 2.4 3 .2 
3 1 0 1 3  2 0.2 2.4 1 027 1 0 . 1  0.3 1 0 1 0  7 0.7 3 .9 
4 969 4 0.4 2.8 98 1 3 0.3 0.6 968 1 5  1 .6 5 .4 
5 923 1 0. 1 2.9 93 1 1 0. 1 0.7 9 1 8  1 2  1 .4 6.7 
6 836 4 0.5 3 .4 842 1 0. 1 0.8 830 5 0.7 7.3 
7 695 1 0.2 3 .5 697 1 0.2 1 .0 691 2 0.3 7.6 
8 502 l 0.2 3.8 505 0 0.0 1 .0 503 4 0.9 8.5 
9 356 1 0.4 4. 1 358 0 0.0 1 .0 355 I 0.4 8.8 
10 1 79 0 0.0 4 . 1  1 78 0 0.0 1 .0 1 78 1 0.8 9.5 
1 1+ 77 0 0.0 4. 1 77 1 2 .2 3.2 77 1 2.2 1 1 .5 
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Table 3 Annual incidence rate and cumulative incidence of relaese 
Disease-free survival survival 
year number at number at 
lost 
risk 
events* rate lost 
risk 
deaths rate 
1 086 6 35 96.8 1 086 8 1 5  98.6 
2 1 045 6 44 92.7 1 063 8 26 96.2 
3 995 14 29 89.0 1 029 1 5  30 93.4 
4 952 1 9  33 86.8 984 2 1  26 90.9 
5 900 53 32 83.6 937 62 28 88. 1 
6 8 1 5  1 26 12  82.3 847 1 35  9 87. 1 
7 677 1 74 9 8 1 .0 703 1 86 1 0  85.6 
8 494 139  7 79.7 507 142 5 84.6 
9 348 1 67 7 77.6 360 1 74 6 82.8 
1 0  1 74 l 77.0 1 80 0 82.8 
* Loco-regional recurrences, contra-lateral recurrences, distant metastasis or death 
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Table 4 Compliance with follow-up 9uidelines 
Years after primary treatment Fol low-ups N % 
In the first year Zero 246 23 . l  
Number of patients surviving 1 -3 57 1 53.8 
the first year N"' l 063 :::: 4 246 23 . l  
In the first two years Zero 1 98 1 9.2 
Number of patients surviving 1 -3 400 38.9 
the first two years N= 1 029 4-7 345 33.5 
::::8 86 8.40 
In the first 5 years zero 1 3 1 1 5 .5 
Number of patients surviving 1 -3 24 1 28.5 
the first five years N=84 7 4-7 273 32.2 
8-1 3  1 68 1 9.8 
:::: 14- 34 4.0 
* For 23 patients there is no information up to one year 
* For 57 patients there is no information up to two year 
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ABSTRACT 
Purpose: To determine the contribution of surveillance mammography to 
the early detection of meta-chronous contra-lateral breast cancer (MCBC) 
and to assess its impact on the survival of breast cancer patients with 
relation to compliance. 
Method: 5,589 breast cancer patients were identified using files from the 
regional cancer registry of the Comprehensive Cancer Centre North 
Netherlands (CCCN Groningen, The Netherlands). The programme 
sensitivity and the impact on prognosis of follow-up mammography with 
relation to compliance was evaluated in 114 patients who developed MCBC 
during hospital follow-up. 
Results: The cumulative MCBC incidence rate at year 10 was 3.4% (95% Cl: 
2.8-4.0% ). The programme sensitivity of surveillance mammography was 
59.6% (95% Cl: 50.6-68.7). In patients who complied with annual 
mammography, sensitivity was increased to 70.8% (95% Cl:  61.7-80.0). 
Patients with MCBCs detected by routine mammography have better 
survival rates than patients with MCBCs detected by other means (HR: 3.18; 
95% Cl: 1.59-6.34). Though there was a trend towards improved survival in 
patients being compliant with regular clinical follow-up (HR: 1.69; 95% Cl: 
0. 72-3.96), this was not the case for patients being compliant with annual 
mammography (HR: 1.02; 95% Cl:0.50-2.09). 
Conclusion: Mammography is a valuable tool for the early detection of 
MCBC during hospital follow-up of breast cancer patients and is probably 
beneficial to survival. The utilization of follow-up surveillance in breast 
cancer patients and its potential impact on survival deserve further 
investigation. 




Contra-lateral breast cancer (CBC) is the most common second primary 
malignancy in patients with a history of breast cancer [1]. For meta-chronous 
contra-lateral breast cancer (MCBC) a constant annual incidence of 0.3-1.0 
percent is observed [2-6]. 
Contra-lateral surveillance mammography is recommended in the follow­
up of patients treated for breast cancer and aims at early detection of MCBC 
to optimize the outcome [7-9]. Observational studies suggest that a 
secondary primary tumour detected before its symptomatic onset has a 
favourable impact on the survival of patients with MCBC [10-11] However, 
the survival benefit of diagnosing MCBC by mammography has not yet been 
studied thoroughly [12-13] Mammography surveillance in breast cancer 
follow-up has been shown to be underutilized, with the proportion of patients 
receiving a contra-lateral mammography varying from 80% in the first year to 
60% in the fifth year of follow-up [14-16] This study was designed to 
evaluate the diagnostic value of annual surveillance mammography and its 
impact on survival. In addition, the compliance with annual mammography 
was evaluated in MCBC patients, as was its potential impact on the 
diagnostic performance of mammography and MCBC patient survival. 
Patients and methods 
Settings and subjects 
All the consecutive breast cancer patients diagnosed in four hospitals in the 
North Netherlands (an academic hospital, a large teaching hospital and two 
non-teaching hospitals) from January 1989 to January 2003 were selected 
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from the files of the regional cancer registry of the Comprehensive Cancer 
Centre North Netherlands (CCCN Groningen, The Netherlands). This cancer 
registry contains data on diagnosis, stage and treatment, actively abstracted 
from the patients' medical records in all hospitals within the CCCN 
catchment area using the registration and coding manual of the Dutch 
Association of Comprehensive Cancer Centres. Passive follow-up of the vital 
status through municipal population registries was conducted. The censoring 
date was 05-01-2007. 
All women with newly diagnosed breast cancer were included. A new 
primary tumour was defined as any new tumour that is not a recurrence or a 
direct extension of a known tumour. All women with evidence of distant 
metastasis at the moment of primary diagnosis were excluded, as were 
patients who had a prior cancer other than non-melanoma skin cancer. A 
total of 5,589 women were selected. The occurrence of any subsequent 
MCBC was ascertained by means of computerized record linkage. MCBC 
was defined as any contra-lateral breast cancer occurring at least six months 
after the first breast cancer. All other contra-lateral cancers were considered 
as synchronous bilateral breast cancers. Patients with synchronous bilateral 
breast cancer (N=94) were excluded from the cohort and thus the final 
cohort consisted of 5,495 patients with primary ipsilateral breast cancer. 
Of these 5,495 women diagnosed with ipsilateral breast cancer, MCBC 
was reported in 139 patients during follow-up. For each of these patients, 
four to five patients without evidence of MCBC (n=597) - matched for 
hospital of diagnosis, age at first primary tumour and duration of follow-up -
were selected randomly from the cohort. Follow-up information was retrieved 
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actively from medical documents in hospitals for all 736 patients in our study. 
Follow-up information was not available for 67 patients (12 with MCBC and 
55 without MCBC). For 1 3  patients, the MCBC was diagnosed after the 
hospital follow-up had ended, thus these MCBCs were not included in the 
evaluation of the contribution of surveillance mammography. Therefore, the 
study finally included 656 breast cancers with 1 1 4 occurrences of MCBC 
during hospital follow-up and 542 non-MCBCs. 
Defin itions 
Surveillance mammography was defined as mammography undertaken with 
or without physical breast examination and other tests, in patients without 
any symptoms of relapse. The programme sensitivity of surveillance 
mammography was evaluated by calculating the number of MCBCs as 
detected by mammography divided by the total number of MCBC. Specificity 
was defined as the proportion of normal mammograms (BIRADS 1 and 2) 
out of the mammograms of the 542 patients without evidence of MCBC. All 
mammograms with BIRADS 3, 4 and 5 were considered as suspect for 
malignancy. In the case of BIRADS 3 the strategy was to perform additional 
diagnostics or to repeat the mammogram after six months, depending on the 
other patient characteristics. For mammograms without BIRADS 
classification, there was a classification with four categories (negative / 
benign / doubtful / malignancy). Negative and benign findings were 
categorized as Bl RADS 1 and 2, doubtful findings which needed further tests 
were considered as BIRADS 3 or BIRADS 4, and those highly suggestive of 
malignancy were considered as Bl RADS 5. The follow-up was considered as 
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over when the patient was diagnosed with distant metastases, when there 
was a note in the files that the patient was discharged from further hospital 
follow-up, when the patient was referred to the National Breast Cancer 
Screening Programme, when the patient was transferred to a general 
practitioner for further follow-up or when the patient died. Overall survival 
and distant metastasis-free survival of MCBC patients was measured from 
the date of diagnosis of the first breast cancer. 
Compliance with routine clinical examination and routine mammography 
were considered for patients with MCBC diagnosis. If the interval between 
the diagnosis of MCBC and the last clinical examination was less than or 
equal to the scheduled interval of clinical examinations (2-6 months in the 
first year; 4-8 months in the second year; 10-14 months in the following 
year), the patient was considered to be compliant with routine follow-up. If 
the interval between MCBC diagnosis and the previous mammography was 
less than or equal to 14 months, the patient was considered to be compliant 
with annual mammography. 
Patients with MCBCs were divided into three groups by mode of 
detection. "Routine mammography" consisted of patients with MCBC 
detected by mammography alone in routine follow-up. "Routine others" 
consisted of patients with MCBC detected in other ways, usually physical 
examination, during routine follow-ups with or without mammography. 
"Interval" consisted of patients with MCBC presenting between two 
scheduled follow-up appointments. 
Statistical analysis 
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The incidence of MCBC and the confidence intervals (95% Cls) were 
calculated by the use of life tables. Both the sensitivity and the specificity of 
the mammography and their 95% Cls were calculated. Generalized 
estimating equations (GEE) was used to estimate the 95% Cls for specificity 
estimates, which accounted for dependent outcomes among women who 
received more than one mammography during the study period. In addition, 
positive predictive values (PPVs) were calculated. 
The mode of detection of MCBC was compared with chi-square tests among 
groups with regard to the year of first tumour, patient age at MCBC, time to 
MCBC occurrence from first tumour and MCBC characteristics. Kaplan­
Meier survival analysis was used to compare the overall and distant 
metastasis-free survival of the groups with regard to mode of detection, 
compliance with routine follow-up visit and compliance with annual 
mammography. The association of mode of detection with survival of MCBC 
patients was examined by a multivariate Cox proportional hazard model, 
adjusted for tumour characteristics at the first breast cancer and time from 
first tumour to MCBC. The impact (hazard ratios) of compliance with routine 
follow-up visits and annual mammography on survival was evaluated by 
univariate Cox proportional analysis. 
Results 
Incidence of MCBC 
Of the 5,495 women diagnosed with ipsilateral breast cancer, MCBCs were 
reported in 139 patients. The cumulative MCBC incidence rate at years 5 
81 
and 1 0  was 2.0% (95% Cl: 1 .6-2.4%) and 3.4% (95% Cl: 2.8-4.0%), 
respectively (See Figure 1 ). 
Compliance, programme sensitivity and specificity of mammography 
One hundred and fourteen MCBCs were included in the evaluation of the 
contribution of surveillance mammography of patients followed up in hospital. 
Nine (7.9%) patients were considered as not complying with routine clinical 
examinations because they missed at least the former scheduled clinical 
examinations. Eighteen ( 1 5.8%) patients were considered as not complying 
with annual mammography because they missed at least the previous 
scheduled mammography. 
The programme sensitivity of surveillance mammography was 59.6% 
(68/1 1 4; 95% Cl: 50.6-68.7%; see Table 1 ). In the 105 patients complying 
with routine clinical examination, the sensitivity was 64.8% (68/1 05; 95% Cl: 
55.6-73.9%). In the 96 patients complying with annual mammography, the 
sensitivity was 70.8% (68/96; 95% Cl: 6 1 .  7-80.0%). The specificity of 
mammography was 98.3% (95% Cl: 97.9-98.7%). 
Positive predictive values related to BIRADS scores (if available) 
For 40% (n=1 392) of the mammograms the BIRADS score was available. 
The PPVs for BIRADS 3, 4 and 5 were 0% (0/12), 25% (1 0/40) and 91% 
(1 9/21 ) , respectively. The overall PPV for the mammograms with Bl  RADS 
classification regarding the presence of MCBC was 40% (29/73) which is 
somewhat higher than the PPV related to the mammograms without 
Bl RADS classification (31 %; 39/1 25). 
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Mode of detection 
Forty-two (36.8%) MCBCs were detected by mammography alone. Thirty­
three (29.0%) MCBCs were in the "routine others" group, of which seven 
(6.2%) MCBCs were detected by physical examination alone, twenty-six 
(22.8%) were identified by both physical examination and mammography. 
Thirty-nine (34.2%) tumours were diagnosed as interval cancers. 
There were trends indicating that MCBC was more likely to be detected by 
mammography in patients with the first tumour diagnosed after 1994 (Chi­
square=15.075, P=0.005) and in patients with MCBC at pathological T stage 
1 or Tis (Chi-square=5.925, P=0.052; See Table 2). 
Comparison of MCBC patient survival by mode of detection 
The patients with MCBC detected by mammography alone had better 
overall survival and distant metastasis-free survival rate than patients with 
MCBC detected by "routine others" and "interval". (Log-rank=11.598, 
P=0.003 and Log-rank=10.401, P=0.006, Figures 2a and 2b). 
Multivariate analysis indicates that the patients with MCBC detected by 
mammography have better survival rates than patients with MCBC detected 
by other means during routine follow-up (HR: 2.59;95% Cl: 1.17-5.75), and 
with MCBC arising as interval cases (HR: 3.63; 95%CI: 1.74-7.54). When we 
combined "routine others" and "interval", due to the overlap of the 95% Cls 
of the HRs, the HR of death was 3.18 (95% Cl: 1.59--6.34) in patients with 
MCBC detected by other means compared to patients with MCBC detected 
by routine mammography alone. Patients with a first tumour at the 
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pathological T2/3/4 stages have worse survival rates (HR: 1.90; 95% Cl: 
1.09-3.30) than patients with a first tumour at the pathological T1/Tis stage. 
Patients with involved lymph nodes at first tumour diagnosis have worse 
distant metastasis-free survival rates (HR: 1.91; 95% Cl: 1.09-3.35) than 
those without involved lymph nodes. Patients with MCBC occurring earlier 
after the first tumour have worse overall and distant metastasis-free survival 
rates than patients with MCBC occurring later (HR: 0.86; 95% Cl: 0. 76-0.96 
and HR: 0.86; 95% Cl: 0.77-0.95, respectively; Table 3). 
Comparison of MCBC patient survival by compliance 
In addition, we evaluated the potential impact of compliance with routine 
clinical examinations and compliance with annual mammography on MCBC 
patient survival. Nine patients who missed at least the former scheduled 
clinical examinations showed worse survival (HR: 1.69; 95% Cl: 0.72-3.96) 
and distant metastasis-free survival (HR: 1.91; 95% Cl: 0.82-4.45) but 
neither result was statistically significant due to the small sample of non­
compliant patients (See also Figures 2c and 2d). There is no significant 
association of survival (HR: 1.02; 95% Cl: 0.50-2.09) or distant metastasis 
free-survival (HR: 1.00; 95% Cl: 0.19-2.04) with compliance with annual 
mammography in patients with MCBC. The survival curve of the compliant 




This study is one of the largest studies to evaluate the impact of surveillance 
mammography on the survival of MCBC patients. The cumulative MCBC 
incidence rate at years 5 and 10 was 2.0% and 3.4% , respectively. The 
programme sensitivity of follow-up mammography was 60%. The patients 
with MCBC detected by mammography alone had better survival rates than 
patients with MCBC detected by other means with or without mammography 
(p=0.004). For patients complying with annual mammography, sensitivity 
was increased to 71 %. Though there was a trend towards improved survival 
in patients being compliant with regular follow-up (HR: 1 .69; 95% Cl: 0. 72-
3.96), this was not the case for patients being compliant with annual 
mammography (HR: 1 .02; 95% Cl: 0.50-2.09). 
Women diagnosed with a primary breast cancer are at increased risk of 
developing a second breast cancer. Markedly increased risks of MCBC have 
also been observed among breast cancer patients in many other studies [1 , 
4, 6, 1 7] The annual risk of developing MCBC remained constant at 0.3-
0.4 % per year after treatment in this series, which indicates that patients 
remain at risk of contra-lateral breast cancer for at least ten years, which is 
consistent with findings in other studies [6] This emphasizes the importance 
of surveillance and treatment of MCBC even at ten years after primary 
treatment to prevent the increased morbidity and mortality caused by MCBC. 
We estimated the programme sensitivity of surveillance mammography to 
be 60% and the specificity to be 98%. These estimates are comparable with 
other studies, including studies of the breast cancer screening programme 
(sensitivity: 58-75%; specificity: 97-99%) [1 8-20] and studies of the follow-
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up of breast cancer survivors (sensitivity: 44%-70%) [21-23]. Reported 
proportions of MCBC detected by mammography vary from 40% to 70% 
between studies because of dissimilarities in the patient populations, the 
frequency of mammography and MCBC case definition[2, 21-23]. Due to the 
biological behaviour of tumours, some tumours will be missed by annual 
mammography. In this study we were not able to review mammograms to 
assess whether cancers had been missed or should have been considered 
as real interval cancers, which can be considered as a limitation of the study. 
The proportion of MCBC detected by mammography alone was 37% in our 
study, which was less than the rate reported in the studies mentioned above. 
There was a trend that occurred in younger patients that MCBC is less likely 
to be detected by mammography, and the efficacy of mammography was 
also questioned in younger patients [23] The patients in our series are 
relatively young compared to other studies, which could partly explain the 
lower proportion of MCBC detected by mammography alone[24]. We found a 
statistically significant association between the method of MCBC detection 
and the year of diagnosis. The proportion of MCBC detected in this study by 
mammography alone was higher when the patients developed MCBC after 
1994. One review paper also implied that the contribution of mammography 
appeared to be of increasing importance over time[12]. A possible 
explanation for this could be technical improvements in mammography and 
the more effective use of mammography, as a consequence of the national 
guidelines on follow-up and the implementation of a national breast cancer 
screening programme in this country. Women with DCIS are at a two to 
fourfold greater risk of developing cancer in the contra-lateral breast than 
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women without prior DCIS [25]. Due to the limited number of patients with 
prior DCIS, we could not separately evaluate the value of surveillance 
mammography in women with prior DCIS. 
Since 2000, there is a guideline in the Netherlands to use the BIRADS 
system. As a consequence, for about 60% of the mammograms the Bl RADS 
score was not available in this study. The overall PPV for the mammograms 
with BIRADS classification regarding the presence of MCBC was 40% which 
is somewhat higher than the PPV related to the mammograms without 
Bl RADS classification (31 %). The higher PPV in mammograms with a 
BIRADS classification might be a reflection of an improved classification. 
The higher the BIRADS score, the higher the related PPV. It should be 
mentioned that the follow-up information was collected only for a stratified 
sample of this population (n=656), including all patients with a MCBC and a 
selection of patients without MCBC. As a consequence, this sample does 
not give a reflection of the true prevalence of MCBC, which was only 2.5% 
(1 39/5495) in the original sample. At can be expected that the PPV will be 
lower in clinical follow-up practice. 
The tumour size of MCBC detected by mammography alone was smaller 
than that found for "routine others" and "interval" cases, as expected, though 
the differences were not statistically significant, probably due to the 
reduction of sample size by missing values. The proportion of smaller 
tumours (less than 2 cm) was much higher (86%) in MCBC detected by 
mammography, which accords with the study by Samant and colleagues [2]. 
We did not find any significant difference in the histological characteristics of 
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MCBC between the patients with MCBC detected by mammography and 
other methods. 
The characteristics of the primary tumour were associated with the overall 
survival rate and the distant metastasis-free survival rate of MCBC patients. 
The mode of detection of MCBC remained significantly associated with both 
the overall survival rate and distant metastasis-free survival rate in MCBC 
patients after adjustment for the first primary tumour characteristics, which 
indicated that the impact of detection mode on survival could not be 
explained by any difference in the pathological stage of the first tumour [21, 
26]. A population-based study revealed that MCBC at stage II or higher 
worsens the patient survival rate whereas the MCBC at stage I does not [27]. 
As with earlier diagnosis of first tumours, the early detection of MCBC was 
associated with an 81 % reduction in risk of breast cancer death in the SEER 
database[28]. We presume the impact of the mode of detection of MCBC on 
survival was mainly due to the early detection of MCBC by mammography. 
Additionally, our results indicate that the interval between MCBC occurrence 
and the first tumour was associated with MCBC patient survival, which is in 
line with another study [29]. The goal of surveillance mammography not only 
includes the early detection of MCBC but also the early detection of 
ipsilateral tumour recurrences. One review found that 30% of all ipsilateral 
tumour recurrences were detected by mammography in patients after breast 
conserving surgery; however, no significant reduction of mortality was found 
in patients with ipsilateral tumour recurrences detected by 
mammography[12]. Further research is warranted to investigate the impact 
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of mammography on survival with regard to early detection of ipsilateral 
tumour recurrence. 
Although the benefit of mammography is unbiased by lead time because 
survival was measured from the first primary breast cancer, a length bias is 
unavoidable in studies comparing mammography detected cancers with 
interval cancers. The slow-growing MCBC are more likely to be detected by 
mammography. Nevertheless, although length bias was also claimed to 
affect the evaluation of mammographic efficacy in the breast cancer 
screening programme, periodic mammography was well accepted as the 
most cost-effective method for screening for breast cancer in many countries, 
supported by evidence from randomized controlled studies[30]. Therefore, 
although the observed survival improvement associated with the mode of 
detection of MCBC might be partially explained by length bias, it appears 
that surveillance mammography is effective for the early detection of MCBC 
and for improving those patients' survival. 
Competing risk is always an issue when investigating the prognostic 
factors of one disease with all-cause mortality. The patients could die from 
diseases other than breast cancer. It is reasonable to suppose that older 
patients are more likely to die due to competing risks. However, patients with 
MCBC detected by mammography alone were not younger than those in the 
"routine others" and "interval" groups. The findings were also not reversed 
when distant metastasis was taken into account as a substitute for breast 
cancer specific mortality. Therefore, competing risk is unlikely to explain the 
better survival in mammography detected MCBC patients. 
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Eighteen patients did not receive annual mammography in the preceding 
fourteen months. In other words, the interval between the tumour detection 
and the last mammography was greater than one year for these patients. It 
is possible that MCBCs were detected early by mammography where 
patients complied with annual mammography. In this study, we found a trend 
indicating that the sensitivity of mammography was improved in patients 
being compliant with routine clinical examinations and patients being 
compliant with mammography. There was a trend of improvement of 
prognosis in patients who complied with routine follow-up, though the 
differences were not statistically significant, probably due to the small 
sample size of non-compliant patients. Regarding compliance with 
mammography, we did not find a significant association between the 
compliance with annual mammography with the prognosis of patients with 
MCBC, despite the 11 % (from 59.6% to 70.8%) improvement in the 
sensitivity of annual mammography. Though annual mammography could 
improve the early detection of MCBC and could improve the chances of 
improving survival, it is not yet clear that the detection of MCBC by 
mammography will result in better survival, due to the varying behaviour of 
tumours and the characteristics of patients. The cohort in this study, though 
very large in comparison to previous studies, is still too small to answer 
these important questions. Our findings indicate the 11 % improvement in 
sensitivity in compliant patients is unlikely to be sufficient to reduce mortality 
among women with MCBC, which is in line with another study [31 ]. The 
same analysis should be repeated with a much larger cohort of women. A 
generally considered disadvantage of routine follow-up is that patients who 
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had suspicious symptoms wait for their clinic visit rather than going to 
hospital, which probably worsens prognosis. Patients should be strongly 
advised to see their doctors whenever suspicious symptoms are found [7, 8]. 
In summary, the risk of contra-lateral breast cancer remains constant 
after primary breast cancer, even after ten years at 0.3-0.4% per year. 
During routine follow-up, this study convincingly shows that mammography 
can identify MCBC at an early stage and thereby improve the survival of 
these patients. Mammography is a valuable tool for the early detection of 
MCBC during hospital follow-up of breast cancer patients and is probably 
beneficial to survival. The utilization of follow-up surveillance in breast 
cancer patients and its potential impact on survival deserve further 
investigation. 
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Table 1 Sensitivitl of mammo�raphl in follow-up of breast cancer patients 
Patients n/N 
Sensitivity 
% 95% CI 
All patients (programme 68/1 14  59.6 50.6-68.7 
sensitivity) 
Compliant with routine clinical 68/ 105 64.8 55 .6-73 .9 
examination 
Compliant with annual 68/ 96 70.8 6 1 .7-80.0 
mammography 
Table 2 Comparison of mode of detection for 114 MCBCs 
Routine 
Routine others Interval 
x
2 
Characteristics mammography P value 
(n=42) 
(n=33) (n=39) 
Year of diagnosis of 1 5 .075 0.005 
MCBC 
1 989- 1993 1 (9) 2 ( 1 8) 8 (73) 
1 994-1998 1 9  (37) 21 (4 1 )  1 1  (22) 
1 999-2004 22 (42) 1 0  ( 1 9) 20 (39) 
Time from first 
tumour 
6m 10 (39) 9 (34) 7 (27) 1 .007 0.907 
2yrs 20 (37) 1 5  (28) 19 (35) 
5yrs 12 (35) 9 (27) 13 (38) 
Age group at MCBC 
<50 5 (23) 6 (27) 1 1  (50) 4.359 0.628 
50-59 1 1  (37) 9 (30) 1 0 (33) 
60-74 16 (40) 1 1  (28) 13 (32) 
75+ 10  (45) 7 (32) 5 (23)  
Pathologic T stage 
pT l /Tis 36 (47) 19 (25) 22 (28) 5 .925 0.052 
pT2/3/4 5 (2 1 )  1 1  (46) 8 (33)  
Missing 1 (8) 3 (23) 9 (69) 
Pathologic N stage 
NO 26 (36) 20 (27) 27 (37) 1 .796 0.407 
N+ 10 (36) 1 1  (39) 7 (25) 
Missing 6 (46) 2 ( 1 5) 5 (39) 
Histology 1 .69 1 0.429 
Invasive 36 (36) 3 1  (3 1 )  3 3  (33)  
Non-invasive 6 (43) 2 ( 14) 6 (43) 
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Table 3 Multivariate Cox regression analysis of prognosis in patients with MCBC 
Factors Hazard ratio 95% CI P-value 
Death 
Method of detection 
Routine mammography alone 1 0.003 
Routine physical examination 2.59 1 . 1 7-5.75 
Interval 3.63 1 .74-7.54 
Pathologic T stage of first tumour 
pT l ffis 1 0.023 
pT2/3/4 1 .90 1 .09-3.30 
Time between first tumour and 0.86 0.76-0.96 0.008 
MCBC (yrs) 
Distant metastasis and Death 
Method of detection 
Routine mammography 1 0.0 1 1 
Routine physical examination 2.09 1 .00--4.37 
Interval 2.90 1 .45-5.78 
Pathologic N stage of first tumour 
NO 1 0.023 
N+ 1 .9 1  1 .09-3.35 
Time between first tumour and 0.86 0.77-0.95 0.004 
MCBC(�s) 
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Chapter 6 
The value of routine physical examination in the fol low up 
of women with a history of early breast cancer 
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ABSTRACT 
Purpose: Routine physical examination is recommended in follow up 
guidelines for women with a history of breast cancer. The objective of this 
paper is to assess the contribution of routine physical examination in 
addition to mammography in the early diagnosis of breast cancer 
recurrences. 
Patients and methods: The medical follow-up documents of 669 patients 
were reviewed. 127 contra-lateral breast cancers (CBCs) and 58 loco­
regional recurrences (LRRs) in 163 patients were included. The additional 
contribution of routine physical examination over mammography was 
evaluated with the proportions of CBCs or LRRs detected by physical 
examination alone. Chi-square tests were used to compare the difference of 
contribution of physical examination among subgroups. 
Results: Seven (6%) out of 127 CBCs and 13 (22%) out of 58 LRRs were 
detected by routine physical examination alone. Six LRRs (17%; 6/35) were 
in patients after breast conserving surgery and seven LRRs (30%; 7/23) in 
patients after mastectomy. There was a trend that the contribution of 
physical examination is higher in women under 60 years of age in the 
detection of CBCs (9%; 5/57) and LRRs (28%, 8/29) than in women over 60 
years of age (CBCs:3%; 2/70 and LRRs:17%, 5/29; Chi-square=3.090, 
P=0.079). 
Conclusions: 22% of loco regional breast cancer recurrences would have 
been detected later without physical examination. Routine physical 
examination may be most valuable for women with a history of breast cancer 
younger than 60 years at follow-up visit. 
Key words: Breast neoplasm; Contra-lateral breast cancer (CBC); Loco­
regional recurrence (LRR); Physical examination 
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Introduction 
A combination of high incidence and good survival makes breast cancer the 
most prevalent cancer in women [1]. This puts an increasing burden on 
follow-up oncology clinics. It is predicted that there will be a 48% increased 
need for cancer services by 2020 [2].Specialists are facing an ever­
increasing workload of providing long-term follow-up care for women with a 
history of early-stage breast cancer. This will call for guidelines and 
programs to provide comprehensive, compassionate and cost-effective 
follow-up care [3]. 
One of the main purposes of follow-up after breast cancer is early 
detection of isolated breast cancer recurrences such as loco-regional 
recurrence (LRR) and contra-lateral breast cancer (CBC), because these are 
the kind of recurrences that could be treated aiming at cure or long term 
disease free survival. A meta-analysis suggested that early detection of 
isolated breast cancer recurrences is associated with an increased chance 
of survival [4]. Routine mammography and physical examination is 
recommended in the follow up guidelines for women with a history of breast 
cancer to detect these LRRs and CBCs early [5-7]. The value of 
mammography for early detection of CBC has been confirmed in several 
studies [8-10]. In addition, LRR in the conserved breast can often be 
detected early by mammography [11-12]. However, the contribution of 
routine physical examination to the early detection of a recurrence is 
debatable and estimates for the proportion of recurrences detected by 
physical examination alone vary from 6% to 40% [13]. It is known that the 
performance of physical examination is at least influenced by age and 
previous surgical treatment (breast conserving surgery versus mastectomy) 
[14-15]. In addition, a higher frequency of physical examinations in the first 5 
year after primary treatment has been recommended [16]. It was 
hypothesized that there might be more LRRs and CBCs detected by routine 
physical examination due to the intensive follow-up in the first five years after 
primary treatment. The aim of the current study is to evaluate the 
contribution of physical examination in addition to mammography during 
following up of women with a history of breast cancer, and to assess the 
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influence of patient's age at follow-up visit, previous surgical treatment and 
the time since primary diagnosis on the diagnostic value of physical 
examination. 
Patients and methods 
Settings and subjects 
Patients with breast cancer were selected from the files of the regional 
cancer registry of the former Comprehensive Cancer Centre North­
Netherlands (CCCN, merged into the Comprehensive Cancer Centre 
Northeast-Netherlands in 2009). This cancer registry contains data on 
diagnosis, stage, and treatment actively abstracted from the medical records 
of all hospitals within the CCCN catchment area using a national registration 
and coding manual of the Dutch Association of Comprehensive Cancer 
Centres. 
For 5,589 consecutive women, breast cancer was the first primary 
cancer diagnosed in four hospitals in the Northern part of the Netherlands 
(an academic hospital, a large teaching hospital and two non-teaching 
hospitals) from January 1989 to January 2003. A new primary tumour was 
defined as any new tumour that was not a recurrence or direct extension of 
the known tumour. All these women were without evidence of distant 
metastasis at the moment of primary diagnosis. Of these 5,589 women a 
total of 139 patients developed CBC at least six months after the first tumour 
and those CBCs were registered in the database. Because the information 
on follow-up and LRRs is not available in the cancer registry, this additional 
follow-up information was retrieved from the medical documents in the four 
participating hospitals. Follow-up information was collected for all 139 
patients with a CBC and for a sample of the patients (n=597) without a CBC. 
To minimize bias, patients without a CBC were stratified on hospital of 
diagnosis, age at first primary tumour, and duration of follow-up before 
sampling. 
For these 736 patients, follow-up information was retrieved from medical 
documents in the four participating hospitals (Fig. 1 ). Follow up documents 
were unavailable for 67 patients (9%) of whom 12 patients had CBCs. Of the 
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remaining 669 women included in this cohort, 51 patients were found to 
have developed a total of 58 LRRs (recurrences in the conserved breast, 
chest wall, axilla or supraclavicular nodes at the same side of the primary 
tumour). Recurrences that were detected in the same patient within a six 
months period were considered as one recurrence. 
Therefore, a total of 127 CBCs and 58 LRRs in 163 patients were 
reported in this cohort. In the other 506 patients there was no evidence of 
LRRs or CBCs. Patients who developed distant metastases before or at the 
time of CBC or LRR were not included. 
Data abstraction 
For all patients included in our study cohort, the information regarding 
appointments and tests were retrieved, including date of appointment, 
symptoms reported by the patients during or pending the appointment (yes 
or no; and kind of symptoms if applicable), findings of routine physical 
examination (mass, abnormality in scar, abnormality in axilla or supra­
clavicular) and mammography. For the analyses, all follow-up visits were 
regrouped into episodes, which were defined as 45-day periods. It was 
assumed that follow-up appointments that happened within these episodes 
were related to each other, so the information was combined. 
Definitions 
Routine physical examination was defined as the physical examination 
undertaken by a physician during the routine follow-up visits with or without 
mammography. Routine mammography was defined as a mammography 
that was undertaken during routine follow-up visits with or without physical 
breast examination. 
The mode of detection of CBCs and LRRs was classified as 
mammography alone (in case of normal findings on physical examination 
and abnormal mammograms in asymptomatic patients); physical 
examination alone (in case of abnormal findings on physical examination 
and normal mammograms in asymptomatic patients); both mammography 
and physical examination (in case of abnormal findings of physical 
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examination and abnormal mammograms in asymptomatic patients) and 
symptoms (reported by patients at interval visits between two scheduled 
follow-up visits or presented at scheduled follow-up visits). 
The contribution of routine physical examination was evaluated by 
assessing the proportion of recurrences detected by routine physical 
examination alone. The analysis of the contribution of physical examination 
was based on the number of recurrences. 
Statistical analysis 
Comparisons of the contribution of physical examination were performed by 
chi-square tests among subgroups with respect to the type of recurrences, 
the surgical treatment of the first tumour, age of the patient at the time of 
recurrence, and the time from the first tumour. For all the patients included in 
this sample, the information on follow-up and LRR was collected from the 
documents in hospital including the follow-up appointments and the follow­
up procedures. The number of mammographies and physical examinations 
performed during the follow-up of each patient was analyzed aiming to give 
a profile of the burden of follow-up in case of a LRR. Because CBC events 
were oversampled, the burden of follow-up to early detect CBCs could not 
be assessed. The number of routine physical examinations undertaken for 
the early detection of one additional loco-regional recurrence in addition to 
routine mammography were calculated in subgroups with respect to surgical 
treatment modality, patients' age and the time from the first tumour. 
Results 
Characteristics of patients and the primary breast cancer 
Of the 669 included patients, 56% (n=375) were younger than 60 years of 
age when the primary breast cancer was diagnosed (Table 1 ). 32% (n=2 14) 
of patients received breast conserving surgery as primary treatment, 57% 
(n=383) of the patients received radiotherapy, 15% (n= 101) chemotherapy 
and 21  % (n= 139) hormonal therapy, respectively. The median follow-up time 
was 1 1.0 years (1.6-18. 1). 
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Characteristics of CBCs and LRRs 
Out of 127 CBCs, 45% (n=57) were diagnosed in patients under the age of 
60 (Table 1 ). Seventy-five percent ( n=84) out of 112 CB Cs with specified 
pathological T stage were detected at stage T1 or Tis. Of all CBCs, 70% 
(80/114) were detected without lymph nodes involved. 31 %( n=39) of 127 
patients with CBC received radiotherapy for the CBC, 13% (n=16) received 
chemotherapy and 26% (33) received hormonal therapy. 34% of CBCs 
(n=43) were diagnosed more than five years after primary treatment. 
Out of the 58 isolated LRRs, 50% (29) were diagnosed in patients under 
the age of 60 (Table 1 ). 49% of the LRRs (n=25) were treated with 
mastectomy, where 51 % of LRRs (n=26) were treated with local excision. 
Five LRRs were detected in women who had breast conserving surgery 
previously and 21 LRRs were detected in women who had mastectomy 
previously. For seven LRRs the type of surgical treatment was unknown. 
For 34% of LRRs (n=20), patients received radiotherapy, for 85% of 
LRRs (n=49), patients received chemotherapy and for 33% of LRRs (n=19) 
patients received hormonal therapy. Thirty-one (53%) out of 58 LRRs 
developed more than five years after the primary treatment. 
Detection of contra-lateral breast cancers 
Of 127 CBCs, seven ( 6%) were detected by routine physical examination 
alone, 42 ( 33%) were detected by mammography alone and 26 ( 21%) were 
detected by both follow-up modalities (Table 2). Of the 75 asymptomatic 
patients with CBCs, 33 (44%; 95%CI: 32-56%) were palpable by the 
physician at routine follow-up visits. Out of 52 patients (41%) who reported 
symptoms leading to the diagnosis of a CBC, 11 (9%) presented at 
scheduled follow-up visits and 41 (32%) presented as interval cases. 
In total, 86 patients (67.7%) patients with CBCs were detected during 
routine follow-up visits and 41 (33.3%) presented as interval cases. Out of 
86 patients detected during routine follow-up visits, 33 patients (38.4%) with 
CBCs were palpable in routine physical examiantions. 
Detection of loco-regional recurrences 
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In 214 patients who received breast conserving surgery for the primary 
tumour, 16% (n=35) of LRRs were diagnosed. Eleven LRRs after BCS were 
diagnosed because of symptoms reported by the patient (31 %) between two 
scheduled follow-up visits and none at the moment of a scheduled visit. Of 
the 24 asymptomatic LRRs, 17 (71%; 95%CI: 51-91%) were palpable by the 
physician at routine follow-up visits. Six of the LRRs (17%) were diagnosed 
by routine physical examination alone, 20% (n=7) by routine mammography 
alone and 31 % (n=11) by both {Table 2). 
Of the 429 patients treated with mastectomy, 5% (n=23) LRRs were 
diagnosed. Of these, 30% (n=7) were detected by routine physical 
examination alone {Table2). 70% (n=16) presented with symptoms in which 
40% (n=9) presented at scheduled follow-up visits and 30% (n=7) presented 
as interval cases. 
In total, 40 patients (69.0%) patients with LRRs were detected during 
routine follow-up visits and 18 (31.0%) presented as interval cases. Out of 
40 patients detected during routine follow-up visits, 24 patients (60.0%) with 
LRRs were palpable in routine physical examinations. 
When considering only the first recurrence in each patient, it was found 
that seven (6%) out of 120 CBCs and six (14.0%) out of 43 LRRs (4 LRRs 
after breast conserving surgery and two LRRs after mastectomy) were 
detected by routine physical examination alone. 
Contribution of physical examination 
Seven (6%) out of 127 CBCs and 13 (22%) out of 58 LRRs in which six 
LRRs (17%;6/35) in patients after breast conserving surgery and seven 
LRRs (30%;7/23) in patients after mastectomy were detected by routine 
physical examination alone. The incremental contribution of physical 
examination was higher in detecting LRRs than in detecting CBCs (Chi­
square=11. 797, P=0.001 ). 
Seventeen percent (n=6) of 35 LRRs after breast conserving surgery 
and 30% (n=7) of 23 LRRs after mastectomy would have been detected later, 
if there was no routine physical examination. The difference in the 
contribution of physical examination in the detection of LRRs after BCT or 
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after mastectomy was not statistically significant (Chi-square= 1 .41 0, 
P=0.235). 
There was a trend that the proportion of recurrences detected by 
physical examination alone was higher in women under 60 years of age at 
follow-up visit than in those over 60 years (Chi-square=3.090, P=0.079). In 
women under 60 years of age at follow-up visit, 9% (n=5) of 57 CBCs and 
28% (n=8) of 29 LRRs would have been missed, if there was no routine 
physical examination. For women over 60, 3% (n=2) of 70 CBCs and 1 7% 
(n=5) of 29 LRRs would have been detected later if there was no routine 
physical examination, respectively. 
Of the recurrences occurring within five years after the primary tumour, 
4% (n=3) of 84 CBCs and 26% (n=7) of 27 LRRs were detected with routine 
physical examination alone. For recurrences occurring after five years from 
the first tumour, 9% (n=4) of 43 CBCs and 1 9% (n=6) of 31 LRRs were 
detected with routine physical examination. There is no significant 
association between the proportions of recurrences detected by physical 
examination alone and time from the first tumour (Chi-square=0.934, 
P=0.334). 
801 (1 041 1 /1 3) physical examinations were done to detect one 
additional LRR. In patients after breast conserving surgery, 71 6 (4298/6) 
physical examinations were done to detect one additional LRR. In patients 
after mastectomy, 873 (61 1 3/7) physical examinations were done to detect 
one additional LRR. For patients younger than 60 years, 644 (51 52/8) 
physical examinations were done to detect one additional LRR, whereas the 
number was 1 052 (5259/5) for patients older than 60. In the first five years, 
1 041 (7286/7) physical examinations were done to detect one additional 
LRR, whereas this number was 521 (3125/6) more than five years after 
primary treatment (Fig. 2). 
Discussion 
If there was no routine physical examination, 22% of 58 LRRs and 6% of 
1 27 CBCs would have been detected later. There was a trend towards a 
higher contribution of physical examination in detecting LRR in younger (<60) 1 06 
patients than in older (�60) patients. For patients younger than 60 years at 
follow-up visit , 644 physical examinations were performed to detect one 
additional LRR, whereas, for patients older than 60 years at follow-up visit, 
the number was 1052. 
Regular mammography has proven its benefit in the early detection of 
CBC [8, 17]. There are only a few studies to evaluate the contribution of 
physical examination in early detection of CBC. In this study the number of 
CBCs was enriched to evaluate the contribution of physical examination on 
detecting CBCs by including all available patients with CBCs of 5589 
patients with a history of breast cancer. The overall detection rate of CBC by 
routine physical examination alone is low in this study, which is consistent 
with results from a recent study (6%) [13, 18]. This result is also in line with 
one study adding routine physical examination to mammography for the 
screening for breast cancer, which reported an additional 5% of tumours 
detected by physical examination alone [19]. 
There is a trend that the contribution of physical examination is higher in 
detecting LRRs in patients after mastectomy, however the difference was 
not statistically significant, probably due to the small number of LRRs in both 
groups. Seven asymptomatic LRRs (30%) in patients after mastectomy were 
detected by physical examination alone during routine follow up. In patients 
treated with breast conserving surgery, mammography is available and 
useful for the detection of a LRR although the sensitivity of mammography 
will be decreased in the conserved breast due to the scar and changes in 
density of the breast after surgery [20]. After mastectomy, the detection of 
LRRs was therefore expected to depend more on physical examination. 
However, this did not translate into a lower number of physical examinations 
performed to detect one additional LRR after mastectomy due to the lower 
incidence of LRR in this group and because these patients often perceived 
their own recurrences. Overall, the absolute number of physical 
examinations to be performed to detect one additional LRR is therefore still 
higher after mastectomy than after breast conserving surgery. 
The contribution of physical examination was larger in detecting CBCs 
and LRRs among women younger than 60 at follow-up visit. This finding was 
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in line with that of another study which evaluated the incremental 
contribution of physical examination over mammography in a breast cancer 
screening program [21]. Age has been reported to have an important 
influence on the sensitivity of mammography and the value of physical 
examination. Tumour characteristics are different across ages that might 
influence the performance of routine physical examination [17, 19,22]. In 
addition, it is possible that physicians might pay more attention when they 
examine younger patients due to the debatable performance of 
mammography. To our knowledge, the age of the patient has not been taken 
into account specifically yet during the follow up of patients with breast 
cancer. Our results indicate that more LRRs would be missed in the younger 
patients than in older patients if there was no routine physical examination 
although the numbers are too small to draw a firm conclusion. If the routine 
physical examination for patients older than 60 years of age was no longer 
performed, there would be a reduction up to 50% of the number of physical 
examinations at follow-up visits and 3% CBCs and 17% LRRs would be late 
detected. Though there is evidence that early detection of breast cancer 
recurrence has beneficial effects on survival [4] there is no convincing 
evidence that delayed detection of a LRR or CBC leads to increased 
mortality. The randomised trial that would be necessary to prove such an 
effect on survival is unlikely to be performed so that these data will not 
become available. The possible impact of a reduction of the frequency of 
follow-up visits on survival or cost-effectiveness of follow-up remains unclear 
and may be the subject of future studies. 
The purposes of follow-up of women with breast cancer are not only 
early detection of recurrences but also meeting the needs of patients with 
respect to psychosocial problems and side effects, especially in the initial 
years. Regarding side effects and psychosocial problems, patient initiated 
follow-up is an alternative for patients with breast cancer [23,24]. Younger 
patients with breast cancer are a vulnerable group in terms of more severe 
psychosocial effects than older patients [25]. It is unlikely that stopping 
routine physical examination after the age of 60 changes the management of 
side effect and psychosocial problems. 
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Although the frequency of physical examination was higher in the first 
five years after primary treatment, this did not result in a significant increase 
of the proportion of tumours detected by routine physical examination alone. 
In the first five years after primary treatment, follow-up visits were scheduled 
with a decreasing frequency from four times in the first year to once in the 
fifth year. After five years from primary treatment, follow-up visits were 
scheduled once a year. Thus more physical examinations (n=1041) were 
done to detect one additional LRR in the first five years than after five years 
since the primary treatment (n=521 ). This could be an argument to reduce 
the number of follow-up visits during the first years after primary treatment 
although the goal of these visits is also to counsel patient and to detect side­
effects of the treatment besides the early detection of LRRs and CBCs. The 
feasibility of reducing frequency of physical examination in the initial years 
after primary treatment deserves further investigation. 
The workloads of physical examination for the early detection of one 
additional LRR were higher in patients after mastectomy, older patients and 
in the first five years after primary treatment. The estimates of the number of 
routine physical examination undertaken for the early detection of one 
additional recurrence are not applicable in detection of CBCs. The cohort in 
this study is a CBCs enriched cohort in which the proportion of CBCs is far 
higher than that in general cohort of patients with a history of breast cancer. 
As the incidence of CBC was lower than that of LRRs and the contribution of 
physical examination was less in detecting CBC than loco-regional breast 
cancer as well, we presume, more physical examinations were needed for 
one additional CBC detected than LRRs as showed in this study. It is should 
be noted that our findings are only a descriptive cost-effectiveness analysis 
and more analytical cost-effectiveness and cost-benefit studies are needed. 
In conclusion, 22 % of loco-regional recurrences of breast cancer and 6% 
of contra-lateral breast cancers would have been detected later without 
physical examination. Routine physical examination probably has the 
highest contribution in younger patients (<60). This needs to be confirmed by 
studies with larger sample size before an advice can be given on follow-up 
regimens. When formulating policy and new guidelines of follow-up for 
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patients with breast cancer, patients' age at follow-up and previous 
treatment should be taken into account. The impact of (less frequent) 
physical examination on survival deserves further study. 
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Table 1 Characteristics of patients and their tumours* n (%) 
Characteristics Primary tumour CBC LRR 
N=669 N= l 27 N=58 
Age group at  diagnosis 
<60 375 (56) 57 (45) 29 (50) 
60+ 294 (44) 70 (55) 29 (50) 
Pathologic T stage 
pTis 57 ( 9) 14 ( 1 2) 
pT l 32 1 (49) 70 (63) 
pT2/3/4 28 1 (42) 28 (25) 
Unknown 1 0  1 5  
Pathologic N stage 
NO 439 (67) 80 (70) 
N+ 2 1 5  (33) 34 (30) 
Unknown 1 5  1 3  
Surgery 
Lumpectomy / Local excision 2 14 (33) 35 (34) 26 (5 1 )  
Mastectomy 429 (67) 68 (66) 25 (49) 
Unknown 26 24 7 
Radiation therapy 
Yes 383 (57) 39 (3 1 )  20 (34) 
No 286 (43) 88 (69) 38 (66) 
Chemotherapy 
Yes 1 0 1  ( 1 5) 1 6  ( 1 3) 49 (85) 
No 568 (85) 1 1 1  (87) 9 ( 1 5) 
Hormonal therapy 
Yes 139 (2 1 )  3 3  (26) 1 9  (33) 
No 530 (79) 94 (74) 39 (67) 
Time of follow up [median(range) yrs] l 1 .0 ( l .6- 1 8 . l )  1 0.0 ( l .6-1 8 . l )  1 1 .6 (2.2- 1 7.5) 
Time from first tumour (yrs) 3.8 (0.6-1 1 .9) 5 .0 (0.6-1 5 .6) 
<5 years 84 (66) 27 (47) 
5 years or more 43 (34) 3 1  (53) 
* Recurrences-based analysis 
1 1 1  
Table 2 Contribution of physical examination to mammography in follow-up of patients with breast cancer * n(¾) 
Method of detection 
Routine physical examination alone 
Routine mammography alone 
Both 
Symptoms reported by patients 
* Recurrences-based analysis 
b, 
CBC 




52(4 1 )  
LRR_BCS: Loco regional recurrence i n  patients after breast conserving surgery 
# LRR _ Mastectomy: LRR in patients after mastectomy 1 12 b, LRR_BCS (n=35) 6(17) 7(20) 1 1  (3 1 )  1 1  (3 1 )  LRR _ Mastectomy# (n=23) 7(30) 1 6(70) 
5589 patients with a new breast cancer 1 94 patients with I synchronous CBC 
5495 patients with a (excluded) ipsilateral breast cancer 
i i 
139 patients with 597 patients MCBC* without MCBC 12 without I 55 without available follow- I + + : available follow-up file ( excluded) up file ( excluded) 127 patients with 542 patients without MCBC MCBC 
i i J 
112 patients 15 patients with 36 patients 506 patients without with MCBC MCBC & LRR with LRR MCBC or LRR 
i i 
127 patients with 127 MCBCs 51 patients with 58 LRR.s MCBC : Meta-chronous contra-lateral breast cancer 
Fig . 1  Graphical i l lustration of the sampling of study cohort 
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BCS 1\/astectomy age<60 age�60 <5 years �5years 
Surgery Age lirre from first tumour 
Fig . 2 Number of routine physical examinations performed to detect one additional LRR 1 14 
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ABSTRACT 
Background: In The Netherlands after treatment for breast cancer, the first 
five years of follow-up are performed in the hospital with a yearly 
mammography. After this period, and when a patient is over the age of 60, 
after mastectomy, there is a shift of care to the National Screening Program 
(NSP) for a two-yearly mammography, or after breast conserving therapy to 
the General Practitioner (GP) for a two-yearly mammography and a yearly 
physical examination. The aim of this study was to evaluate the clinical 
effects and costs of four different strategies for the follow-up after breast 
cancer treatment in a simulation study. 
Method: A simulation model, extended and validated for breast cancer 
follow-up was used where the baseline strategy and three less intensive 
follow-up strategies were evaluated. The main outcome was the detection 
rate of small tumours (S 2 cm) and the related costs. 
Results: Shortening the follow-up time in hospital by a care shift from 
hospital to the NSP or GP after two years of hospital follow-up (instead of 
five), lowering the age of referral from 60 to 50, and termination of yearly 
physical examination by the GP after hospital follow-up did not show a 
substantial decrease in the percentage of small tumours detected. In 
addition, a substantial decrease in costs was observed. 
Conclusion: Decrease of hospital follow-up time, lowering the age of 
referral and termination of yearly physical examination will lead to a 
substantial reduction in costs while maintaining the same clinical effects. 




Breast cancer is the most common malignancy in women in North America 
and Western Europe, accounting for more than 1 in 4 cancers diagnosed [1-
2]. In addition, substantial improvements in survival have been achieved and 
the 5 year age-adjusted relative survival of breast cancer patients increased 
from 74% to 83% in European countries from 1988 to 1999 [3]. As a 
consequence, the absolute number of breast cancer survivors has increased 
in recent years. 
Routine follow-up to early detect new primary breast cancer is 
recommended to breast cancer patients after primary treatment and is the 
major part of healthcare for breast cancer survivors [4] which has increased 
the burden on oncology clinics in hospitals [5]. There are several potential 
pathways to diminish this workload of follow-up of breast cancer survivors on 
hospitals [6-7]. Firstly, less frequent follow-up contacts including 
mammography and a shorter duration of follow-up can be implemented 8-9. 
Secondly, alternative follow-up models where follow-up is provided by 
nurses or general practitioners (GP) are developed. These strategies 
showed acceptable patient satisfaction and comparable quality of life 
outcomes as standard in hospital follow-up [10-12]. Third, tailored 
approaches can be developed including individual risk assessment of new 
primary breast cancers, as well as competing risks associated with age and 
co-morbidities and even psychological preferences [13]. Though there are a 
few randomised controlled trials evaluating these alternative follow-up 
models, none of these studies had enough power or duration to establish the 
ideal frequency of hospital follow-up or the safety of alternative follow-up 
methods [7]. 
In the absence of adequate trial data regarding follow up strategies, 
simulation modelling can provide guidance on the risks, benefits and 
resources required to evaluate different strategies for routine follow-up care 
to early detect new primary breast cancers. The aim of the present study 
was to evaluate the effectiveness and costs of different strategies to reduce 
the workload of follow-up for women with a previous breast cancer. We did 
this by extending a previously validated simulation-based decision model [14, 120 
15]. Several relevant components such as the event death and different 
follow-up strategies were modelled and simulated for a longer time period. 
The extended model was validated based on the input parameters needed 
for the current and alternative screening, comparing the simulation results to 
the observed results from a large database of 5,073 women after a mean 
follow-up of five years. The main outcomes of this study were the detection 
rate of early detected tumours (� 2 cm) and the related additional costs. 
Materials and Methods 
Population screened by the model 
The input population screened by the model was based on a database of 
5,073 women with a history of breast cancer being representative for the 
Dutch breast cancer population with respect to age at diagnosis, stage, 
nodal status and treatment of the first tumour. For an overview of this 
population, see Table 2. These women were diagnosed from January 1989 
to January 2003 and treated in four hospitals in the North Netherlands (an 
academic hospital, a large teaching hospital and two non-teaching hospitals). 
Data on diagnosis, stage and treatment of the first tumour and secondary 
tumour, were actively abstracted from the patients' medical records in all 
hospitals using the registration and coding manual of the Dutch Association 
of Comprehensive Cancer Centres. 
Description of the simulation model 
The structure of the model is indicated in figure 1. The simulation of the life 
of each woman from the moment of first breast cancer is simulated for each 
year until death or until a second breast cancer is detected. First, for each 
woman it is simulated whether or not she dies. If she does not die, the event 
'second breast cancer' and detection of this second breast cancer is 
simulated. The probability of a second breast cancer is calculated based on 
her current age and the number of years since primary treatment. Tumours 
are selected randomly based on this probability and allowed to grow 
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according to the preclinical growth model. When a tumour is diagnosed 
based on symptoms, it is considered as an interval tumour. Otherwise it is 
checked whether a physical examination and /or mammography is 
scheduled based on the selected scenario and if so, whether the woman will 
undergo this examination based on the compliance function. If the physical 
examination and/or mammography is performed a possible tumour can be 
detected based on the sensitivity. If a developing tumour is detected in that 
year, the woman is diagnosed with a second cancer, and the screening is 
terminated, and the simulation ends in that year. If the tests are negative, i.e. 
the cancer is not detected, the woman's age is increased and the loop starts 
all over again. 
Clinical parameters in the simulation model 
For a detailed description of the clinical parameters of the simulation model 
see also previous publications [14, 15]. For the purpose of follow-up of 
women after primary breast cancer the input parameters of the model were 
adapted to the current screening scenario (Table 1 ), and in addition the 
model was extended and subsequently validated (see below). As compared 
to previous publications [14,15], the model was extended with the population 
death rates, risk to develop a second primary tumour, sensitivity of physical 
examination, specificity of mammography and physical examination, and 
compliance rate. In addition, the input parameters of the model were 
changed and were derived from literature (Table 1 ). 
The population death rate model consisted of the cumulative death rates 
derived from Dutch data [www.rivm.nl]. The risk to develop a second primary 
breast cancer was based on a recent publication on the incidence of breast 
cancer among female cancer survivors diagnosed in the 1990s, which was 
about 1 % per year [16]. The parameters of the compliance model were 
estimated on a database of 669 women with a history of breast cancer [17]. 
Finally, the sensitivity and specificity model was extended with an estimate 
for an age-dependent sensitivity of physical examination and was derived 
from published data from Fryback et al [18]. The specificity of physical 
examination (97.1 %) was added [19]. The sensitivity for screening 122 
mammography depended on tumour size was based on the results of study 
on screening mammography in women with a personal history of breast 
cancer [20]. The specificity of mammography (98.3%) was added [21]. 
Follow up strategies studied 
After treatment for breast cancer, in The Netherlands, based on current 
guidelines hospital follow-up is performed for five years with a yearly 
mammography (Table 3). After this follow-up, and when a patient is over the 
age of 60, after mastectomy she is referred to the National Screening 
Program (NSP) for a two-yearly mammography, or after breast conserving 
therapy she is referred to the General Practitioner for a two-yearly 
mammography and a yearly physical examination. The current guidelines is 
indicated as the current strategy. In the first alternative strategy, follow-up 
time in the hospital is shortened by a care shift from the hospital to the NSP 
or GP after two years of follow-up (instead of five years, see Table 4 ). In the 
second alternative strategy, hospital follow-up time is reduced by a care shift 
from the hospital to the NSP or GP after two years of follow-up and by 
lowering the referral age from 60 to 50. In the third alternative strategy, 
follow-up workload is diminished by a care shift after two years of follow-up 
and by lowering the discharge age to 50, and by ending yearly physical 
examination in general practice. The current guidelines were used as a 
reference strategy. The simulation model runs until every woman leaves the 
model (by death or by secondary primary breast cancer). 
Economic evaluation 
A cost effectiveness analysis (CEA) was undertaken to evaluate the balance 
between costs and effects of the several follow-up strategies. The CEA 
depicts the additional costs associated with an increase of 1 % in the number 
of early detected tumours (i.e. the percentage of diagnosed second primary 
tumour with a tumour size less than 2 cm). The cost of mammography in 
hospital was € 92 [22] and in NSP it was € 53 [23]. The cost per false 
positive result for pathological evaluation was € 75 24. The cost for a 
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specialist visit, including consult and physical examination, was € 25. The 
total costs for treatment were estimated at € 5,857 for tumours diagnosed at 
a size of s 2 cm, € 6,485 for tumours diagnosed at a size between 2 and s 5 
cm, and € 7,006 for tumours at a size diagnosed over 5 cm [24]. A life time 
horizon was considered. Discounting was not applied. 
Statistics 
Median values and 2.5 and 97.5 percentile credible intervals were estimated 
based on 1,000 replications of the simulation performed for each scenario. 
Validation of the model 
The validation of the model was based on a comparison of the results from 
the simulation with the observed numbers in the database on the following 
parameters: the number of deaths, the number of tumors and the number 
and percentage of small, medium and large tumors and their credible 
intervals. The number of women at follow-up each half year in the database 
(average follow-up 5.1 years, range 0.5 - 18 years) was used as an input for 
the simulation, and as a weighting factor for the number of tumors found. 
First, we found only 384 (347-421) simulated deaths compared to observed 
number of 518 in the observed database. This smaller number can be 
explained by the fact that in the database of 5047 women all deaths are 
considered, and thus also deaths after detection of a second primary breast 
cancer, where in the simulation women leave the model when a second 
primary breast cancer is detected. Secondly, we found 141 (114-167) tumors 
in the simulation, which corresponds well with the 136 tumors found in the 
observed database (figure 2). Thirdly, the number and percentage of 
simulated small, medium and large tumors in the simulation corresponded 
also very well with the number and percentage of small, medium and large 
tumors found in the observed database. Fourthly, the credible interval for the 
median tumour size (1.4-2.1) cm covered the tumour size of 1.5 cm in the 
observed database. Finally, in the simulation the age of women at their 
second tumor of 67.0±13.0 years was higher but within the credible interval 
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of the age of the women at their second tumor in the observed database 
62. 1 ±1 3.0 years. 
Results 
The strategy for follow-up based on the current guidelines as well as the 
three alternative strategies showed no substantial differences in the number 
of second tumours detected, in the program sensitivity, and in the program 
sensitivity of physical examination or mammography (see Table 5). When 
applying the current guideline, 51 .7(48.6-54.7)% of the second tumours were 
detected at a small size with a median diameter of 1 .8(1 .6-2. 1 )  cm. The first 
alternative strategy, in which follow-up time in the hospital is shortened by a 
care shift from the hospital to the NSP or GP after two years of follow-up 
instead of five years, showed a comparable rate of small tumours 
(51 .5(48.4-54.6)%) and a comparable median tumour size (1 .9(1 .6-2.2) cm). 
In the second alternative strategy in which hospital follow-up time is reduced 
by a care shift to the NSP or GP after two years of follow-up and by lowering 
the referral age from 60 to 50, a comparable rate of small tumours 
(50.7(47.6-53.7)%) and a comparable median tumour size was found 
(1 .9(1 .7-2.2) cm). The same was true for the third alternative strategy, in 
which the follow-up workload is diminished by a care shift after two years of 
follow-up and by lowering the discharge age to 50, and by ending yearly 
physical examination in general practice. The reported rate of small tumours 
was 50.5(47.6-53.4)% and the reported median tumour size was 2.0(1 .8-2.2) 
cm. 
There were substantial differences in number of clinical examinations, 
number of mammographies and in number of false positive 
findings.Consequently, there were substantial differences in costs. When 
applying the current guideline, the total screening cost was estimated at 
4.31 (4.23-4.40) million euros involving clinical examinations, 
mammographies, false positive findings and treatment. The three alternative 
strategies showed a remarkable smaller mean screening costs, namely 
3.99(3.91 -4.07), 3.53(3.46-3.59), and 3. 1 7  million euros respectively. The 
third alternative strategy was the least costly strategy with an estimated cost 125 
of detecting per 1 % additional small tumour of 64.0(60.1-68.6) thousand 
euros. 
Discussion 
Shortening the follow-up time in hospital by a care shift from hospital to the 
NSP or GP after two years of hospital follow-up (instead of five), lowering the 
age of a care shift from 60 to 50, and stopping yearly physical examination 
by the GP after hospital follow-up did not show a substantial decrease in the 
percentage of small tumours detected. In addition, a substantial decrease in 
costs was observed. 
The three alternative strategies considered all suggested that the follow­
up for breast cancer patients can be transferred to the (NSP) for the follow­
up by mammography or to general practice for the follow-up by physical 
examination. This finding is considered a safe recommendation and 
consistent with findings from a randomised clinical trial in which follow-up of 
breast cancer in general practice was not found to be associated with an 
increase in time to diagnosis of recurrence [11 ,26]. We found no publication 
which suggests that the performance of follow-up by mammography in the 
NSP differs from mammography in the hospital. Based on that, in our 
simulation, it was assumed that there were no differences in efficacy of 
mammography between the NSP and the hospital. 
In the second and third alternative strategy, compared with the first 
alterative strategy, the age of a care shift from hospital to NSP or general 
practice was lowered from 60 to 50. The women would be recommended to 
have a two-yearly mammography instead of yearly mammography after the 
care shift. This implied that the number of mammographies for women 
between 50 and 60 years of age was reduced from 1 0  to 5. In this simulation, 
this was a strategy as safe as the current guideline strategy that was in line 
with other studies which demonstrated that there were no apparent adverse 
effects associated with a 2-year screening interval among women who were 
in and after their fifties [27-28]. 126 
In the third alternative strategy, physical examination was no longer 
performed after two years of follow-up. This also turned out to be a safe 
strategy, with a comparable median invasive tumour size and percentage of 
small tumours. This is in line with a recent meta-analysis which indicated that 
there were few relapses detected by physical examination and those which 
are diagnosed clinically may do less well [29]. 
The model used in this study is an extension of a validated model for the 
simulation of effects of breast cancer screening [14, 15]. Our simulation 
model was developed with incorporation of risk of contralateral breast cancer 
after primary breast cancer, preclinical tumour growth rate, sensitivity of 
mammography and physical examination related to tumour size and 
specificity of mammography and physical examination. The radiation­
induced tumour probability and the compliance to follow up strategy were 
also taken into account. The values for these parameters were derived from 
published estimates and observed Dutch breast cancer population data. 
There is no different result between the expectations under the current 
strategy in the model and the observed follow-up database and published 
findings of Dutch breast cancer population [30,31]. 
Several potential limitations that have not yet been acknowledged 
should be noted. The percentage of smaller tumours was used as outcome 
instead of quality adjusted life years (QALYs). It is generally accepted that 
when a second breast cancer is detected earlier, i.e. with a smaller tumour 
size, this will result in improved survival of breast cancer patients [32]. A 
population-based study revealed that MCBC at stage I I  or higher worsen the 
patient survival rate whereas the MCBC at stage I did not [31]. A previous 
systematic review concluded that early detection of isolated recurrences in 
patients without symptom during follow-up had a substantially better survival 
as compared to late detected recurrences [32]. It is unlikely that the relative 
cost-effectiveness of four strategies would change when QALYs were 
simulated as outcome. Regarding cost estimates.we adopted a health care 
perspective, meaning that the travelling expences and related productivity 
losses were not accounted for. In the current analysis this factor would be 
unlikely to have a negative impact on the conclusions, because the relative 
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contribution of trevelling expences in the current guideline strategy is higher 
than in the alternative strategies. Another potential limitation of our study 
could be the use of preclinical tumour growth parameters from the general 
population instead of a population of women with a history of breast cancer. 
It is uncertain whether tumour growth in women with a history of breast 
cancer would differ from that in the general population. Although the model 
incoporates the Dutch cumulative death rates, it is well known that women 
surviving their breast cancer are at an increased risk of death. Last, the local 
recurrence was not taken into account in this model simulation due to the 
lack of conclusive information on the parameters of local recurrences. The 
model would be improved after extending the model with the early detection 
of loco-regional recurrences (LRR) which would cause a decrease in 
sensitivity. However, as this would be the case for all follow-up scenarios, 
we do not expect this will change our conclusion. 
We found that shortening the follow-up time in hospital by a care shift 
from hospital to the NSP or GP after two years of hospital follow-up (instead 
of five) , lowering the age of referring from 60 to 50, and stopping yearly 
physical examination by the GP after hospital follow-up did not show a 
substantial decrease in the percentage of small tumours detected. In 
addition, a substantial decrease in costs was observed. Therefore we 
conclude that a decrease of hospital follow-up time, lowering the discharge 
age and stopping yearly physical examination leads to a substantial 
reduction in costs and maintains the same clinical effects. 
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Table 1 Input parameters of the screening model 
Model component 
Population death rate 
Risk to develop a second primary 
breast cancer * 
Compliance 
Sensitivity and Specificity 
Input parameter 
Cumulative Dutch death rates 
Mean preclinical period [years] * 
< 50 years 
50 - 70 years 
> 70 years 
Standard deviation [years] * 
< 50 years 
50 - 70 years 
> 70 years 
Tumour doubling times [days] * 
< 50 years 
50 - 70 years 
> 70 years 
Risk per year 
Dose [mSv] * 
Probability of tumour induction * 
Compliance function 
a l  
a2 
a3 
Sensitivity function mammography 
� l  
�2 
Sensitivity physical examination 
Specificity mammography 



























Table 2 Characteristics of the population screened by the model (n=5 ,073) 
Characteristics 
Age at diagnosis 
Follow-up time ( Median, Range years ) 
Pathological T stage 
Tis 





Pathological N stage 
NO 













6 1 . 1±14.4 
7.2 ( 0.03-1 8.2 ) 
324 ( 6.4 ) 
2463 (48.6 ) 
1 842 ( 36.3 ) 
1 84 ( 3 .6 ) 
202 ( 4.0 ) 
58 ( l . l ) 
2962 ( 58 .4 ) 
1946 ( 38 .4 ) 
75 C 1 .5 )  
90 ( 1 .8 )  
3297 ( 65 .0 ) 
1 776 05.0 ) 
2374 ( 46.8 ) 
2699 ( 53 .2 )  
976 ( 1 9.2 ) 
4097 ( 80.8 ) 
Table 3 Guideline recommedations (Current strategy) for hospital follow-up in de first five years after 
primary treatment 
(start at the end ofradio/chemo therapy) 
--
Physical Breast Examination Mammography 
First year Every 3 mnths Yearly 
- --
Second year Every 6 .mnths Yearly 
� 
3rd to 5th year Yearly Yearly 
- -
Differentiated follow-up is proposed (at least) 5 years after primary treatment (start at the end of radio / 
chemotherapy) 
- - -


































> 75 years Follow-up can be ended 
**: once in two years 
1 3 1  
-
Table 4 Alternative strategies compared with guideline recommedations Change points First alternative Strategy Second alternative Strategy Third alternative Strategy Starting time of differentiated follow- Two years after primary Two years after primary Two years after primary up treatment treatment treatment Patient1s age for discharge 60 years SO years r 2o y�s 
- · - ·- - -Provider of Physical Examination Hospital General Practitioner None during differentiated follow-up -
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Table 5 Outcomes of follow-up of breast cancer survivors with different strategies. Median (Pencentile 2.5- Pencentile 97 .5) from 1 000 simulations 
Outcome Current strategy First alternative strategy Second alternative Third alternative strategy 
strategy 
Number of second tumours 1 023 (966 - 1 080) 1 026 (972 -1082 ) 1 025 (97 1 -1 080 ) 1 037 (984 -1 094 ) 
Programme sensitivity 55.9 (52.6 -59.0) 56.2 (52.8 -59.5 ) 56. 1 (53 .0 -59.3 ) 57.5 (54.5 -60.4) 
Sensitivity of clinical examination 1 0.6 (8.7 - 12.5 ) 1 0.5 (8.7 -1 2.3 ) 1 0.7 (8.7 -1 2.5 ) 9.9 (8. 1 -1 1 .9 )  
Sensitivity of mammography 47.4 (44.3 -50.4) 47.5 (44. 1 -50.6) 47.3 ( 44.3 -50.3 ) 48.4 (45.4 -5 1 .2) 
Total number of clinical examinations (x 1 000) 42.0 (4 1 .3 -42.7 ) 36.4 (35 .7 -37.0) 36.4 (35.7 -37.0 ) 24.7 (24.5 -25.0 ) 
Total number of mammography (x 1 000) 34.0 (33 .2 -34.7 ) 32.2 (3 1 .4 -32.8) 27.2 (26.6 -27 .8 ) 26.7 (26 . 1  -27.3 ) 
Median invasive tumour size ( cm) 1 .8 ( 1 .6 -2. 1 ) 1 .9 ( 1 .6 -2.2 ) 1 .9 ( 1 .7 -2.2 ) 2.0 ( 1 .8 -2.2 ) 
Percentage of small tumours 5 1 .7 (48.6 -54.7) 5 1 .5 (48.4 -54.6) 50.7 (47.6 -53.7 ) 50.5 (47.6 -53.4) 
Percentage of medium tumours 30.3 (27.6 -33 .2 ) 30.4 (27.7 -33 .5 ) 30.9 (28 . 1  -33 .6 ) 29.8 (27 . 1  -32.5) 
Number of false positive findings (x 1 000) 1 .8 ( 1 .7 - 1 .9 ) 1 .66 ( 1 .58 -1 .74 ) 1 .5 1  ( 1 .44 - 1 .60 ) 1 .3 ( 1 .20 -1 .34 ) 
Number of tumours in patients older than 75 253 (224.0 -285.0) 256 (227 -286 ) 254 (224 -286) 264 (232 -293) 
Screen Cost (million euros) 4.3 1 (4.23 -4.40 ) 3 .99 (3 .9 1 -4.07 ) 3 .53 (3.46 -3 .59 ) 3 . 1 7  (3 . 1 0  -3 .23 ) 
Cost per 1 % increase in small tunours (thousand euros) 85.4 (80.4 -9 1 .6) 69. 1  (65 .5 -72.9 ) 69. 1  (65.4 -72.9 ) 64.0 (60. 1 -68.6) 
Total Cost (million eu�os) 1 1 .2 __ (1 0.8 - 1 1 .6 )  1 0.9 ( 1 0.6 - 1 1 .3 ) 1 0.4 . (10. 1 - 1().8 ) 1 0.2 (9.8 - 1 0.5 ) 1 33 
Population deatl 
Preclinical tumour grO'YVth 
Tumour induction 
Increase age 
Risk to develop breast cancer 
Compliance 
Sensitivity and specificity 




Figure1 The structure of the simulation model for follow-up of patients 
after curative treatment for breast cancer. The circles correspond to states 
the patients can be in, the diamonds correspond to decisions made in the 
simulation program, and the rectangles correspond to the different model 





















Nsma Nmid Nlar 
Figure 2 Validation of the simulation program. The number of deaths 
(Ndeath), the total number of tumors (Ntum), and small (Nsma), middle 
(Nmid) and large (Nlar) tumors found is compared with the numbers found in 
the observed database (top). Also the percentages of small, middle and 
large tumors simulated and found in the observed database is compared 
(bottom). 135 
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The early detection of loco-regional recurrences and contra-lateral breast 
cancers remains a central purpose of follow-up after breast cancer [1,2]. At 
the time when the here presented studies were initiated there was limited 
detailed information on the performance of follow-up test for breast cancer 
patients on the early detection of curable recurrences. Findings from small 
previously published studies were reviewed and pooled to study the effect of 
early detection curable recurrences (Chapter 2). Meanwhile, the medical 
follow-up documents of 669 patients out of 5,589 patients with a history of 
breast cancer were reviewed to evaluate the performance and utilization of 
routine mammography and physical examination (Chapters 3. 5 and 6). A 
simulation model was developed to compare four breast cancer follow-up 
strategies proposed by the Dutch institute for healthcare improvement 
(Chapter 7). In the following section, the overall findings and implications for 
practice will be discussed including the potential alternative follow-up 
approaches and recommendations for further research. Methodological 
issues encountered in this study and the limitations and advantages of this 
study will be presented and discussed. In addition, a retrospective study was 
conducted (Chapter 4) to determine the patients and tumour features, 
survival rate, relapse and prognostic factors in Chinese breast cancer 
patients. The interests of the authors on future research in China were 
discussed as well. 
Main findings 
The effect of early detection of curable recurrences on survival 
The pooled finding of thirteen studies concerning 2,263 patients shows that 
early detection of isolated recurrences in patients without symptom during 
follow-up have a significantly better survival as compared to late detected 
recurrences (HR: 1 .68; 95%-CI :  1.48-1.91, Chapter 2). These data support 
the hypothesis that early detection of isolated loco-regional or contra-lateral 
breast cancer recurrences in patients without symptoms has a beneficial 139  
impact on survival of breast cancer patients when compared to late 
symptomatic detection. There is no statistically significant difference in HR 
for survival between studies in this meta-analysis that used an intensive 
regimen compared to a standard regimen for follow-up. This is in line with 
previous publications in which it is found that intensive follow-up schemes 
focusing on the early detection of distant metastases does not improve the 
chances of survival [3,4]. 
Utilization of hospital follow-up care 
Information regarding the utilization of routine hospital follow-up care was 
retrieved from hospital documents of 662 patients treated for breast cancer 
(Chapter 3). We found sizable numbers of long term breast cancer survivors 
did not use hospital follow-up care in the hospital. Hospital follow-up was 
ended for 413 (62.4%) recurrences-free patients of the 662 women often 
after six to ten years. At fifth and tenth year after diagnosis, 16.1 % and 
33.5% of the patients had less follow-up visits than recommended in the 
national guideline, and 33.1 % and 40.4% had less frequent mammography 
than recommended. Less frequent mammography was found in older 
patients (age>?0; OR: 2.10; 95%CI: 1.62-2.74), patients with co-morbidity 
(OR: 1.26; 95%CI: 1.05-1.52) and patients using hormonal therapy (OR: 
1.51; 95%CI: 1.01-2.25). 
The clinical characteristics and prognosis of Chinese early stage 
breast cancer patients 
In China, there is no nationwide breast screening program because of 
relatively lower breast cancer incidence and resource constraint. Breast 
cancer patients in this series were younger and had more advanced tumour 
status at diagnosis than those in the United States and European studies 
(Chapter 4 ). After more aggressive treatment, patients with breast cancer 
showed a low incidence of relapse and good overall survival in this study. 
The main prognostic factors were T-stage and N-stage. The number of 
patients being fully compliant with follow-up was rather low (34 out of 84 7 
patients (4%)). Patients received physical examinations during most of their 
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follow-up visits (91.5%). Many patients received additional tests including 
chest X-rays (21.5%), ultrasound tests (22.3%), CTs (2.9%) and 
mammography (1.3%). 18 (38.3%) out of 47 patients with loco-regional 
recurrence or contra-lateral breast cancer and 18 (22.0%) out of 82 patients 
with distant metastasis were diagnosed during routine follow-up visits. 
The contribution of post-treatment mammography on early detection of 
curable recurrences 
The performance of mammography was demonstrated in Chapters 2 and 5. 
Thirty-eight percent of contra-lateral breast cancers were detected by 
mammography alone. Patients with meta-chronous breast cancers (MCBCs) 
detected by routine mammography had better survival rates than patients 
with MCBCs detected by other means (HR: 3.18; 95% Cl: 1.59-6.34; 
Chapter 2) which was probably because of the favourable stage of tumour 
detected by mammography alone. The results were consistent with the 
findings of a sub-group analysis that survival was better when the recurrence 
was found by mammography instead of physical examination (HR: 2.44 
(95% Cl: 1.78-3.35)). Concerning loco-regional recurrences, though the 
performance of mammography was influenced by the previous surgery in 
conserving breast, there were still about 18% loco-regional recurrences 
detected by mammography alone (chapter 6). These findings support the 
ongoing guidelines on follow-up of breast cancer patients that breast cancer 
patients should receive routine mammography in the conserved breast and 
the contra-lateral breast [2]. 
The contribution of physical examination on early detection of curable 
recurrences 
Seven (5.5%) out of 127 contra-lateral breast cancers and 13 (22.0%) out of 
58 loco-regional recurrences were detected by physical examination alone 
(Chapter 6). Routine physical examinations were more important in detecting 
loco-regional recurrences than contra-lateral breast cancers. We found a 
trend that the contribution of physical examination was higher in women 
under 60 years of age than in patients over 60 years of age (15.1% vs. 7.6% 
1 4 1  
of recurrences were detected by physical examination alone). That was 
probably due to the relative low sensitivity of mammography in younger 
patients. Regarding to the workload, for patients younger than 60, 644 
physical examinations were performed to detect one additional LRR, 
whereas, for patients older than 60, the number was 1,052. Patients with 
contra-lateral breast cancers detected by routine physical examination with 
or without mammography didn't show an improved survival than patients 
with interval contra-lateral breast cancers. We didn't evaluate the value of 
clinical breast examination in improving survival of breast cancer patients 
with loco-regional recurrences due to the small number of recurrences. 
Cost-effectiveness analysis of follow-up strategies for breast cancer 
patients (Chapter 7) 
After treatment for breast cancer, in The Netherlands, based on current 
guidelines, hospital follow-up is performed for five years with a yearly 
mammography. After this follow-up, and when a patient is over the age of 60, 
after mastectomy she is referred to the National Screening Program (NSP) 
for a two-yearly mammography, or after breast conserving therapy she is 
referred to the General Practitioner for a two-yearly mammography and a 
yearly physical examination. 
In this study, we applied an already validated simulation-based decision 
model to evaluate the effectiveness and costs of the alternative strategies to 
reduce the workload of follow-up for women with a previous breast cancer [5, 
6] 
The strategy for follow-up based on the current guidelines as well as the 
three alternative strategies showed no significant differences in the number 
of early detected second tumours, in the program sensitivity, and in the 
program sensitivity of physical examination or mammography. However, 
there were significant differences in number of clinical examinations, number 
of mammographies and in number of false positive findings, and related to 
these, there were significant differences in costs. We conclude that the 
strategy shortening the follow-up time in hospital by a care shift from hospital 
to the NSP or GP after two years of hospital follow-up (instead of five), 
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lowering the age of referring from 60 to 50, and stopping yearly physical 
examination by the GP after hospital follow-up leads to a significant 
reduction in costs and maintains the same clinical effects. 
Implications for practice 
Regarding follow-up procedures 
There is little doubt that mammography is essential during the follow-up of 
breast cancer patients after primary treatment of first tumour [7-9]. Patients 
with a mammographically detected contra-lateral breast cancer had 
improved suNival compared with patients whose cancer was detected 
clinically, irrespective of the stage of ipsi-lateral breast cancer. In patients 
treated with breast conseNing surgery, mammography is available and 
useful for the detection of a LRR although the sensitivity of mammography 
will be decreased in the conseNed breast due to the scar and changes in 
density of the breast after surgery [ 10, 11]. 
Routine follow-up physical examination has less value than 
mammography and is still reasonable to be considered as a complementary 
testing of mammography especially in younger patients and in detecting 
loco-regional recurrences. In older patients, discontinuing regular physical 
examination might not impact the suNival of patients. Additionally, the 
workload could be relived a great deal and it is possible to unburden the 
specialist and to spare more staff to provide efficient post-treatment care for 
breast cancer patients who have needs. 
Ensuring adherence of routinely follow-up 
The findings in Chapter 3 showed that the percentage of women having 
routine follow-up visits and mammograms decreased over time. Older 
women, particularly those with co-morbid illnesses and hormonal therapy 
were less likely to have routinely mammograms after treatment for breast 
cancer. Since not a single follow-up strategy would have an efficient yield 
given a low compliance, we should be careful to ensure the use of routinely 
mammography. Mechanisms to improve coordination of care between 
cancer specialists and primary care physicians are needed that includes 143 
defined roles and responsibilities for surveillance testing. It might be helpful 
that breast cancer survivors and their physicians receive a comprehensive 
care summary and follow-up plan at the completion of primary cancer 
treatment [ 1 2-1 3]. Previous studies have shown that physician 
recommendation is a strong predictor of the take-up in cancer screening [1 4]. 
Thus, increasing awareness of the need for regular surveillance 
mammography among primary care physicians may be beneficial [1 5]. 
Implication for the feasibility of less frequent follow-up 
The strategies compared in chapter 7 recommended less hospital follow-up 
visits considering the time from primary treatment, surgical modality and 
patients' age at follow-up. To our knowledge, follow-up of breast cancer 
patients continues primarily in hospital clinics. There is a trend of more 
involvement of oncology specialist in follow-up of breast cancer survivors 
[ 1 6]. It is predicted that there will be a 48% increased need for cancer 
services by 2020. This puts an increasing burden on follow-up oncology 
clinic [1 7]. The revision of the follow-up strategy we considered did not aim 
to modify the first two years visits for any patient, as optimising quality of life 
including dealing with physical side-effects of treatment and psychosocial 
rehabilitation is equally relevant to all patients following treatment for the 
breast cancer that will in general take one to two years [ 1 8]. Since one of the 
main aims of follow-up after two years since primary treatment is to early 
detect loco-regional recurrences and contra-lateral breast cancer, less 
frequent follow-up would preferable for patient who has less risk of loco­
regional recurrences and contra-lateral breast cancer. Patients treated with 
breast conserving surgery are at higher risk for loco-regional recurrences 
than patients treated with a radical mastectomy [1 9]. It is acceptable that 2 
yearly mammography started at 50 years of age instead of 60 for women 
with a history of breast cancer and was considered to be safe (Chapter 7). 
Regarding to the patients age, older patients had less risk of local regional 
recurrences and contra-lateral breast cancer [1 9]. We found that routine 
physical examination is more valuable in younger patients (Chapter 6). The 
findings in this thesis support the proposed follow-up strategies by the Dutch 
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institute for healthcare improvement recommending less frequent physical 
examination for patients older than 60 year of age and for patients who had 
mastectomy. Decrease of hospital follow-up time, lowering the discharge age 
and stopping yearly physical examination is expect to lead to a significant 
reduction in costs while maintaining the same clinical effects. 
The possibility and potential for individualized follow-up 
All patients have different characteristics. The risk of LRRs and CBCs are 
different among patients after their primary treatment. Compared with a 
same follow-up scheme for all breast cancer patients, a individualistic 
approach might be more acceptable. Individualize follow-up plan can be 
made by patients and oncologists according to the patients personal needs 
and the estimated risk of LRRs and CBCs which is associated with patients' 
age, surgical modalities and other relevant characteristics. Then patients 
with good prognoses will receive less intensive follow-up. Our findings 
support that differentiated follow-up strategies based on age and surgical 
treatment are safe and cost-effectiveness. Since there are other 
characteristics also having influence on the prognosis, like tumour stage, 
lymph node status, adjuvant treatment and patients genetic profile, more 
individualistic choice for follow-up could be make by patients and oncologists. 
Methodological considerations 
Representativeness of the study population 
As described in the Chapter 3. 5 and 6, the clinical data collection start with 
selection of patients with contra-lateral breast cancer from the registry 
database of Comprehensive Cancer Centre North Netherlands. For each of 
these patients, four to five patients without evidence of meta-chronous 
contra-lateral breast cancer - matched for hospital of diagnosis, age at first 
primary tumour and duration of follow-up - were selected randomly from the 
CCCN database. As a result, this study cohort is not representative of the 
general population of breast cancer patients instead a contra-lateral breast 
cancer patient enriched cohort. One of the advantages of the sampling 
procedure is the contribution of follow-up procedures on detection of contra-
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lateral breast cancers were well assessed due to the enriched number of 
contra-lateral breast cancer patients. We found the incidence of loco­
regional recurrences is comparable to those of other studies [19,21]. That is, 
the findings in chapter 3 and § regarding to the detection of loco-regional 
recurrences were unlikely biased due to the sampling procedures. Even 
though the potential impact of early detection of loco-regional recurrences 
needs to be studied in a larger population as the statistical power is relatively 
low to reach a firm conclusion on the performance of either routine 
mammography or routine physical examination due to the small number of 
loco-regional recurrences. 
The nature of retrospective studies 
These present studies in this thesis are retrospective cohort studies partially 
in nature which makes them susceptible to significant biases a tendency to 
overestimate the magnitude of the effect of routine follow-up testing, for 
example, length bias in the evaluation of the contribution or surveillance 
mammography in Chapter 5. There are also challenges in using historical 
medical record documentation. We ascertained receipt and findings of 
surveillance follow-up test through medical record review. We may not 
capture some follow-up test if they were not documented. This would lead to 
an underestimate of utilization of follow-up test. Cohort members were those 
diagnosed with breast cancer between 1989 and 2003, and typical practice 
patterns may have changed since. Another potential limitation relevant to the 
data collection is that we reviewed the documents in hospital including the 
use and findings of follow-up test. The performance of routine physical 
examination and mammography found in this study may not be generalized 
to those breast cancer patients who have physical examination by their 
general practitioner and mammography in National Breast Cancer Screening 
Programme. 
Strengths and limitations of model simulation 
A contribution of this thesis is to develop a model to compare cost­
effectiveness of four follow-up strategies before the coming of convincing 
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evidence from large randomised trial. As mentioned above - the strength of 
the evidence is limited by problems inherent in observational designs such 
as selective bias, length and lead time bias and a tendency to overestimate 
the magnitude of the effects as well as the limited power due to the relatively 
small number of relevant event. Some other studies point to the need for a 
randomized clinical trial to evaluate the benefit of routine physical 
examination and surveillance mammography after primary treatment of 
breast cancer patients for the outcomes after loco-regional recurrences and 
contra-lateral breast cancer [7,22]. As routine follow-up is already a standard 
practice, there is reason to doubt whether the proposal of no or less frequent 
follow-up would be acceptable to care providers or patients. The large size 
and expense of such a trial, which require stratification for important patient 
factors, might make it impractical. Modelling offers a way to use available 
data- including that from observational or single randomised control studies­
to inform those who are making current screening decisions. 
The model we used was based on a validated model on the simulation of 
breast cancer screening [5,6]. We adopted the model modules to a 
population of women with a history of breast cancer. The starting population 
was formulated according to a Dutch database of about 5,000 women with a 
history of breast cancer. Sensitivity analyses were used to assess the 
influence of changes of input parameters. The model simulation supports the 
differentiated follow up at 2 years after primary treatment with all women of 
50 years and over receiving 2-yearly mammography in National screenings 
program and no routine physical examination. 
Gaps in available data are responsible for several limitations of our model. 
First there is still short of sufficient evidence and information on the 
sensitivity and specificity of mammography and clinical breast examination in 
follow-up of women with a history of breast cancer due to the rather small 
sample size in the study cohort. Reasonable assumptions had to be made. 
Second, the challenges also existed due to the lack of information on the 
sensitivity and specificity of routine physical examination by general 
practitioner and on the sensitivity and specificity of mammography in 
National breast cancer screening for breast cancer patients. We assumed 
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routine physical examination performed by general practitioner had the same 
sensitivity and specificity as the routine physical examination performed by 
specialists in hospital. We only predicted the cost-effectiveness of follow-up 
strategies in detecting CBC. An extension of the model would be the early 
detection of loco-regional recurrences (LRR) which would cause a decrease 
in sensitivity. However, as this would be the case for all follow-up scenarios, 
we do not expect this will change our conclusion. 
Recommendations 
-❖- Detection of isolated loco-regional or contra-lateral breast cancer 
recurrences in patients without symptoms has beneficial impact on 
survival of breast cancer patients when compared to late symptomatic 
detection. Routine follow-up aiming to early detection of loco-regional or 
contra-lateral breast cancer recurrences is warranted. 
-❖- Mammography is a valuable tool for the early detection of MCBC during 
hospital follow-up of breast cancer patients and is probably beneficial to 
survival. 
-❖- Routine physical examination may be most valuable for women with a 
history of breast cancer younger than 60 years at follow-up visit. 
-❖- In older patients, patients with co-morbidity and patients receiving 
hormonal therapy we should be careful to ensure the use of yearly 
mammography. 
-❖- Decrease of hospital follow-up time, lowering the discharge age and 
stopping yearly physical examination will lead to a significant reduction 
in costs while maintaining the same clinical effects. 
-❖- Individual follow-up scheme based on age and surgical treatment is 
cost-effective and safe. 
Recommendations for further research 
-❖- The performance of routine physical examination and routine 
mammography on detection of loco-regional recurrences and potential 
impact need further investigation in a larger population. 
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-❖- The performances of routine physical examination by general 
practitioner and mammography in National breast cancer screening 
programme for patients with a history of breast cancer need to be 
assessed. 
-❖- More individualistic follow-up strategy based on patients' risk profile of 
recurrences and patients individual needs deserves further studies. The 
feasibility of patients initiated follow-up scheme in breast cancer patients 
at a lower risk of recurrences deserves further study. 
Breast cancer screening for Chinese women 
There is no national screening program in China yet. The incidence of breast 
cancer in China is lower than that in western countries. The median age of 
diagnosis of breast cancer is younger in China than those in European 
Countries and the United States [23-26]. Breast cancer screening guidelines 
may not suitable to China [27]. 
It could be more applicable to screen breast cancer in women with a 
higher risk of breast cancer that addressed the necessarily of development 
breast cancer risk assessment tool. Wenli Lu and her colleagues are working 
on a project aiming to investigate the appropriate national screening 
strategies in China. About 530 000 women aged from 35-69 were screened 
in 2008 to 2010. Data on performance of clinical examination, breast 
ultrasound and mammography were collected. Publications on the predictor 
of occurrence of breast cancer in Chinese women will be reviewed and a 
prediction model will be formulated and validated to the information collected. 
The cost effectiveness of screening strategies in women at high risk of 
breast cancer according to their predicted score of risk assessment would be 
compared. 
Upcoming research on follow-up Chinese women with a history of early 
breast cancer 
There are several differences between the characteristic of breast cancer in 
china and that in western countries. The current guidelines on follow-up in 
China is adopted according to the one recommended by ASCO. In practice, 149 
most patients (96%) had less follow up visits than recommended in this 
hospital. The advances in the treatment of breast cancer have yielded 
remarkable improvement in survival [28], which, in conjunction with the rising 
incidence of breast cancer in the rather big population in china result in a 
rather large number of breast cancer survivors. The impact of follow-up on 
survival of Chinese breast cancer patients is not sufficient investigated yet. It 
is reasonable to question the performance of mammography. Routine 
physical examination might be more useful in detection loco-regional 
recurrences for patients after mastectomy. Wenli Lu and her colleagues are 
working on a project aiming to assess the performance of follow-up tests and 
economic effect of current follow-up strategies for Chinese breast cancer 
patients and to formulate an appropriate follow-up strategy within a limited 
budget for a rather large population. 
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Summary 
1 5 1  
Summary 
Breast cancer is the most common malignancy in women in North 
America and Western Europe, accounting for more than 1 in 4 cancers 
diagnosed in US and European women. Substantial improvements in 
survival have been achieved. The 5 year age-adjusted relative survival of 
breast cancer patients increased from 74% to 83% in European countries 
from 1988 to 1999. As a consequence of increasing incidence and 
improvement of survival, breast cancer is now recognised as a chronic 
disease that can recur even after 20-30 years, and that will put an increasing 
burden on follow-up oncology clinics. 
Breast cancer survivors who have completed their initial treatments will 
live with an increased risk for recurrences and second cancers. To address 
this increased risk, subsequently several international practice guidelines all 
recommend that breast cancer survivors should receive routine follow-up 
care. The challenge is to develop follow-up programmes that reflect current 
knowledge and meet the ongoing needs of this growing number of breast 
cancer survivors. The main objective of this thesis is to evaluate the 
performance of follow-up for women with a history of breast cancer. 
In chapter 2, a meta-analysis was carried out using Cochrane review 
manager software (RevMan version 4.2). Thirteen studies concerning 2,263 
patients were included, in which women were treated for primary breast 
cancer without evidence of distant metastasis at primary diagnosis and 
which concerned routine follow-up strategies focusing on the early detection 
of curable recurrences. Data regarding the risk for death were derived from 
each study. Early detection of breast cancer recurrences during follow-up 
gave a significantly better survival as compared to late detected recurrences 
(Hazard Ratio (HR): 1.68 (95% Cl: 1.48 to 1.91 )). Survival was better when 
the recurrence was found by mammography instead of physical examination 
or in patients without symptoms as compared to those with symptoms (HR: 
2.44 (95% Cl :  1. 78-3.35); HR: 1.56 (95% Cl: 1.36-1. 79), respectively). If all 
breast cancer recurrences would be detected asymptomatically, than 5-8 
deaths (i.e. an absolute reduction in mortality of 17-28%) would be avoided 
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by performing routine follow-up during a 10 year-period for 1,000 breast 
cancer patients. These data support the hypothesis that the early detection 
of isolated loco-regional or contra-lateral breast cancer recurrences in 
patients without symptoms has a beneficial impact on survival of breast 
cancer patients when compared to late symptomatic detection. 
Breast cancer patients diagnosed (n=S,589) in four hospitals in the North 
Netherlands (an academic hospital, a large teaching hospital and two non­
teaching hospitals) from January 1989 to January 2003 were selected from 
the files of the regional cancer registry of the Comprehensive Cancer Centre 
North Netherlands (CCCN). Patients with synchronous bilateral breast 
cancer (N=94) were excluded from the cohort and thus the final cohort 
consisted of 5 ,495 patients with primary ipsilateral breast cancer. Of these 
5,495 women diagnosed with ipsilateral breast cancer, MCBC (meta­
chronous contra-lateral breast cancer) was reported in 139 patients during 
follow-up. For each of these patients, four to five patients without evidence of 
MCBC (n=597) - matched for hospital of diagnosis, age at first primary 
tumour and duration of follow-up - were selected randomly from the cohort. 
Follow-up information was retrieved actively from available medical 
documents in hospitals for 662 patients in our database. At the time of this 
project proposed, there were a limited number of studies examining the 
health care use of long-term follow up care of breast cancer survivors 
including hospital visits (history taking and clinical examination) and 
mammography. In Chapter 3, results were presented on the evaluation of 
the utilization of hospital follow-up in a cohort of 662 patients with a median 
follow-up time of 9.0 years (range: 0.1-18.2). Routine hospital follow-up care 
was ended for 37.3% (n=247) recurrence-free patients. For one-third of 
these patients (n=90; 36.4%) the time of stopping their hospital follow-up 
was earlier than it should have been based on the guidelines. 
Mammography is the only recommended imaging test for the routine follow­
up of women with a history of breast cancer and is recommended in most 
guidelines. Underutilization of mammography among patients in routine 
hospital follow-up was still found in 30-40% patients during hospital follow-up 
in this study. In older patients, patients with co-morbidity and patients 
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receiving hormonal therapy we should be careful to ensure the use of yearly 
mammography. 
The author comes from China and she is interested in the research on 
the efficient follow-up strategy in China. The incidence of breast cancer in 
China has been increased from 1 1 .7  per 1 00,000 in 1 998 to 1 8.7  per 
1 00,000 in 2002. Compare to the lower incidence of breast cancer in China, 
the absolute number of new cases is high due to the large population (there 
are 1 .31 billion inhabitants), and 21 .3% of new cases of breast cancer 
worldwide are diagnosed in China. In addition, cancer registries in China 
have recorded annual increases in incidence of 3% to 4% which is higher 
than in other countries. A random selection was made of 1 , 1 97 records out 
of 5,987 patients diagnosed with breast cancer in Tianjin Medical University 
Cancer Institute and Hospital. The results were presented in Chapter 4. The 
median age at diagnosis of patients was 48.0 years (range 1 9-80 years). 
The patients in this study had more advanced stages of breast cancer than 
those in studies from the United States and Europe. The proportion of 
patients with early breast cancer (stage T1 and T2) was rather low as 
compared to studies from Western countries (75% versus 83 - 88%), 
especially the percentage of T1 breast cancer was much lower (1 6% versus 
34% - 57%). Despite the unfavourable primary tumour status, the patients in 
our study show a good disease-free survival and overall survival, being 84% 
and 88% at five years and 77% and 83% at 1 0  years respectively. The 
incidence of relapse was smaller compared to some other studies (4% 
versus 4-9%). The combination of mastectomy with adjuvant radiotherapy 
and chemotherapy was a reasonable explanation for the lower incidence of 
loco-regional recurrence. There might be some other genetic and 
environmental factors that need to be clarified. Most patients (96%) had less 
follow up visits than recommended. Some patients ( 16%) hadn't visited the 
hospital in the first five years. History taking was the most common item 
taken during follow-up visits of breast cancer patients, and the proportion of 
women receiving mammography after primary treatment was very small (72 
in 5720 follow-up visits). In contrast, 2 1 .5% (1 230/5720) of the patients 
received a chest X-ray and 22.3% (1 275/5720) of the patients received an 
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ultrasound in the present study. Compliance of guidelines and possible 
related factors deserve further research attention because not a single 
follow-up strategy would have an efficient yield given such low compliance. 
Further investigation of the potential factors related to low compliance is 
already under way. 
In chapter 5, we studied the value of surveillance mammography of the 
contra-lateral breast. 114 occurrences of MCBC during hospital follow-up out 
of 139 MCBCs were included in the evaluation of the contribution of 
surveillance mammography for the MCBC. The results show that patients 
with MCBCs detected by routine mammography have better survival rates 
than patients with MCBCs detected by other means (HR: 3.18; 95% Cl: 
1.59-6.34 ). Mammography is a valuable tool for the early detection of MCBC 
during hospital follow-up of breast cancer patients and is probably beneficial 
to survival. The programme sensitivity of surveillance mammography was 
59.6% (95% Cl: 50.6-68.7). In patients who complied with annual 
mammography, sensitivity was increased to 70.8% (95% Cl : 61.7-80.0). In 
younger patients MCBC was less likely to be detected by mammography. 
In chapter 6 we assessed the contribution of routine physical examination 
in addition to mammography in the early diagnosis of breast cancer 
recurrences. The contribution of physical examination was evaluated with 
the proportion of MCBCs or LRRs (loco-regional recurrences) detected by 
physical examination alone. Seven (6%) out of 127 MCBCs and 13 (22%) 
out of 58 LRRs were detected by routine physical examination alone. The 
incremental contribution of physical examination was higher in detecting 
LRRs than in detecting MCBCs. The potential impact of patients' age on the 
contribution of physical examination was evaluated. Six LRRs (17%; 6/35) 
were observed in patients after breast conserving surgery and seven LRRs 
(30%; 7/23) in patients after mastectomy but the difference was not 
statistically significant. There was a trend that the contribution of physical 
examination was higher in women under 60 years of age in the detection of 
MCBCs (9%; 5/57) and LRRs (28%, 8/29) than in women over 60 years of 
age. Routine physical examination may be most valuable for women with a 
history of breast cancer younger than 60 years. 
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In Chapter 7, a micro-simulation model was developed to generate the 
occurrence and detection of second tumours in woman with a history of 
breast cancer. During each cycle of the model, a woman could remain 
healthy, develop a recurrence, or die of breast cancer or other causes. The 
input parameters were collected from the literature and the registry database 
of Dutch breast cancer patients. The strategy for follow-up based on the 
current guidelines as well as the three alternative strategies showed no 
significant differences in the number of second tumours, in the program 
sensitivity, and in the program sensitivity of physical examination or 
mammography. However, there were significant differences in number of 
clinical examinations, number of mammograms and in number of false 
positive findings, and related to these, there were significant differences in 
costs. Shortening the follow-up time in the hospital by a care shift from the 
hospital to the National Screening Program (NSP) or the general practitioner 
(GP) after two years of hospital follow-up (instead of five), lowering the age 
of referring from 60 to 50, and stopping yearly physical examination by the 
GP after hospital follow-up leads to a significant reduction in costs and 
maintains the same clinical effects. 
Chapter 8 describes the main implications from all the studies presented 
in this thesis for the strategies to follow up breast cancer patients after 
primary treatment. In conclusion, breast cancer survivors who have 
completed their initial treatments should be advised to receive routine follow­
up care which might be beneficial in their survival. Yearly mammography can 
early detect second tumours in breast cancer patients. Patients with second 
tumours detected by yearly mammography have a better survival than 
patients with second tumours detected by other means. Routine follow-up 
physical examination is more valuable in younger patients than in older 
patients. Decrease of hospital follow-up time, lowering the discharge age 
and stopping yearly physical examination will lead to a significant reduction 
in costs while maintaining the same clinical effects. An individual follow-up 
scheme based on age and surgical treatment was found to be cost-effective 




Mammacarcinoom is de meest voorkomende maligniteit bij vrouwen in 
Noord-Amerika en West-Europa. 1 op de 4 vormen van kanker betreft 
borstkanker bij Noord-Amerikaanse en Europese vrouwen. De overleving 
van patienten met borstkanker is door de tijd heen aanzienlijk verbeterd. Zo 
is de (relatieve) overleving na vijf jaar gestegen van 75% in 1970 tot 89% in 
2000. Door de toenemende incidentie en de verbetering in overleving is 
borstkanker een chronische ziekte geworden die zelfs kan terugkeren na 20-
30 jaar, met een toenemende druk op de kankerzorg tot gevolg. 
Vrouwen met mammacarcinoom in de voorgeschiedenis hebben na 
beeindiging van de primaire behandelingen een verhoogd risico op 
recidieven en tweede tumoren. Internationale richtlijnen geven daarom aan 
dat deze vrouwen routinematig gecontroleerd moeten warden. Het is een 
uitdaging om follow-up programma's te ontwikkelen die zowel de huidige 
kennis weerspiegelen als voldoen aan de huidige behoeften van de 
groeiende groep vrouwen die borstkanker hebben overleefd. De 
belangrijkste doelstelling van dit proefschrift is het evalueren van de follow­
up voor vrouwen met borstkanker in de voorgeschiedenis. 
Hoofdstuk 2 van dit proefschrift beschrijft een meta-analyse die is uitgevoerd 
met behulp van Cochrane review Manager software (RevMan versie 4.2). In 
deze analyse werden dertien studies betrokken met in totaal 2263 patienten. 
De patienten werden behandeld voor een eerste diagnose borstkanker en zij 
waren vrij van metastasen op afstand ten tijde van de diagnose. De follow­
up strategieen in de studies waren erop gericht om logoregionale recidieven 
en contralaterale borsttumoren vroegtijdig op te sporen. Gegevens met 
betrekking tot het risico op overlijden werden verzameld voor elke studie. De 
analyse liet zien dat vroege opsporing van borstkankerrecidieven tijdens 
follow-up een significant betere overleving geeft in vergelijking met late 
opsporing van borstkankerrecidieven (Hazard Ratio (HR): 1,68 (95% 
betrouwbaarheidsinterval (Bl): 1 ,48 tot 1,91 )). De overleving was beter bij 
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opsporing van het recidief door middel van mammografie in vergelijking met 
lichamelijk onderzoek en bij patienten zonder symptomen in vergelijking met 
patienten met symptomen (respectievelijk HR: 2,44 (95% Bl: 1,78-3,35) en 
HR: 1,56 (95% Bl: 1,36-1, 79 )). Als alle borstkankerrecidieven eerder 
zouden warden ontdekt, dan zouden 5-8 sterfgevallen kunnen warden 
vermeden door het uitvoeren van follow-up bij 1000 borstkankerpatienten 
voor een periode van 10 jaar (een absolute daling in mortaliteit van 17-28%). 
Deze uitkomsten ondersteunen de hypothese dat vroege opsporing van 
ge"isoleerde logoregionale recidieven of contralaterale borsttumoren bij 
patienten zonder symptomen een betere overleving tot gevolg heeft dan late 
symptomatische opsporing. 
Voor de studies uit de Hoofdstukken 3, 5 en 6 werden 5.589 patienten met 
borstkanker geselecteerd uit de bestanden van het lntegraal Kankercentrum 
Noord-Nederland . Dit betroffen patienten waarbij tussen januari 1989 en 
januari 2003 borstkanker werd gediagnosticeerd in vier ziekenhuizen in 
Noord-Nederland (een universitair medisch centrum, een perifeer 
opleidingsziekenhuis en twee perifere ziekenhuizen) .  Patienten met 
synchrone bilaterale borstkanker (N = 94) werden uitgesloten van verdere 
analyse. Van de 5495 overgebleven vrouwen met ipsilaterale borstkanker 
ontwikkelden zich bij 139 patienten metachrone contralaterale borstkanker 
tijdens de follow-up. Voor de analyse werd elk van deze 139 patienten 
gematcht met vier of vijf patienten zonder metachrone contralaterale 
borstkanker (in totaal 597 patienten) op ziekenhuis ten tijde van diagnose, 
leeftijd ten tijde van diagnose en duur van de follow-up. Om deelname van 
patienten aan het follow-up programma in de ziekenhuizen te kunnen 
beoordelen en de bijdrage van mammografie en lichamelijk onderzoek 
tijdens follow-up te evalueren werden voor 669 patienten gegevens over 
follow-up verzameld uit de beschikbare medische documenten in de 
ziekenhuizen. 
Ten tijde van dit project waren er slechts een beperkt aantal studies 
uitgevoerd naar het zorggebruik van vrouwen met borstkanker in de 
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voorgeschiedenis met betrekking tot follow-up bezoeken in het ziekenhuis 
(bestaande uit anamnese en lichamelijk onderzoek) en mammografie. In 
Hoofdstuk 3 warden de resultaten gepresenteerd van een onderzoek naar 
het zorggebruik van 662 patienten met een mediane follow-up tijd van 9.0 
jaar (range: 0, 1 -1 8,2 jaar). Voor 24 7 recidiefvrije patienten (37 .3%) was de 
routinematige controle beeindigd. Voor een derde van deze patienten (n = 
90; 36,4%) werd de follow-up in het ziekenhuis eerder stopgezet dan werd 
voorgeschreven in de richtlijnen. Hoewel mammografie de enige aanbevolen 
beeldvormende techniek is voor routinematige controle van vrouwen met 
borstkanker in de voorgeschiedenis, was er bij 30-40% van de patienten in 
het onderzoek sprake van onderbenutting van mammografie tijdens de 
ziekenhuis follow-up. Voorzichtigheid is geboden bij het aanbevelen van 
jaarlijkse mammografie voor oudere patienten, patienten met comorbiditeit 
en patienten die hormonale therapie krijgen. 
De auteur van dit proefschrift komt uit China en zij is ge'interesseerd in 
onderzoek naar efficiente follow-up strategieen voor Chinese vrouwen met 
borstkanker. In China is de incidentie van borstkanker toegenomen van 1 1 , 7 
per 1 00.000 in 1 998 tot 1 8,7 per 1 00.000 in 2002. Ondanks de lagere 
incidentie in China - vergeleken met die in Noord-Amerika en West-Europa -
is het absolute aantal nieuwe gevallen van borstkanker hoog door de grate 
populatie ( 131 0 miljoen inwoners). Zo wordt 21 ,3% van de nieuwe 
borstkankergevallen wereldwijd gediagnosticeerd in China. Daarnaast laten 
kankerregistraties in China een jaarlijkse toename van de incidentie (3% tot 
4%) zien die hoger is dan in andere landen. In Hoofdstuk 4 worden de 
resultaten beschreven van een retrospectieve studie naar de kenmerken en 
follow-up van Chinese borstkankerpatienten. Uit een populatie van 5987 
patienten die tussen 1 september 1 995 en 1 september 2000 waren 
gediagnosticeerd met borstkanker werd een systematische steekproef van 
1 1 97 patienten getrokken. De mediane leeftijd van de patienten ten tijde van 
diagnose bedroeg 48,0 jaar (range 1 9-80 jaar). Zij hadden vaker borstkanker 
in een verder gevorderd stadium dan patienten uit studies in de Verenigde 
Staten en Europa. Het percentage patienten met borstkanker in een minder 
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ver gevorderd stadium (T1 en T2) was tamelijk  laag in vergelijking met 
studies uit Westerse landen (75% versus 83 - 88%), met name het 
percentage patienten met een T1 tumor ( 16% versus 34 - 57% ). Ondanks de 
ongunstige tumorstatus is er in deze studie sprake van een goede ziektevrije 
overleving en totale overleving van respectievelijk 84% en 88% na 5 jaar en 
77% en 83% na 10 jaar. De incidentie van locoregionale recidieven was in 
deze studie lager dan in sommige andere studies (4% versus 4-9%) . Een 
aannemelijke verklaring voor de lage incidentie van recidieven betreft de 
combinatie van mastectomie met adjuvante radiotherapie en chemotherapie 
in het ziekenhuis, maar er zijn mogelijk ook genetische factoren en 
omgevingsfactoren die nog nader onderzocht moeten worden. De meeste 
patienten in deze studie (96%) hadden minder follow-up bezoeken in het 
ziekenhuis dan aanbevolen. Een deel van de patienten (16%) had het 
ziekenhuis niet bezocht in de vijf jaren na beeindiging van de primaire 
behandelingen. Anamnese werd het meest frequent uitgevoerd tijdens de 
follow-up bezoeken. Het aandeel van mammografie tijdens de follow-up was 
erg klein (72 van de 5720 follow-up bezoeken), in tegenstelling tot 
aanvullend onderzoek: 21,5% van de patienten (1230/5720) kreeg een 
thoraxfoto en 22,3% van de patienten (1275/5720) kreeg een echo in de 
huidige studie. Verder onderzoek naar de naleving van de richtlijnen en 
daaraan gerelateerde factoren is nodig omdat geen enkele follow-up 
strategie een optimaal rendement zal geven bij zo'n lage compliance. 
Onderzoek naar factoren die samenhangen met naleving van de richtlijnen 
is reeds opgestart. 
Hoofdstuk 5 beschrijft een evaluatie van de waarde van mammografie van 
de contralaterale borst. De gegevens van 656 vrouwen met ipsilaterale 
borstkanker, waarvan 1 14 vrouwen met metachrone contralaterale 
borstkanker tijdens de follow-up werden in de evaluatie meegenomen. Uit de 
resultaten blijkt dat patienten waarbij metachrone contralaterale borstkanker 
is opgespoord door routine mammografie een betere overleving hebben dan 
patienten waarbij de metachrone contralaterale borstkanker op een andere 
manier is ontdekt (HR: 3, 18; 95% Bl: 1 .59-6.34). Mammografie is een 1 6 1  
waardevol hulpmiddel voor de vroege opsporing van metachrone 
contralaterale borstkanker tijdens follow-up van patienten met borstkanker in 
de voorgeschiedenis en heeft mogelijk een positief effect op hun overleving. 
De sensitiviteit van mammografie was 59,6% (95% Bl: 50,6-68,7). Bij 
patienten die een jaarlijkse mammografie kregen was de sensitiviteit hoger, 
namelijk: 70,8% (95% Bl: 61.7-80.0). Bij jongere patienten werd metachrone 
contralaterale borstkanker minder vaak opgespoord door mammografie. 
In hoofdstuk 6 warden de resultaten gepresenteerd van een onderzoek naar 
de bijdrage van routine lichamelijk onderzoek - als aanvulling op 
mammografie - in de opsporing van borstkankerrecidieven. De bijdrage van 
het lichamelijk onderzoek werd geevalueerd door het aandeel te berekenen 
van contralaterale borstkankers en locoregionale recidieven die zijn ontdekt 
met behulp van alleen lichamelijk onderzoek. Zeven (6%) van de 127 
contralaterale borstkankers en 13 (22%) van de 58 locoregionale recidieven 
werden opgespoord door lichamelijk onderzoek alleen. De toegevoegde 
waarde van het lichamelijk onderzoek was hoger bij het opsporen van 
locoregionale recidieven dan bij het opsporen van contralaterale 
borstkankers. De invloed van de leeftijd van de patienten op de bijdrage van 
lichamelijk onderzoek werd eveneens geevalueerd. Zes locoregionale 
recidieven (17%, 6 I 35) werden ontdekt na een borstbesparende operatie 
en zeven locoregionale recidieven (30%, 7 / 23) na een borstamputatie, 
maar het verschil was niet statistisch significant. Bij vrouwen jonger dan 60 
jaar was de bijdrage van het lichamelijk onderzoek in het opsporen van 
contralaterale borstkankers (9%, 5 I 57) en locoregionale recidieven LRRs 
(28%, 8 I 29) grater dan bij vrouwen ouder dan 60 jaar. Routine lichamelijk 
onderzoek kan daarom het meest waardevol zijn voor vrouwen met 
borstkanker in de voorgeschiedenis jonger dan 60 jaar. 
Hoofdstuk 7 beschrijft een model dat is ontwikkeld om het voorkomen en 
opsporen van tweede tumoren bij vrouwen met borstkanker in de 
voorgeschiedenis te simuleren. Tijdens elke cyclus van het model kan een 
vrouw gezond blijven, een recidief ontwikkelen of sterven aan borstkanker of 1 62 
aan andere oorzaken. De inputparameters werden uit de literatuur en uit de 
database met Nederlandse borstkankerpatienten gehaald. De follow-up 
strategie gebaseerd op de huidige richtlijnen en de drie alternatieve 
strategieen toonden geen significante verschillen in het aantal tweede 
tumoren en in sensitiviteit van het follow-up programma, lichamelijk 
onderzoek en mammografie. Er waren echter grote verschillen in het aantal 
klinische onderzoeken, het aantal mammografieen en in het aantal fout­
positieve resultaten en daarmee ook in de kosten. Verkorting van de follow­
up tijd in het ziekenhuis en verschuiving van de follow-up naar het 
bevolkingsonderzoek of de huisarts na twee jaren (in plaats van na vijf jaren), 
verlaging van de terugverwijzingsleeftijd van 60 naar 50 jaar en beeindiging 
van het jaarlijks lichamelijk onderzoek bij terugverwijzing naar de huisarts 
leidt tot een significante vermindering van de kosten waarbij de klinische 
effecten gelijk blijven. 
In hoofdstuk 8 worden de hoofdbevindingen van dit proefschrift samengevat. 
Vrouwen met borstkanker in de voorgeschiedenis waarbij de primaire 
behandelingen zijn afgerond dienen routine follow-up te ontvangen 
aangezien dit een gunstig effect heeft op hun overleving. Jaarlijkse 
mammografie kan tweede tumoren vroegtijdig ontdekken. Daarbij hebben 
patienten met een tweede tumor opgespoord door mammografie een betere 
overleving dan patienten met een tweede tumor die op een andere manier is 
ontdekt. Lichamelijk onderzoek is meer waardevol voor jongere 
borstkankerpatienten dan voor oudere borstkankerpatienten. Het verkorten 
van de follow-up tijd in het ziekenhuis, het verlagen van de 
terugverwijzingsleeftijd en het beeindigen van het jaarlijks lichamelijk 
onderzoek na twee jaar zal leiden tot een aanzienlijke kostenvermindering 
met behoud van dezelfde klinische effecten. Een individuele follow-up 
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